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Abstract 
Cortical spreading depression (CSD) is a propagating neuronal/glial excitation, 
followed by depression in cerebral cortex and subcortical regions. It is known to 
be the underlying cause of migraine with aura in humans. CSD can also lead to 
migraine-like behavior by triggering pannexin1 (Panx1) channels opening and 
induce the release of calcitonin gene-related peptide (CGRP) that plays a key 
player in migraine patients. Increasing evidence points to an essential role of 
NR2A-containing NMDA receptors in CSD propagation in vitro; however 
whether NR2A also mediates CSD genesis and its downstream signaling 
associated with CSD is unknown. The purpose of this thesis is to clarify the 
contribution of NR2A-containing receptors to CSD propagation and determine 
their role in CSD genesis in vivo, and if so, to further explore the mechanism 
underlying the action of NR2A relevant to Panx1 channels opening and CGRP 
gene expression in rats. In the present study, CSD was induced both in vitro and 
in vivo. Multi-disciplinary methods were used including electrophysiology and 
intrinsic optical imaging for CSD recording, western blot, immunoprecipitation 
and immunohistochemistry for protein detection, and qPCR for gene expression 
analysis. 
The results demonstrated that NR2A-containing receptor inhibition using 
NR2A-preferring antagonist, TCN-201, suppressed CSD propagation in a 
concentration-dependent manner in the chick retina. In addition, both the NR2A 
antagonists, NVP-AAM077 and TCN-201, concentration-dependently suppressed 
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CSD genesis but not propagation in the microdialysis-based CSD model in rats. 
Differently, perfusion of 0.3 nmol NVP-AAM077 into contralateral 
cerebroventricle considerably suppressed CSD propagation in rats. These data 
suggests a key role of NR2A in mediating both CSD genesis and propagation. 
Further mechanism study showed that CSD not only promoted sarcoma family 
kinases (SFKs) activation, but also SFKs-Panx1 interaction and neuronal Panx1 
channels opening in the ipsilateral cortex of rats. Corresponds to this finding, 
inhibition of SFKs by intracerebroventricle (i.c.v.) perfusion of 2.5 nmol PP2 not 
only attenuated both SFKs activation and Panx1 channels opening induced by 
CSD, but also suppressed CSD propagation. Furthermore, the CSD-induced SFKs 
activation, SFKs-Panx1 interaction and neuronal Panx1 channels opening were 
significantly suppressed under NR2A inhibition by i.c.v. perfusion of 0.3 nmol 
NVP-AAM077. Finally, pre-treatment with 0.3 nmol NVP-AAM077 prevented 
the elevation of CGRP mRNA 24 hour after multiple CSD in the ipsilateral visual 
cortex of rats. 
In summary, this study provides strong evidence that NR2A-containing NMDA 
receptors contribute to CSD genesis and propagation, and reveals a previously 
unknown migraine mechanism of NR2A involving SFKs, Panx1 and CGRP 
during CSD, i.e. NR2A regulates single CSD-induced opening of neuronal Panx1 
channels via coupling activated SFKs to Panx1 in cortex, and that NR2A regulates 
multiple CSD-induced CGRP gene expression in visual cortex. These findings 
provide new insights into CSD involving NR2A-containing receptor and 
downstream signals. Selectively antagonizing these elements might constitute a 
highly specific strategy treating migraine and other diseases associated with CSD.  
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Chapter 1 General introduction 
 
1.1 Cortical spreading depression 
 
1.1.1 Definition and brief history of its discovery 
Cortical spreading depression (CSD) is a temporary excitation of synaptic activity 
followed by depression that propagates slowly (~ 3 mm/min) across the unilateral 
cerebral cortex and subcortical regions (Somjen, 2005). CSD was first described 
by Leão as an unexpected silencing of the ongoing electrical activity from the 
cortical surface of anesthetized rabbits, when he wanted to study the cortical 
electrogram of experimental epilepsy (Leao, 1944b) in 1944. Leão further 
recorded the negative slow potential change, including a depolarization followed 
by prolonged repolarization, associated with CSD from the cortical surface using 
string galvanometer and vacuum tube amplifier in 1947 (Leao, 1947). From then 
on, increasing studies have been attempting to explain its mechanism although it 
still remains far from clear. 
 
1.1.2 Key features of CSD 
Neurons and especial their proximal dendrites are the main active players of 
neuronal hyperexcitability, which is considered as the initiation of CSD (Dreier, 
2011). However, the process of CSD is not only a local, temporary disruption of 
ionic homeostasis in neurons but also relevant to glia cells, e.g. microglia (Pusic et 
al., 2014) and astrocyte (Seidel and Shuttleworth, 2011, Seidel et al., 2016). 
The experimental CSD can be triggered by electrical pulses, alkaline pH, low 
osmolarity, mechanical stimuli such as pressure on or puncture of the cerebral 
cortex, and a variety of chemicals such as K
+
, N-methyl-D-aspartic (NMDA) or 
glutamate (Smith et al., 2006), in which the high-K
+
 is used as one of the most 
common triggers for inducing single (Bolay et al., 2002) and multiple (Godukhin 
and Obrenovitch, 2001) CSD by either topical (Godukhin and Obrenovitch, 2001) 
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or through microdialysis (Obrenovitch et al., 1993) application for the study of 
both CSD genesis and propagation. 
CSD is known to be associated with various physiological changes not only in the 
central nervous system (CNS), e.g. cortex (Feuerstein et al., 2016)and thalamus 
(Tepe et al., 2015), but also in the peripheral nervous system (PNS), e.g. 
trigeminal ganglion (Smith et al., 2006), in different species and humans (Somjen 
et al., 1992, Bowyer et al., 1999a, Bowyer et al., 1999b, Smith et al., 2000).  
 
1.1.2.1 Changes in cerebral blood flow 
Leão (Leao, 1944a) first described the dilation of pial blood vessels 
accompanying CSD in 1944, which is further examined using hydrogen clearance 
method (Matsushima et al., 1996), laser Doppler flowmetry (Back et al., 1994) 
and blood-oxygen level-dependent (BOLD) contrast (Cao et al., 1999). The 
regional cerebral blood flow (CBF) change response to CSD is typically 
composed of four distinct vasomotor phases: i) an initial hypoperfusion coincident 
with the depolarization of CSD; ii) a rapid hyperemia during and after the 
repolarization of CSD; iii) a smaller hyperemia followed the first hyperemia; and 
iv) a prolonged oligemia lasting an hour or more (Ayata and Lauritzen, 2015). 
Meanwhile, the regional CBF is not changed at any time in subcortical regions by 
either single or multiple CSD (Kuge et al., 2000). 
Various vasoactive substances being released from, or produced by, brain cells is 
likely to be the underlying mechanisms of CBF change during CSD. These mainly 
include calcitonin gene-related peptide (CGRP), glutamate, acetycholine (ACh), 
cGMP and ATP (Colonna et al., 1994, Basarsky et al., 1999, Rodrigues and 
Martins-Ferreira, 1980, Read et al., 2001, Schock et al., 2007). For example, 
topical administration of CGRP, an extremely potent dilator of brain vessels 
(Arulmani et al., 2004) on meninges strongly increases dural blood flow (Levy et 
al., 2005), while CGRP receptor antagonist not only suppresses CSD (Tozzi et al., 
2012) but also attenuates pial dilation induced by CSD (Colonna et al., 1994). It is 
known that glutamate receptor activation leads to vasodilation (Fergus and Lee, 
1997), and that glutamate also triggers CSD (Lauritzen et al., 1988), which could 
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in part support the contribution of glutamate receptor to the CSD-induced CBF 
response. Because both NMDA (Peeters et al., 2007) and non-NMDA (i.e.  
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, AMPA) (Holland et al., 
2010) subtypes of glutamate receptors antagonists inhibit the CBF change, 
whereas only NMDA subtype suppresses CSD (Nellgard and Wieloch, 1992, 
Peeters et al., 2007), it possibly appears that the vasomotion response to glutamate 
via NMDA receptor mechanism under CSD condition. 
CSD-induced vascular response may proceed independently via its direct vascular 
conduction. This notion is supported by the following evidences. Firstly, dilation 
of arterioles on the cortical surface propagates at a greater velocity than the 
underlying CSD wave and spread into areas not reached by CSD wave (Brennan 
et al., 2007). Secondly, multiple CSD waves induce an additional spontaneous 
CBF changes that spread to the contralateral cortex (Eftekhari, 2016). However, 
since CSD can proceed without alteration in the absence of the vascular response 
(Dahlem and Muller, 2000), the vascular response is apparently not essential for 
CSD process. 
 
1.1.2.2 Changes in cellular ionic homeostasis and energy metabolism 
The CSD phenomenon is associated with transient, localized redistribution of ions 
between the extracellular and intracellular. The extracellular concentration of K
+
 
rapidly rises and reaches levels as high as 30-60 mM. At the same time, the 
extracellular Na
+
 and Cl
-
 levels decrease to approximately 50-70 mM as these ions 
enter cells and cause the neuronal excitation followed by depolarization and a 
period of electrical silence. Ca
2+
 enters after the outward movement of K
+
, 
resulting in a net decrease in extracellular Ca
2+
 to approximately 0.2-0.8 mM 
(Pietrobon and Moskowitz, 2014). Selective blocking of ion channels, e.g. Na
+ 
channel, depresses CSD (Tozzi et al., 2012), while increasing the concentration of 
K
+
 in the perfusion medium restores CSD propagation (Obrenovitch and Zilkha, 
1995). In the absence of Ca
2+
 in the perfusion medium, the initiation of CSD is 
completely prevented (Obrenovitch et al., 1993). All of the above evidences 
suggest the critical roles of ions in CSD. These fluxes also result in a transient 
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cellular swelling and an accompanying decrease in the volume of extracellular 
fluid (Zhou et al., 2010). Additionally, pH selective microelectrode in the 
extracellular space shows a rapid transient alkalinisation followed by a large, 
prolonged acidification (Mutch and Hansen, 1984).  
It is well established that CSD stimulates energy demand (Krivanek, 1961, Mies 
and Paschen, 1984, Mayevsky and Weiss, 1991), which is directly linked to the 
disruption of the K
+
 and Na
+
 gradients across the cellular membrane because 
restoration from the ionic homeostasis requires energy (Hansen and Lauritzen, 
1984). During this process, CSD-induced rise in cerebral metabolic rate of O2 
(CMRO2) supports the increased Na
+
-K
+
-ATPase activity for transporting Na
+
 out 
of, and K
+
 into, the cells (Cruz et al., 1999), which uses more glucose (Shinohara 
et al., 1979) and lactate efflux (Cruz et al., 1999). The accumulation of 
intercellular Ca
2+ 
during CSD may trigger an increase in CMRO2 via the uniporter 
of Ca
2+
 in the membrane of mitochondria (Zhou et al., 2010). CSD can also 
activate glycolytic pathways. For example, CSD is accompanied with the rise of 
lactate and reduction of glycogen in the brain (Lauritzen et al., 1990). The 
activation of glycolytic pathway is also consistent with intracellular alkalinisation 
of astrocytes during CSD (Chesler and Kraig, 1987), which promotes the 
glycogen phosphorylase and lactate production (Hof et al., 1988, Cruz et al., 
1999). 
 
1.1.2.3 Changes in neurotransmitters and receptors 
CSD is known to be associated plenty of neurotransmitters and receptors. 
Neurotransmitters mainly include glutamate, ACh, dopamine, CGRP, NO, 
gamma-aminobutyric acid (GABA) and serotonin (5-HT) (Fabricius et al., 1993, 
Yavich and Ylinen, 2005, Shi et al., 2010, Read et al., 1997, Storer and Goadsby, 
1997, Rodrigues et al., 1988). The release of these neurotransmitters correlates 
with the dramatic changes in extracellular and intracellular ions during CSD and 
they play important roles in the initiation of CSD. For example, the concentration 
of glutamate in dialysate samples from cortex increases during CSD (Fabricius et 
al., 1993) and glutamate is required for CSD genesis (Van Harreveld, 1959, 
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Lauritzen, 1994, Smith et al., 2006). CSD initiation is known to attribute to 
glutamate actin on NMDA receptor, but not the other two ionotropic glutamate 
receptors, AMPA and Kainite (KA) receptors. This is supported by that: (i) 
NMDA, the specific agonist of NMDA receptor has similar effect with glutamate 
on eliciting CSD (Curtis and Watkins, 1961), which is in line with that inhibition 
of NMDA receptor but not AMPA receptor or KA receptor suppresses CSD 
(Smith et al., 2006); (ii) activation of AMPA receptor prevents, but not facilitates 
NMDA-induced CSD (Addae et al., 2000). In addition, CGRP receptor is proved 
involving into CSD as BIBN4096, the small molecular inhibitor of CGRP 
receptor, suppresses CSD propagation in the chick retina (Wang et al., 2016a). By 
contrast, GABAA receptor α2 subtype is considered as negative regulator in 
mediating CSD because both GABAA receptor and the α2 subtype-preferring 
positive modulators suppress CSD propagation in the retina model (Wang et al., 
2015). Furthermore, local inhibition of NO synthesis delays the genesis of CSD 
repolarization in rats (Wang et al., 2003). These evidences suggest a complex 
phenomenon resulting from the interaction of various processes in CSD initiation, 
and that diverse cellular elements involve in different properties of CSD. 
 
1.1.2.4 Changes in gene expression 
CSD can cause changes in the expression of a large number of genes mainly 
associated with neuroinflammation, apoptosis and synaptic transmission 
(Choudhuri et al., 2002, Sintas et al., 2016). For example, the gene related to 
L-type calcium channels are upregulated 2 hours after multiple CSD induction in 
the brain of mouse (Choudhuri et al., 2002). 24 hours after multiple CSD, there is 
an increase in mRNA level of CGRP in discrete cortex of rats (Yan Wang, 2016), 
whereas the content of AMPA receptor is reduced (Chazot et al., 2002). The fact 
that certain genes associated with hormonal stimulus, apoptosis and interleukin 
signaling induced by multiple CSD are not altered by anti-CSD drugs, e.g. 
topiramate and valproate, in cortex of rats (Sintas et al., 2016), represents the 
needs for exploring targets associated with CSD in migraine therapy. 
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1.2. Clinical relevance of CSD 
 
1.2.1. Migraine and CSD 
Migraine is a disabling neurovascular disorder characterized by severe, episodic 
and unilateral headache lasting hours to days, affects an estimated 16% of the 
population worldwide (Lauritzen, 1994, Tfelt-Hansen, 2010) and up to 25% of 
migraineurs experience transient focal neurologic symptoms (aura), including 
visual disturbance, unilateral paresthesias, motor symptoms, and language 
disturbances (Viana et al., 2016). The initiation of a migraine attack is frequently 
associated with a wide variety of internal and external triggers such as stress, 
hormonal fluctuations, sleep disturbances, and meal skipping. The accumulating 
evidences are in favour of, although still be debated, the neural and vascular 
mechanisms underlying migraine with or without aura (Hargreaves, 2007, Cutrer, 
2010). With respect to this theory, the brain state of altered excitability and the 
abnormal brain vascular state is capable of activating the trigeminal vascular 
system, meningeal nociceptors and then leading to the onset of headache (Noseda 
and Burstein, 2013). 
It is generally recognized that single CSD causes migraine aura, and is proposed 
as the putative mechanism of migraine headache (Hadjikhani et al., 2001, Smith et 
al., 2006, Ayata, 2010). In 1941 Lashley firstly described a scotomas invasion 
during migraine headache (Lashley, 1941). A dozen years later, Milner stated a 
possible correspondence between migraine aura and CSD because of the striking 
similarity of the time courses between the scintillating scotomas and Leão’s 
spreading depression (Milner, 1958). This opinion is further supported by the 
clinical study in which spontaneous and exercise-triggered migraine aura can be 
acquired by magnetic resonance imaging (MRI) before and during the BOLD 
changes and headache phase (Hadjikhani et al., 2001). In addition, CSD causes 
large rise in vasoactive neuropeptides such as substance P, CGRP and vessel 
dilation in rodents (Noseda and Burstein, 2013), activates meningeal nociceptors  
and the central trigeminovascular neurons (Zhang et al., 2011, Zhang et al., 2010). 
Furthermore, CSD triggers migraine-like behavior in mice (Karatas et al., 2013). 
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Specifically, CSD activates the pannexin1 (Panx1) channels with subsequent 
sustained release of high-mobility group box 1 (HMGB1) from neurons. HMGB1 
release promotes inflammation stress via translocation of nuclear factor-κB into 
nucleus of astrocytes followed by the formation of cytokines, prostanoids and 
inducible NO from glia limitans and, hence, causes trigeminovascular activation, 
vessel dilation and headache-like headache in mice. However, how CSD leading 
to migraine still needs to be further elucidated. 
 
1.2.2. Stroke, brain injury and CSD 
In addition to migraine, CSD is also associated with stroke and traumatic brain 
injury (TBI). Stroke is the rapid loss of brain function due to disturbance in the 
blood supply to the brain. This can be due to ischemia caused by blockade of 
blood vessel, or hyperaemia caused by hypertension (Cahill et al., 2006). 
Spontaneous CSD-like depolarization can be observed in the vicinity areas of 
ischemic infarct in cortex (Strong et al., 1983) and subcortical regions (Dreier, 
2011). CSD represents as an irreversible depolarization at the region where suffers 
persistent hypoxia or hypoglycemia (Farkas et al., 2010). CSD can cause ischemic 
cell death following the onset of spreading depolarization (Dreier et al., 1998). 
CSD also occurs following acute TBI that often accompanied with hemorrhage 
(Dreier, 2011, Hartings et al., 2009). Whereas the pattern of TBI-triggered CSD is 
heterogeneous and influenced by many factors, a common feature is that multiple 
CSD events are observed lasting hours to days in patients (Lauritzen et al., 2011) 
and also in some, but not all, animal TBI models (Hartings et al., 2016). It is 
worthy to mention that whether the TBI-induced CSD aggravates brain injury is 
still controversial. Baumgarten group found that the additional CSD has no effect 
on injury volume at 24 hours (Lauritzen and Hansen, 1992). A different result is 
obtained in an in vitro model, where the single CSD wave caused by trauma 
enlarged the volume of cortical damage compared with the traumatic cortex 
without CSD (von Baumgarten et al., 2008), suggesting that both single and 
multiple CSD may worse TBI. 
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1.3. NMDA receptor signaling in CNS diseases 
 
1.3.1 NMDA receptor properties and distribution 
Glutamate is the one of main excitatory neurotransmitters in the CNS and can 
bind to its specific glutamate receptors (Flores-Soto et al., 2012). The large family 
of excitatory glutamate receptors is classified as metabotropic and ionotropic 
receptors, in which NMDA receptor constitutes the ionotropic subfamily 
identified by specific molecular composition and unique pharmacological 
properties (Dingledine et al., 1999).  
It is widely accepted that NMDA receptor forms tetrameric structures (Michaelis, 
1998) by combinations of different subunits: NR1, NR2 (A-D) and NR3 (A and 
B). Functional NMDA receptor is generally formed by heterotetramers 
comprising of two mandatory NR1 subunits and two functional NR2 subunits 
(Sasaki et al., 2002, Flores-Soto et al., 2012). These NMDA receptor subunits 
share a common membrane topology characterized by an amino-terminal 
extracellular domain; a ligand binding domain; a transmembrane region formed 
by 4 hydrophobic segments, and a carboxyl tail domain in the intracellular region, 
which varies in size depending upon the subunit and provides multiple sites of 
interaction with numerous intracellular proteins. Activation of NMDA receptor 
requires simultaneous binding by glutamate and glycine (or D-serine) as agonists, 
and the depolarisation of the cell membrane (Lynch and Guttmann, 2001). The 
agonist binding domain binds glycine in NR1 and NR3, whereas glutamate binds 
with NR2 subunit (Furukawa et al., 2005). Once the receptor is activated, its 
affinity for endogenous pore blocker Mg
2+ 
is reduced and therefore permeability 
of Ca
2+
 increased. 
The four NR2 subunits show a distinct distribution in the CNS, e.g. NR2A is 
ubiquitously expressed in synapses, while NR2B is enriched in extra-synaptically 
in the forebrain of adult rat (Watanabe et al., 1994, Sanz-Clemente et al., 2013). 
Besides that, NMDA receptor is also widely distributed in PNS and other organs 
including lungs and liver (Nasstrom et al., 1993).  
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1.3.2 NMDA-containing receptor and CSD 
NMDA receptor contributes to CSD genesis, as evidenced by that CSD can be 
blocked by the antagonists of NMDA receptor MK-801 (Peeters et al., 2007, Bu et 
al., 2016) and ketamine (Hernandez-Caceres et al., 1987), and partially suppressed 
by L-701,324 (Obrenovitch and Zilkha, 1996a) and memantine (Peeters et al., 
2007). MK-801 is not considered as an anti-CSD candidate for the migraine 
treatment because of its unacceptable side effects caused by the blockade of 
normal neuronal function (Chen and Lipton, 2005, Chen and Lipton, 2006). 
Ketamine, another noncompetitive antagonist only shows efficacy in reducing the 
aura symptoms but fails to reduce the pain severity resulting from familial 
hemiplegic migraine in a small clinical trial (Kaube et al., 2000). Differently, 
memantine can reduce the headache frequency when given as a preventive 
treatment of refractory migraine in an open-label study (Bigal et al., 2008). 
Nevertheless, a randomized, placebo-controlled trial is required for further 
confirmation and that the side effects, although generally mild, but of high ratio, 
e.g. somnolence (25%), asthenia (11%) and anxiety (11%) still need to be 
considered (Huang et al., 2014).  
NR2B subunit also involves in mediating CSD. Inhibitory effect of NR2B 
preferring antagonists, e.g. CP-101 606, ifenprodil and Ro 25-6981 are observed 
to suppress CSD in rats (Menniti et al., 2000, Faria and Mody, 2004, Peeters et al., 
2007). However, mediation of NR2A-containing receptor to CSD is still a matter 
of debate, which is shown as that BOLD accompanied with CSD is not altered by 
NR2A antagonist in rats (Shatillo et al., 2015); In contrast, NR2A inhibition 
suppresses the propagation of CSD in the chick retina (Wang et al., 2012). In that 
case, the involvement of NR2A-containing receptor in CSD needs to be further 
investigated. 
 
1.3.3 Key signaling associated with NMDA receptor 
Multiple cell signaling is associated with NMDA receptor, which is implicated in 
many neuropathological states (Farinelli et al., 2009, Kemp and McKernan, 2002, 
Sheng and Kim, 2002, Salter and Kalia, 2004) (Figure 1). Among these, the 
second messenger is probably one of the best understood. For example, glutamate 
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toxicity is capable of Ca
2+
 influx through NMDA receptor and leads to neuronal 
death (Chen et al., 1997). NMDA receptor activation also stimulates neuronal 
nitric oxide synthase (nNOS) (Garthwaite et al., 1988, Bredt and Snyder, 1992), 
which may be the underlying cause of the NO formation-induced rapid recovery 
from the depolarization of CSD (Wang et al., 2003). In addition, cytoplasmic 
scaffolding protein and kinases are also implicated in the NMDA receptor 
signaling. For instance, NMDA receptor contributes to the amplitude of CSD by 
interacting with postsynaptic density protein (PSD)95 (Kucharz et al., 2016). 
Uncoupling NMDA receptor-NADH dehydrogenase subunit 2 (ND2) complex 
from SFKs relieves neuropathic pain (Liu et al., 2008). Activation of NMDA 
receptor can couple SFKs to Panx1 channels during neuronal excitotoxicity 
(Weilinger et al., 2016). Furthermore, the NMDA receptor also regulates gene 
expression of neurotransmitters. For example, the elevation of CGRP mRNA can 
be prevented by NMDA receptor blocker kynurenic acid in peripheral and central 
nervous systems in nitroglycerin-induced migraine model in rats (Greco et al., 
2016).  
NR2 subunits, especially 2A and 2B, largely determine the distinct 
pharmacological and pathological properties of NMDA receptor (Cull-Candy and 
Leszkiewicz, 2004, Paoletti and Neyton, 2007, Gielen et al., 2009). For instance, 
NR2A promotes the surface insertion of GluR1 into cell membrane in mature 
cultured hippocampal neurons, whereas NR2B prevents it (Kim et al., 2005). 
Selectively blocking NR2A prevents the generation of epilepsy and the 
development of mossy fiber sprouting in the kindling and pilocarpine epileptic 
models of rats, whereas inhibition of NR2B has no effect (Liu et al., 2007). In 
addition, activation of NR2A generates resistance to ischemia by elevating 
cyclic-AMP response element activity levels, and this effect can be abolished by 
NR2A antagonist NVP-AAM077 (Terasaki et al., 2010). 
 
1.3.3.1 Sarcoma family kinases  
SFKs is a family of non-receptor protein tyrosine kinases and first identified as 
the proto-oncogenes that has been linked with the development and progression of 
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cancer (Martin, 2001). Five members of the Src family kinases are expressed in 
the mammalian CNS - Src, Fyn, Yes, Lck and Lyn. These kinases range in size 
from 52 to 62 kDa, and are mainly comprised by four domains: three homologous 
domains Src homology (SH)1, SH2 and SH3 domains, and a SH4 domain that is a 
short sequence at the amino N-terminus of the protein for anchoring the protein to 
cell membrane. The SH1 domain contains the ‘activation loop’ including a 
tyrosine residue at 416 amino acid that confers the catalytic activity by 
autophosphorylation. Between the SH3 and SH4 domains is the unique domain 
that is variable between the subtypes of SFKs. (Salter and Kalia, 2004).  
SFKs widely participant in a variety of physiological and pathological conditions 
e.g. memory, inflammatory, ischemia, epilepsy and neuropathic pain (Roskoski, 
2004, Yeatman, 2004, Salter and Kalia, 2004). For example, peripheral nerve 
injury activates SFKs in the lumbar spinal cord, and intrathecal administration of 
SFKs inhibitor suppresses mechanical hypersensitivity in the nerve-injured mice 
(Katsura et al., 2006). In addition, SFKs activity increases during ischemia 
(Takagi et al., 1999), and that inhibition of SFKs suppresses neuronal 
depolarization when the tissue exposures to anoxia (Weilinger et al., 2012). Given 
ischemia and migraine have the similar part in pathophysiological characters, e.g. 
the spreading depolarization (Kurth et al., 2012), it is plausible to propose that 
SFKs are also activated by CSD and mediate CSD in turn. 
It is known that NMDA receptor can directly interact with SFKs (Salter and Kalia, 
2004). For instance, SFKs are coupled to NMDA receptor through ND2 (Gingrich 
et al., 2004). Uncoupling Src from NMDA receptor complex relieves 
inflammatory and neuropathic pain (Liu et al., 2008). In addition, NR2A is 
subjected to phosphorylation for regulating the function of receptor (Cheung and 
Gurd, 2001, Wang et al., 2014b). For instance, the Y1325 and Y1387 amino acid 
at C-terminus of NR2A is phosphorylated by intracellular SFKs, which promotes 
the receptor current (Yang and Leonard, 2001). However, whether SFKs involve 
NR2A signaling associated with CSD is unknown. 
 
1.3.3.2 Pannexin1 channels 
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Panx family is a class of plasma membrane spanning proteins that presumably 
form a hexameric, non-selective ion channel and made up by 3 isoforms: Panx1, 
Panx2, and Panx3 (Isakson and Thompson, 2014). Similar to the connexins, the 
secondary structure of Panx contains four transmembrane segments, two 
extracellular loops and one intracellular, with its amino N- and C- terminus at the 
intracellular space. However, Panx notably does not form endogenous gap 
junctions due to the N-linked glycosylation preventing docking of Panx channels 
from adjacent cells (MacVicar and Thompson, 2010).  
Panx family is abundantly expressed in the CNS of mammals in many types of 
cells, e.g. microglia, astrocytes, oligodendrocytes and neurons, in which Panx1 
channels are the most-studied member to date (Wang et al., 2014a). Panx1 has 
high permeability to small molecules (up to 1.5 kDa), ATP, Ca
2+
, glutamate and 
some inflammatory mediators. It can be activated by several mechanisms, such as 
mechanical stimulation, increases of extracellular K
+
, proteolytic cleavage of its 
C-terminus, raising of the intracellular Ca
2+
, and several intracellular signaling 
(Penuela et al., 2013).  
Panx1 channels have considerable correlation with NMDA receptors in multiple 
neurological diseases, including epilepsy (Clasadonte et al., 2013), migraine 
(Karatas et al., 2013) and ischemia stoke (Weilinger et al., 2012). For example, 
Panx1 channels opening is triggered by NMDA receptor stimulation and 
contributes to the epileptiform seizure in the hippocampus (Thompson et al., 2008) 
and rhythmic neuronal discharge in the seizure susceptible brain (Hellier et al., 
2009). In addition, CSD triggers headache-like behavior via activating Panx1 
channels, which can be prevented by NMDA receptor blocker (Karatas et al., 
2013). Furthermore, activation of NMDA receptor causes excitotoxicity via 
coupling SFKs to Panx1 channels in both ischemic in vitro and in vivo models 
(Weilinger et al., 2012, Weilinger et al., 2016), raising the possibility that NMDA 
receptor also mediates CSD-induced Panx1 channels opening via SFKs. 
Herein, I propose that NR2A-containing receptor may regulate CSD-induced 
coupling of activated SFKs to Panx1 channels. The hypothesis is mainly 
supported by the following observations: (i) NR2A plays a crucial role in 
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mediating CSD propagation in chick retina (Wang et al., 2012); (ii) NMDA 
receptor contributes to CSD-induced Panx1 opening (Karatas et al., 2013); (iii) 
NMDA receptor activation couples SFKs to Panx1 channels in ischemic model 
(Weilinger et al., 2012, Weilinger et al., 2016); and (iv) NR2A, SFKs and Panx1 
co-localize in postsynaptic dense area (Sugrue et al., 1990, Zoidl et al., 2007, 
Sanz-Clemente et al., 2013). 
 
1.3.3.3 Calcitonin gene-related peptide 
CGRP, a 37-amino acid peptide, is consists of two forms of αCGRP and βCGRP 
(Wimalawansa et al., 1990) that share >90% homology and differ by only three 
amino acids in the human, bearing similar biological activities (Steenbergh et al., 
1986). It is generally considered that αCGRP is the principal form found in both 
CNS and PNS , whereas βCGRP is found mainly in the enteric nervous system 
(Mulderry et al., 1985). CGRP is known to mediate neurogenic inflammation, 
modulate nociceptive input (Russo, 2015) and act as a vasodilator (Brain et al., 
1985). 
Both clinical and preclinical studies support CGRP as a key player in migraine 
(Russo, 2015, Edvinsson, 2008). CGRP levels are elevated in both the serum and 
cerebral spinal fluid (CSF) of migraineurs (van Dongen et al., 2016) and that 
intravenous CGRP administration to migraineurs is sufficient to elicit a 
migraine-like headache (Hansen et al., 2010, Lassen et al., 2002). Similarly, 
CGRP receptor antagonists and anti-CGRP antibodies reduce the headache days 
per month in patients with episodic migraine (Bigal et al., 2015, Edvinsson, 2015, 
Vecsei et al., 2015). Experimental studies show that intracerebroventricular (i.c.v.) 
perfusion of CGRP promotes the behavioral sensitivity to light in transgenic 
CGRP-sensitized mice. It suggests a central mechanism of CGRP in mediating the 
photophobia of migraine. Additionally, multiple, but not single CSD can elevate 
the contents of CGRP mRNA in motor, somatosensory and visual cortices of the 
ipsilateral hemisphere in rats (Wang et al., 2016b), implying an underlying 
relationship between CGRP expression and chronic migraine that is characterized 
by frequency progressively migraine attack over months or years (Lipton et al., 
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2004). The fact that inhibition of CGRP prevents the post-traumatic headache in 
mice suggests a critical role of CGRP in the consequence of TBI (Bree and Levy, 
2016), another disease accompanies with multiple CSD (Hartings et al., 2016). 
However, the mechanism of CSD-induced CGRP gene expression needs to be 
addressed. 
There is a link between NMDA receptor and CGRP. Firstly, perfusion of NMDA 
receptor antagonists, MK-801 and AP-5, prevent capsaicin-induced CGRP release 
in the spinal cord of rats (Garry et al., 2000). Secondly, the endogenous NMDA 
receptor antagonist, kynurenic acid abolishes the headache-like behavior and 
importantly reduces CGRP mRNA level in the trigeminal ganglion, medulla pons 
and cervical spinal cord in a nitroglycerin-induced migraine model of rat (Greco 
et al., 2016). These data suggest that NMDA receptor may influence CGRP gene 
expression in the cortical regions in response to CSD. In that case, it is reasonable 
to propose that NR2A may be a mechanism by which the levels of CGRP induced 
by multiple CSD in discrete cortices become elevated for a prolonged period in 
chronic migraine and TBI patients. 
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Figure 1. Schematic diagram of key signaling associated with NMDA receptor in 
terms of both protein and gene levels in multiple diseases. Abbreviations: CaM, 
Calmodulin; CGRP, Calcitonin gene-related peptide; CSD, cortical spreading 
depression; ND2, NADH dehydrogenase subunit 2; NMDA, N-methyl-D-aspartic 
acid; nNOS, neuronal nitric oxide synthase; Panx1, pannexin1; PSD, Postsynaptic 
density protein; SFKs, sarcoma family kinases.  
 
1.4. Overall aim 
The overall aim of this thesis is to understand the migraine pathophysiology by 
investigating whether NR2A-containing NMDA receptor contributes to the 
genesis and propagation of CSD, and its downstream signaling pathways 
involving Panx1 channels opening via activating SFKs, and CGRP gene 
expression. Specific objectives will be introduced in details in the following 
chapters.  
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Chapter 2 Material and methods 
 
2.1 Animals 
All animal procedures were approved by the Ethical Review Panels of Soochow 
University and performed in accordance with the associated guidelines. All efforts 
were made to minimize animal suffering to reduce the number of animals used. In 
vitro experiments were performed on male chicks (n = 14, WuXi Yangzichang Ltd, 
Wuxi, China) with the age of 8-28 days. In vivo experiments were performed on 
male Sprague Dawley rats (n = 85, 322.98 ± 43.08 g, mean ± SD, Shanghai SLAC 
Laboratory Animal Corporation Ltd, Shanghai, China). All animals were housed 
for at least 7 days before use on a 12 h light/dark cycle with food and water 
available ad libitum. 
 
2.2 In vitro experiment 
The chick retina preparation was regarded as an effective in vitro model for my 
study objective, because: (i) CSD waves can be repeatedly induced by K
+
 over 
several hours (Sheardown, 1993, Hanke and de Lima, 2008); (ii) the intrinsic 
optical signal of CSD waves can be observed and recorded (Dahlem and Muller, 
2000, Dahlem et al., 2003, Farkas et al., 2008), and the signal is very similar to 
that from the electrophysiological recording both in vitro and in vivo (Peixoto et 
al., 2001, Farkas et al., 2008); (iii) is appropriated in testing the NMDA receptor 
pharmacology of CSD (Sheardown, 1993, Kertesz et al., 2010), which is found to 
be very similar to that in mammal (Gill et al., 1992, Kertesz et al., 2010); (iv) 
enables several concentrations of chemicals are tested in one preparation, and the 
concentrations at target level are known. 
The CSD model in our setting up is validated as inhibition of NR2A-containing 
receptor by NVP-AAM077 suppressed the magnitude and propagation of CSD in 
concentration-dependent manner in the chick retina (Jia et al., 2015), which is 
quite similar to the previous description (Wang et al., 2012). 
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2.2.1 Surgical preparation 
As previously described (Farkas et al., 2008), chicks were killed by cervical 
dislocation, decapitated, and the left eye dissected rapidly. The eye was cut at the 
equator, the vitreous humour sucked away. The posterior eyecup was placed in a 
tissue chamber and weighed down to keep it submerged in the medium. Unless 
otherwise stated, the chamber was perfused with Ringer’s solution (concentrations 
in mM: 100 NaCl, 6 KCl, 1 MgSO4, 30 NaHCO3, 1 NaH2PO3, 1 CaCl2 and 20 
glucose; bubbled with 95% O2 and 5% CO2; pH 7.3) using a peristaltic pump 
(Minipuls3, Gilson, France). The perfusion rate was 0.5 ml/min and the medium 
volume in the chamber kept constant by a suction pump (BT100-1L, Longer 
Pump Ltd, China). The tissue was allowed to recover by perfusion of Ringer’s 
solution for 30 minutes before inducing the 1
st
 CSD. The temperature was kept at 
32°C by temperature control system (Figure 2).  
 
 
Figure 2. Diagram showing CSD model based on intrinsic optical imaging in 
chick retina. 
 
2.2.2 SD induction 
One CSD was induced as previously described (Wang et al., 2015). Briefly, 1 μl of 
KCl at 0.1 M was topically perfused at the edge of eyecup by 1 second through a 
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30 gauge needle with flat head connected to a 25 μl volume microsyringe 
(Hamilton, Bonaduz, Switzerland) (Figure 3). 
 
 
Figure 3. Representative image (A and C) and plot of CSD propagation wave (B) 
induced by high-K
+
 in the chick retina. The same area of interest (rectangle within 
left picture, AOI) was selected and used for all pictures of the sequence under 
study. All the averaged gray levels within the AOI were plotted against time to 
generate the CSD wave (B). Area under the curve (AUC), height (H), width at half 
height (WHH), maximum slope of depolarization (Sld) and maximum slope of 
repolarization (Slr) of CSD wave were determined to quantify CSD magnitude. 
Propagation rate was calculated as indicated by the distance (D) between two 
CSD wave fronts within the same AOI dividing the time duration to quantify drug 
effect on tissue excitability to CSD. 
 
2.2.3 Intrinsic optical imaging of CSD 
The retina was illuminated for 25 milli-seconds (ms) every 1 Hz using a 
high-power LED spotlight (625 nm peak wavelength, SLS-0307-A, Mightex, 
Pleasanton, USA) and the illumination was driven by a computer-controlled 
power supply (Sirius LED controller, SLC-SA04-U, Mightex, USA). The 
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reflected light was simultaneously recorded with a monochrome camera 
(QIC-F-M-12, Media Cybernetics, UK) used at a maximal spatial resolution. 
Image sequences were taken at 1 Hz over a 3-minute period, started as CSD was 
elicited. Camera exposure and illumination were synchronized using the same 
external trigger (TG5011, TTi, UK). Image Pro Plus 7.0 software was used for 
image acquisition, storage and analysis (Figure 4). 
 
 
Figure 4. Schematic presentation of the electronic devices used for the recording 
of optical imaging of CSD synchronously with external spotlight triggering. 
 
2.2.4 Agents administered and experimental design 
To further validate whether NR2A inhibition could suppress CSD propagation, 
TCN-201 was used at the concentration range selected to NR2A, and two groups 
were designed: (i) TCN-201 at 1, 3 and 9 μM dissolved in 0.01%, 0.03% and 0.1% 
dimethylsulfoxide (DMSO) in respective order (n = 6); (ii) DMSO at 0.01%, 0.03% 
and 0.1% as TCN-201 vehicle control group (n = 8); It should be noted, the 
maximum solubility of TCN-201 was determined to be 9 μM in 0.1% DMSO, the 
maximum concentration in Ringer’s solution without affecting retinal CSD per 
our investigation (Wang et al., 2015). In each experiment, ten CSD episodes were 
induced with 20 minutes interval for recovery. Two separate CSDs was for each of 
the different and consecutive tests: (i) initial Ringer’s control; (ii) low 
concentration of chemical or vehicle; (iii) medium concentration of chemical or 
vehicle; (vi) high concentration of chemical of vehicle; (v) post-treatment with 
Ringer’s control (i.e. drug removal). For each test sequence, the perfusion medium 
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was changed immediately after the end of the 2
nd
, 4
th
, 6
th
, and 8
th
 CSD recording 
when required, such that the preparation was adequately perfused with the proper 
drug or vehicle or Ringer’s medium for the subsequent test (Figure 5).  
 
 
Figure 5. Experimental protocol for investigating the effect of TCN-201 to CSD 
propagation in chick retina. Two groups were designed with DMSO control and 
chemical groups. In each experiment, ten repeated CSDs were induced by high-K
+
 
with 20 minutes recovery. Two separate CSDs were for each of the different and 
consecutive test. Each CSD was recorded for 3 minutes at the start of high-K
+
 
perfusion. Chemicals at 3 different concentrations were applied 40 minutes before 
and during the 4
nd
, 6
rd
 and 8
th
 CSD. 
 
2.2.5 Data presentation and statistical analysis 
As reported previously (Wang et al., 2012), for each 360-frame sequence, an area 
of interest (AOI) parallel to the CSD wave front was delineated manually (Figure 
2.2.2). For each image within the sequence, the gray levels of the pixels 
constituting the AOI were plotted against the time as an indicator to characterize 
CSD. Excel program was used to determine (i) area under the curve (AUC, gray 
levels×minute) of CSD wave; (ii) height (H, changes of gray levels changes of 
gray levels), the differences of gray levels between peak point and midpoint of 
base line of CSD wave; (iii) width at half height (WHH, second); (iv) maximum 
slope of depolarization (Sld, changes of gray levels/minute); (v) maximum slope 
of repolarization (Slr, changes of gray levels/minute). AUC, H, WHH, Sld and Slr 
were used as the index reflecting the magnitude of propagating CSD (Figure 3 B). 
(vi) propagation rate (mm/minute), the velocity of each CSD wave in each CSD 
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episode, calculated as indicated by the distance (D) between two CSD wave fronts 
within the same AOI at the two different time points dividing the time duration to 
quantify drug effect on tissue excitability to CSD (Figure 3 C). The average of 
CSD in each episode was used for quantified analysis. The calculated values 
within each different test were averaged and all corresponding data was given as 
mean ± SD in percentages of their respective baselines. Mann-Whitney test and 
Wilcoxon matched-pairs test were used for data analysis. Differences were 
considered significant when 
*
p < 0.05, 
**
p < 0.01 and 
***
p < 0.001. 
 
2.3 In vivo experiment 
 
2.3.1 Surgical preparation 
Rat was anaesthetised with isoflurane (5% for induction, 2.5-3.5% during the 
surgery, 1-1.5% for maintenance) in O2:N2O (50:100 cc/min), with the animal 
breathing spontaneously. The anaesthetic depth was monitored and adjusted by 
observation of the electroencephalogram (EEG) and state of the animal. The 
suitable anaesthesia was reflected by regular breathing, absence of whisker 
movements, and unresponsive to tail pinches. Rectal temperature of animal was 
maintained at 37C throughout the experiment using temperature control system 
(TC-10, npi, Germany). 
Rat was fixed on stereotaxic apparatus (Model 900, KOPF, USA) after deeply 
anaesthesia. After making an incision in the scalp along sagittal direction and 
blunt separating soft tissues, parietal bone was exposed. Several bur holes were 
drilled on the parietal bone by dental-feinmechanik dental drill (D-3000 hannover 
91, OTTO MUSS) for CSD induction, CSD recording and drugs administration. 
The coordinates would be introduced in the corresponding sections. Unless 
otherwise stated, these bur holes were kept moisture with artificial cerebral spinal 
fluid (ACSF) throughout the experiment. Further experimental procedure was 
carried out at least one hour stabilization after the surgery. 
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2.3.2 Microdialysis-based CSD experiment 
The unique microdialysis probe incorporating a recording electrode (0.25 mm 
external diameter, ME-H1, Applied Neuroscience, UK) was used to investigate 
the effect of NR2A-containing receptor antagonists on CSD genesis (Figure 6). It 
can simultaneously perform the following operations within the same cortical 
region (Obrenovitch et al., 1993): (i) induction of CSD by perfusion of high-K
+ 
medium; (ii) quantitative recording of electrophysiological variables of CSD; (iii) 
local application of chemicals. The co-localized manipulation at the site of CSD 
recording is especially suitable to the pharmacology of CSD genesis. In addition, 
this technique enables several concentrations of chemicals to be applied in one 
preparation. One more important advantage is that allow us to predict the 
concentration of chemicals perfused into the cortex more precisely.  
 
 
Figure 6. Illustration of the experimental strategy relying on the use of 
microdialysis probes incorporating an electrode for elicitation of CSD by high-K
+ 
medium, recoding of CSD and pharmacology study in rat. 
 
2.3.2.1 CSD induction 
The microdialysis probe was implanted into right cortex 1.3-1.4 mm deep from 
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the cortical surface through a bur (0.8 mm inner diameter) at the coordinate of 2 
mm posterior and 2 mm lateral to Bregma (Figure 7) and held on parietal bone by 
acrylic acid dental cement (Shanghai Medical Instruments Co. Ltd., China). 
Unless otherwise stated, the microdialysis probe was perfused with ACSF 
(composition in mM: 125 NaCl, 2.5 KCl, 1.18 MgCl2, 1.26 CaCl2; pH 7.3 
adjusted with 1 M NaOH, not buffered) at 1 µl/minute with a syringe pump 
(CMA100, CMA/Microdialysis, Sweden). For eliciting CSD, a medium 
containing 250 mM K
+
 (composition in mM: 2.5 NaCl, 250 KCl, 1.18 MgCl2, 
1.26 CaCl2; pH 7.3 adjusted with 1 M NaOH, not buffered) was used. It is noted 
that a higher concentration of K
+
 at 250 mM was required to induce CSD (Bu et 
al., 2016) compared to 160 mM employed when halothane was used as the 
anaesthetic (Wang et al., 2003). This difference in K
+
 requirement could be due to 
the anaesthetics (isoflurane vs halothane) having different effects on CSD. Indeed, 
different inhalational anaesthetics have been reported to show slightly different 
degrees of inhibitory effect on CSD (Piper and Lambert, 1996), but this effect can 
be neglected as all experiments carried out under the same anesthetic condition. 
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Figure 7. Schematic representation of electrode implantation sites (A) and 
representative traces in direct current (DC) potential of CSD (B) induced by 
perfusion of 250 mM KCl through the microdialysis probe in the 
isoflurane-anaesthetised rat. CSD wave in the genesis site was recorded through 
the microdialysis probe implanted at 2 mm posterior to Bregma in the right cortex. 
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CSD propagation wave was simultaneously recorded through the Ag/AgCl 
electrode implanted in the ipsilateral cortex at 1.5 mm anterior to Bregma. 
Chemicals were perfused through the microdialysis probe for pharmacology study. 
Area under the curve (AUC, dotted line), height (H), width at half height (WHH), 
maximum slope of depolarization (Sld) and maximum slope of repolarization (Slr) 
of CSD wave were determined to indicate CSD magnitude. CSD latency (L) and 
CSD number were used to assess the susceptibility of the cortex to K
+
 induced 
CSD. Both CSD magnitude and susceptibility of cortex to CSD were used to 
reflect the genesis of CSD. Propagation rate was used to assess the propagation of 
CSD as calculated by the distance dividing by the time delay (D). 
 
2.3.2.2 CSD recording 
The microdialysis probe incorporating a recording electrode was used for 
recording CSD genesis (Figure 7 A). For recording CSD propagation, an Ag/AgCl 
recording electrode (0.1 mm external diameter, Applied Neuroscience, UK) was 
implanted into the ipsilateral cortex 0.9 mm deep from the cortical surface through 
a bur hole (0.8 mm inner diameter) at the coordinate of 1.5 mm anterior and 2 mm 
lateral to Bregma (Figure 7 A) and held by electrode holder (8309003, CMA, 
Sweden). Ag/AgCl reference electrode (Applied Neuroscience, London, UK) was 
placed under the scalp of rat. 
 
2.3.2.3 Agents administered and experimental design 
The following five series of experiment were carried out to examine the effect of 
NR2A-containing receptor antagonists NVP-AAM077 and TCN-201 on CSD 
genesis and propagation. The known non-competitive NMDA receptor antagonist, 
MK-801, was used for model validation (Obrenovitch and Zilkha, 1996a). The 
concentration ranges of chemicals were carefully selected to ensure their 
selectivity for each targeting (Ogden and Traynelis, 2011). These series are: (i) 
ACSF as the NVP-AAM077 and MK-801 vehicle group (n = 6); (ii) MK-801 
(M107, Sigma-Aldrich, n = 6); (iii) NVP-AAM077 (n = 6, synthesized by Yi Li in 
Department of Chemistry, XJTLU, China), a small molecule compound (542.14 
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KDa) that can competitively act on glutamate pocket of NMDA receptors with 10 
to 100-fold selectivity for NR2A over other subunits of NMDA receptors 
(Auberson et al., 2002, Liu et al., 2004, Neyton and Paoletti, 2006); (iv) DMSO at 
0.05%, 0.15% and 0.5% as the TCN-201 vehicle group in respective order (n = 6). 
Our preliminary experiment demonstrated that DMSO at 0.5% is the maximum 
concentration in ACSF without affecting CSD in microdialysis-based CSD model; 
(v) TCN-201 (4154, Tocris, n = 6), a small compound (461.89 KDa) that can 
noncompetitively act on the glycine binding domains of dimer interface of NR1 
and NR2A (Bettini et al., 2010, Ogden and Traynelis, 2011) with 300-fold 
selectivity for NR2A over other subunits of NMDA receptors in transfected HEK 
293T cells (Bettini et al., 2010). It should be noted that the microdialysis probe 
used in this study has 10~20% recovery rate, i.e. the ratio of the drug penetration 
through the semi-permeable membrane of the probe into the cortex relative to its 
original concentration. For instance, an estimation of 5~10 μM of TCN-201 were 
expected to diffuse into the cortical tissue surrounding the implantation site of 
microdialysis probe when the maximum concentration at 50 μM was applied. 
Five consecutive CSD episodes in each experiment for NVP-AAM077 and 
MK-801 testing were elicited by perfusion of K
+
-medium through microdialysis 
probes for 20 minutes followed by 40 minutes ACSF perfusion to allow tissues 
recovery. These episodes were: (i) initial ACSF control; (ii) low concentration of 
the drug or ACSF; (iii) medium concentration of the drug or ACSF; (iv) high 
concentration of the drug or ACSF; (v) post-treatment with ACSF solution. The 
drug at each concentration (0.3, 1, 3 μM for NVP-AAM077 or 3, 10, 30 μM for 
MK-801) was perfused through microdialysis probes for 20 minutes before and 
during K
+
-medium perfusion for the 2
nd
, 3
rd
 and 4
th
 CSD episodes (Figure 8). 
 
 
Figure 8. Experimental protocol for investigating effect of NVP-AAM077 and 
MK-801 to CSD in microdialysis-based CSD model of the rat. Three groups were 
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designed with ACSF control group and two chemicals groups. In each experiment, 
5 repeated CSD episodes were induced by K
+
-medium for 20 minutes, each 
followed by 40-minutes recovery. Chemicals at 3 different concentrations (L, M 
and H) were applied 20 minutes before and during the 2
nd
, 3
rd
 and 4
th
 episodes. 
 
For testing the effect of TCN-201 on CSD genesis, the 5
th
 episode, i.e. the effect 
of post-treatment with ACSF to CSD, was not performed given the 
non-competitive character of drug. TCN-201 (5, 15, 50 μM) at each concentration 
was perfused through microdialysis probes for 40 minutes before and 20 minutes 
during K
+
-medium perfusion for the 2
nd
, 3
rd
 and 4
th
 CSD episodes (Figure 9). My 
preliminary study showed that the concentration of 50μM is the maximal 
solubility of TCN-201 in 0.5% DMSO. 
 
 
Figure 9. Experimental protocol for investigating effect of TCN-201 to CSD in 
microdialysis-based CSD model of the rat. Two groups were designed with 
DMSO control and chemical groups. In each experiment, 4 repeated CSD 
episodes were induced by K
+
-medium for 20 minutes, each followed by 
40-minutes recovery. Drugs at 3 different concentrations (L, M and H) were 
applied 40 minutes before and 20 minutes during the 2
nd
, 3
rd
 and 4
th
 CSD 
episodes. 
 
2.3.3 Intracerebroventricular perfusion experiment 
 
2.3.3.1 CSD induction 
CSD was induced by 1 μl of KCl at 3 M topically perfused onto cortical surface 
with dura intact for 5 minutes through a bur hole (1 mm inner diameter) on right 
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parietal bone at 5 mm posterior and 2 mm lateral to Bregma (Figure 10 A and C). 
This 5-minute duration of KCl was perfused so that one CSD wave could be 
elicited under the experimental condition with dura intact and anesthetics applied 
(Yan Wang, 2016). After CSD induction, the high-K
+
 was quickly replaced by 
ACSF, allowed quick recovery of the tissue. 
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Figure 10. Schematic representation of electrode implantation sites (A and C) and 
representative traces in DC potential of CSD (B) induced by 3 M KCl through 
topical application in the anaesthetised rat. (A and C) In the i.c.v. based 
experiments, CSD was induced by topical application of high-K
+ 
onto the cortical 
surface with dura intact at 5 mm posterior to Bregma of right parietal bone. CSD 
propagation wave was recorded at different coordinates of ipsilateral cortical side 
in separated sets of experiment: (i) at 3 mm anterior to Bregma for following 
investigation of protein and gene expression (A); (ii) at 0.4 mm anterior to 
Bregma for following investigation of effect of PP2 to CSD-induced Panx1 
opening using immunohistochemistry (IHC) (C); (iii) at 2 mm posterior plus 0.4 
mm anterior to Bregma for following investigation of effect of NVP-AAM077 to 
CSD-induced Panx1 channels opening using IHC (C). The chemicals were i.c.v. 
perfused into contralateral ventricle through a cannula implanted (A and C). Area 
under the curve (AUC, dotted line), height (H), width at half height (WHH), 
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maximum slope of depolarization (Sld) and maximum slope of repolarization (Slr) 
of CSD wave were determined to indicate CSD magnitude. CSD latency (L) was 
indicated as the time difference between the start of high-K
+
 topical application 
and the start of depolarization of the 1
st
 CSD wave. L and CSD number were used 
to assess the susceptibility of the cortex to CSD. CSD propagation rate was used 
to assess the propagation of CSD as calculated by the distance dividing the time 
delay (D). 
 
2.3.3.2 Agents administered 
To ensure chemicals diffusing to distant cortical layers with predictable 
concentrations, a set of in vivo experiment by perfusion of chemicals into the 
contralateral ventricle was designed. A stainless steel cannula (inner diameter: 
0.38 mm, 62002, RWD Life Science, China) was implanted into contralateral 
ventricle 3.5 mm deep from the cortical surface trough a bur hole (1 mm inner 
diameter) at 0.8 mm posterior and 1.8 mm lateral to Bregma and held in place by 
holder (Figure 10 A and C). A matched stainless steel inner pipe (62202, RWD 
Life Science, China) connecting to a 25 μl volume microsyringe via PE tubing 
(62302, RWD Life Science, China) was inserted into lateral ventricle through 
cannula for i.c.v. perfusion. A syringe pump was used to deliver precise 
micro-perfusion.  
NVP-AAM077 
For selective inhibition of NR2A, NVP-AAM077 at 30 μM in ACSF was i.c.v. 
perfused at 1 μl/minute for 10 minutes. In this case, total 0.3 nmol NVP-AAM077 
was perfused into cerebral ventricle. 
PP2 
For selective inhibition of SFKs, PP2, a small-molecule modulator that directly 
bind to the catalytic domain of SFKs and thereby block phosphoryl transfer 
(Salter and Kalia, 2004), at 500 μM in 50% DMSO was i.c.v. perfused at 0.5 
μl/minute for 10 minutes. In this case, total 2.5 nmol PP2 was perfused into 
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cerebral ventricle. PP3, the inactive analog of PP2 was used as negative control. 
The amount of drugs were applied by referencing that only 1/100-1/200 of insulin 
could diffuse into contralateral cortex 30-120 minutes after i.c.v. perfusion 
(Proescholdt et al., 2000), and at the resulting estimated concentration, 
NVP-AAM077 and PP2 in cortical tissue is selective for NR2A (Bu et al., 2016) 
and SFKs (Bain et al., 2003) respectively. 
Propidium iodide 
Propidium iodide (PI) is a membrane-impermeable fluoroprobe with a molecular 
mass of 668.4 Da; it may pass through megachannels and fluoresces in a way by 
interacting with nucleic acids (Thompson et al., 2006). It is known that single or 
multiple CSD can induce PI staining in neurons in mice (Yildirim et al., 2015), 
which can be prevented by Panx1 inhibitors carbenoxolone, probenecid, 
10
Panx or 
siRNA. In addition, PI staining is not anesthetic-specific, e.g. isoflurane 
anesthesia, which also inhibits gap junctions, did not significantly affect PI 
labeling (Karatas et al., 2013), suggesting that PI is appropriate for indicating 
CSD-induced Panx1 channels opening in our preparation. 
Previously, it was demonstrated that neuronal PI uptake reached maximum 5 
minutes after CSD in ipsilateral cortex if contralateral i.c.v. perfusion of 0.5 μg PI 
2 minutes before CSD induction in mice (Karatas et al., 2013). Similar with the 
previous study, 5 minutes before CSD induction, total 2 μg PI (1 mg/ml) or ACSF 
(vehicle control) was i.c.v. perfused at 0.5 μl/minute for 4 minutes, to indicate the 
CSD-induced Panx1 opening in our experiment. The heart of rat was then 
perfused by 4% paraformaldehyde fixative (PFA) 5 minutes after CSD induction. 
Signs indicative of successful i.c.v. perfusion included: (i) needle track connecting 
to cerebral ventricle; (ii) wide diffusion of PI in ventricle in the case of PI was 
applied in experiment (Figure 11). 
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Figure 11. Histological verification of successful i.c.v. perfusion. The 
representative diagram shows coronal section at 0.8 mm posterior to Bregma. Red 
track shows the position of cannula implantation for i.c.v. perfusion. The dissolved 
PI by cerebrospinal fluid in ventricle shows in red. 
 
2.3.3.3 CSD recording by Ag/AgCl electrodes 
One or two Ag/AgCl recording electrode(s) were implanted into the ipsilateral 
cortex (0.9 mm deep from the cortical surface) through bur holes (0.8 mm inner 
diameter) drilled on parietal bone and held by electrode holders at different 
coordinates for CSD recording. The coordinates are: (i) for electrophysiological 
experiments followed by western blot and qPCR, one electrode was implanted at 
2 mm lateral and 3 mm anterior to Bregma (Figure 10 A); (ii) for investigating the 
effect of NVP-AAM077 on CSD propagation and CSD-induced Panx1 channels 
opening, two electrodes were implanted at both 0.4 mm anterior and 2 mm 
posterior, and 2 mm lateral to Bregma (Figure 10 C); (iii) for investigating the 
effect of PP2 on CSD propagation and CSD-induced Panx1 channels opening, 
only one electrode was implanted at 2 mm lateral and 0.4 mm anterior to Bregma 
(Figure 10 C). Ag/AgCl reference electrode was placed under the scalp of rat. 
 
2.3.3.4 Experimental design 
Six series experiments were designed: 
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Series 1: In order to investigate whether NR2A inhibition could suppress CSD 
propagation and CSD-induced Panx1 channels opening, overall two CSD episodes 
were elicited at 40-minute intervals and three groups were designed: (i) 
NVP-AAM077 was administrated immediately after the 1
st
 CSD episode (n = 6); 
(ii) CSD group (n = 7), and (iii) sham group in the absence of high-K
+
 application 
(n = 6). ACSF but not NVP-AAM077 was used in CSD and sham groups. PI was 
administrated 5 minutes before the 2
nd
 CSD episode in all groups. Rat heart was 
perfused immediately 5 minutes after the 2
nd
 CSD episode for 
immunohistochemistry (IHC) experiment in order to make sure that the ipsilateral 
cortex is invaded by CSD (de Lima et al., 2009) (Figure 12). 
 
 
Figure 12. Experimental protocol for investigating whether i.c.v. perfusion of 
NVP-AAM077 suppresses CSD propagation and CSD-induced Panx1 channels 
opening in the rats. Two repeated CSD episodes were induced by topical 
application of high-K
+
 for 5 minutes with 40-minutes interval for drug and control 
groups, whereas in the absence of CSD was carried out as sham in each 
experiment. 10 μl NVP-AAM077 at 30 μM (ACSF as control) was i.c.v. perfused 
30 minutes before the 2
nd
 CSD episode in drug group. 2 μ PI (1mg/ml) was i.c.v. 
perfused 5 minutes before the 2
nd
 CSD episode in all groups.  
 
The previous study showed that PI update was returned in 30 minutes after CSD 
in ipsilateral cortex, compared with the group without CSD elicitation in mice 
(Karatas et al., 2013), suggesting that the Panx1 activation induced by the 1
st
 CSD 
episode would not influence the subsequent PI uptake induced by the 2
nd
 CSD 
episode in our preparation. 
In order to minimize animal use, 5 rats from CSD group and 6 rats from the sham 
group were also used for series 4 (see below). 
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Series 2: In order to detect whether CSD could induce SFKs phosphorylation at 
Y416 amino acid, and that CSD propagation and SFKs phosphorylation could be 
prevented by SFKs inhibitor, one CSD episode was elicited and four groups were 
designed: (i) SFKs selective inhibitor, PP2 was i.c.v. perfused starting from 120 
minutes before CSD induction (n = 6); (ii) PP3 was administrated as the negative 
control (n = 6); (iii) ACSF was perfused in the CSD control group (n = 5); (iv) 
ACSF was applied in the absence of CSD induction in the sham group (n = 3). 
Cortical tissue was rapidly dissected 5 minutes after CSD induction for western 
blot (Figure 13). 
 
 
Figure 13. Experimental protocol for investigating the effect of PP2 and 
NVP-AAM077 on CSD propagation and CSD-induced protein expression. In each 
experiment, 5 μl PP2 (500 μM) or 10 μl NVP-AAM077 (30 μM) was i.c.v. 
perfused 120 before topical application of high-K
+
. ACSF (as control for 
NVP-AAM077) or PP3 (as control for PP2) was perfused into contralateral 
ventricle was carried out in control group. I.c.v. perfusion of ACSF without topical 
application of high-K
+
 was applied in sham group. 
 
In order to minimize animal use, some rats from this series were also used for 
series 3-5 (see below): 3 rats from the sham group and 3 from CSD group were 
used for subsequent cortex dissection in series 4. Three rats from PP3 and 3 from 
PP2 groups were used for subsequent animal perfusion, followed by IHC in series 
5. All 5 rats in the CSD group and 3 rats in the sham group were also used for 
series 3. 
Series 3: In order to examine whether NR2A inhibition could suppress both 
CSD-induced SFKs activation and CSD-induced interaction of SFKs and Panx1, 
three groups were designed with the protocol kept the same as that in series 2 
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except that NVP-AAM077 (n = 5), but not PP2 or PP3, was administrated. ACSF 
was perfused in the presence of high-K
+
 as the CSD group and in absence of 
high-K
+
 in the sham group (Figure 13). 
It needs to mention that as the preliminary study showed that there was no 
difference in CSD induction and Panx1 channels opening between two different 
perfusion rate of ACSF at 0.5 μl/minute and 1 μl/minute, the sham and CSD 
groups from series 1 was therefore used in this series in order to minimize the 
animal use. 
Series 4: In order to test whether CSD could induce Panx1 expression, two groups 
were considered: (i) CSD group; (ii) sham group (Figure 13). 
Series 5: In order to examine whether SFK inhibition could suppress 
CSD-induced Panx1 opening, four groups were designed. The protocol was the 
same as that in series 1 except that both PP2 and PP3, but not NVP-AAM077, 
were applied respectively starting from 120 minutes before CSD induction to 
allow drugs sufficiently entering into the cell (Figure 14). 
 
 
Figure 14. Experimental protocol for investigating whether i.c.v. perfusion of PP2 
could suppress CSD propagation and CSD-induced Panx1 channels opening in 
rats. One CSD episode was induced by topical application of high-K
+
 for 5 
minutes in drug and control groups, whereas in the absence of high-K
+
 was 
carried out as sham in each experiment. 5 μl PP2 at 500 μM (PP3 as control) was 
i.c.v. perfused 120 before CSD induction. 2 μ PI (1mg/ml) was i.c.v. perfused 5 
minutes before CSD induction in all groups.  
 
Series 6: In order to examine whether NR2A inhibition could suppress 
CSD-induced CGRP gene expression, 5 repeated CSD episodes with 40-minutes 
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interval were induced and three groups were designed: (i) NVP-AAM077 group 
(n = 5). NVP-AAM077 was administrated before the 1
st
 high-K
+
 application. (ii) 
CSD group (n = 3) and (iii) sham group in the absence of high-K
+
 application (n 
= 3). ACSF but not NVP-AAM077 was applied in CSD and sham groups (Figure 
15). The electrode was removed and wound sutured 5 minutes after the 5
th
 CSD 
episode. Ibuprofen (5-10 mg) and mupirocin ointment (0.4-0.8 mg) were applied 
on the wound. 24 hours after the 5
th
 CSD episode, rat was re-anaesthetized and 
ipsilateral motor, somatosensory and visual cortices were dissected and store at 
-80℃. 
 
 
Figure 15. Experimental protocol for investigating the effect of NVP-AAM077 
on CSD-induced CGRP mRNA expression in rats. Five repeated CSD episodes 
were induced by high-K
+
 for 1 minute with 40-minutes interval in drug and 
control groups, whereas in the absence of high-K
+
 was performed as sham. 10 μl 
NVP-AAM077 (30 μM) were i.c.v. perfused immediately before the 1
st
 high-K
+
 
application. ACSF but not NVP-AAM077 was applied in control and sham 
groups. 
 
2.3.4 Electronic devices setup 
Both EEG and direct current (DC) potential were derived from the potential 
between the recording electrode (the electrode built into the microdialysis probe in 
microdialysis experiment or the anterior Ag/AgCl recording electrode in i.c.v. 
experiment) and the Ag/AgCl reference electrode (Obrenovitch et al., 1993). 
As reported previously (Wang et al., 2003), EEG and DC signals were first 
amplified with a high-impedance input, AC/DC pre-amplifier (NL834, Neurolog 
System, Digitimer Ltd., UK). The alternating current component in the 1-30 Hz 
window provided the EEG (overall ×5000 amplification) and the 0-30 Hz window 
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provided the extracellular DC potential (overall ×250 amplification). The recorded 
EEG variables were monitored by a digital oscilloscope (DS1000B, RIGOL, 
China). All the recorded variables were continuously digitised, displayed and 
recorded by a computer using Labview 11.0 via an analogue/digital-converter 
(USB6009, NI Instruments, USA) during experiment (Figure 16). 
 
 
Figure 16. Schematic presentation of the electronic devices used for the recording 
of DC and EEG activity with microdialysis probe and Ag/AgCl electrode. 
Pre-amplifier (PREAMP), AC (alternating current), DC (direct current). 
 
In the microdialysis-based experiment, the spreading depolarization wave of CSD 
at the induction site was recognized as a transient, negative shift superimposed on 
the sustained shift resulting from the imposed high extracellular K
+
 concentration 
(Figure 7 B). The spreading depolarization wave of CSD at the propagation site 
was recognized by a transient, negative shift but in the absence of the sustained 
depolarization shift (Figure 7 B and Figure 10 B). 
 
2.3.5 Data presentation and statistical analysis 
Details on CSD number, latency, area under the curve (AUC), height (H), width at 
half height (WHH), maximum slope of depolarization (Sld), maximum slope of 
repolarization (Slr), and propagation rate were quantified as that described 
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previously (Bu et al., 2016, Wang et al., 2003). Labview program was used to 
determine (i) CSD number in each episode; (ii) Latency (minute), the time 
required to elicit the 1
st
 CSD wave from the start of depolarization induced by 
K
+
-medium through microdialysis probe or from the start of topical perfusion of 
K
+ 
on cortical surface. CSD number and latency were used to reflect tissue 
susceptibility to CSD; (iii) AUC (mV × minutes); (iv) H (mV), the distance 
between peak point and midpoint of base line of curve; (v) WHH (second); (vi) 
Sld (mV/minute); (vii) Slr (mV/minute). AUC, H, WHH, Sld and Slr were used to 
reflect the magnitude of CSD waves. Both tissue susceptibility to CSD and CSD 
magnitude were accessed to reflect the genesis of CSD. (viii) Propagation rate 
(mm/minute), the velocity of each CSD wave, to reflect the propagation of CSD 
(Figure 7 B and Figure 10 B). In the case of CSD wave was completely abolished 
by chemicals, the latency was counted as 20 minutes if K
+
-medium perfused 
through microdialysis probe or 10 minutes if K
+
 perfused onto cortical surface; 
AUC, H, WHH, Sld, Slr and propagation rate were counted as zero when CSD 
waves were abolished; The average of each CSD parameter in each episode was 
used for quantified analysis. 
All values were given in mean ± SEM. Unpaired t-test, paired t-test, and One-way 
ANOVA with subsequent Bonferonni test were used for data analysis if data obeys 
normal distribution. The significant difference was showed as 
*
p < 0.05, 
**
p < 0.01 
and 
***
p < 0.001. 
 
2.4 Immunohistochemistry analysis of protein changes 
 
2.4.1 Sample preparation 
CSD-induced Panx1 channels opening under SFKs or NR2A inhibition was 
detected using IHC. After being deeply anesthetized with 5% isoflurane in N2O 
(150 cc/min), rats were transcardially perfused by sodium phosphate buffer (PBS) 
(09-8912-100, Medicago) for 20 minutes at 8 ml/minute, followed by 4% PFA in 
PBS for 10 min at 4 ml/min using peristaltic pump (FH-100, Thermo Scientific). 
Brain was quickly removed, and post-fixed in 4% PFA overnight followed by 
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cryoprotected in 30% (w/v) sucrose solution for 48 hours. 20 μm thick coronal 
sections close to coordinates (0.4 mm anterior to Bregma), where motor, 
somatosensory and cingulate cortices could be seen, were cut in cryostat 
(CM1950, Leica) and stored in -80C.  
 
2.4.2 Immunohistochemistry 
In order to label neurons, brain slices were incubated with NeuN monoclonal 
antibody (anti-mouse, #MAB377, Millipore) (Wolf et al., 1996). Briefly, slices 
were incubated in 0.3% Trition ×100 in PBS for permeabilization for 30 minutes 
at room temperature (RT) and blocked with 5% goat serum (AR0009, Boster 
Biology, China) in PBS for 1 hour to reduce non-specific binding. Sections were 
then exposed to the NeuN antibody at 1:1000 incubation with blocking solution 
overnight at 4℃, followed by a fluorescently-labeled (488) secondary antibody 
(A11029, Invitrogen) at 1:500 in blocking solution for 1 hour at RT. 
Immuno-negative control was performed by staining of NeuN antibody in rat 
purkinje cells (Wolf et al., 1996). Additionally, the secondary antibody only was 
performed for further confirming the specificity of NeuN antibody. 
 
2.4.3 Data presentation and statistical analysis 
NeuN at 488 nm and PI staining at 535 nm were detected under the fluorescence 
microscope (Eclipse Ni-U, Nikon). Labeled cells were counted on one 
microscopic field at 400 × magnification on 2 neighboring coronal sections from 
each ipsilateral cortex of the rat. The differential cortical layers were positioned 
under the guidance of anatomical microstructure of rat neocortex (DeFelipe et al., 
2002) (Figure 35 A). The number of labeled cells in the selected fields was 
averaged by one blinded observer for subsequent data analysis. All values were 
given in mean ± SEM. Unpaired t-test was used for data analysis if data obeys 
normal distribution. Mann-Whitney test was used for data analysis if data obeys 
abnormal distribution. Differences were considered significant when 
*
p < 0.05, 
**
p 
< 0.01 and 
***
p < 0.001. 
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2.5 Western blotting analysis of protein changes 
 
2.5.1 Protein preparation 
The CSD ipsilateral cortex without PI staining was homogenized in the presence 
of protease inhibitor (Complete EASYpacks, 04693116001, Roche) and 
phosphatase inhibitor (#5870, CST) using a tissue ruptor (9001272, GIAGEN) on 
ice for subsequent detection of SFKs phosphorylation. Total protein was harvested 
from supernatant after tissue lysate was centrifuged at 13,000 rpm for 10 minutes 
at 4℃. Protein concentrations were determined using Bicinchoninic acid Protein 
Assay Kit (P0010, Beyotime). 
 
2.5.2 Western blotting 
Protein (30 μg for Panx1, 80 μg for PY416 SFKs, SFKs and β-actin) were 
denatured with 4×NuPAGE
®
 LDS Sample Buffer (NP0007, Invitrogen) and 2% 
SDS by boiling for 5 minutes, then separated on a 10% sodium dodecyl sulfate–
polyacrylamide gel, subsequently transferred onto nitrocellulose membranes 
(66485, Pall Corporation). Non-specific binding was blocked with 5% milk in 
tris-buffered saline with Tween-20 (TBST) for 1 hour at RT.  
In order to detect the expression of Panx1 (~45 kDa), membranes were incubated 
with Panx1 monoclonal antibody (anti-rabbit, LS-C138631, LSBio) at 1:30000 
overnight at 4℃. Once excess primary antibody was washed off by TBST, 
membranes were incubated with heavy+light chains horseradish 
peroxidase-labeled secondary antibody (AB10058, Sangon Biotech) at 1:5000 for 
1 hour at RT. Protein bands were detected by Western bright enhanced 
chemiluminuscence working solution (K-12045-D50, Advansta) and exposed on 
Kodak medical X-ray film (XBT-1, Kodak).  
β-actin (~45 kDa), was detected as the reference (Wang et al., 2016a) after that the 
nitrocellulose membrane stripped by 0.2 M NaOH for 15 minutes at 37℃. 
Stripping was to avoid any interruption from Panx1 as they have similar 
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molecular weight. The membrane was then washed out using TBST and the same 
process was repeated starting from non-specific binding blocking by 5% milk 
except that β-actin monoclonal antibody (anti-rabbit, #4970, CST) at 1:1000, but 
not Panx1 antibody was used.  
In order to detect the level of SFKs (~ 60 kDa) phosphorylation post CSD and 
effects of SFKs or NR2A inhibition on CSD-induced SFKs activity, membranes 
were divided into two parts for detecting PY416 SFKs, a strong indicator of SFKs 
activation (Smart et al., 1981), and β-actin respectively. After non-specific binding 
blocking, membranes were incubated with the PY416 SFKs (anti-rabbit, #6943, 
CST, for detecting effect of PP2 on CSD-induced SFKs phosphorylation; 
anti-rabbit, #2101, CST, for detecting effect of NVP-AAM077 on CSD-induced 
SFKs phosphorylation) antibody at 1:500 and β-actin antibody at 1:1000 
overnight at 4℃ respectively. The same process for incubation of secondary 
antibody and detection of chemilluminescence were performed as that for Panx1 
detection. Additionally, total SFKs was also detected by repeating the same 
process starting from membranes stripping except that SFKs monoclonal antibody 
(anti-rabbit, #2109, CST) but not β-actin antibody was used. The specificity of 
primary antibodies was examined in full gels before formal experiments. The 
secondary antibody only was performed for further confirmation. The stripping 
process followed secondary antibody only was performed to test whether previous 
primary antibody was stripped clearly. 
 
2.5.3 Co-immunoprecipitation 
In order to examine interaction of PY416 SFKs and Panx1 in the cortex, 
co-immunoprecipitation (co-IP) was performed using Pierce Classic IP Kit (26146, 
Thermo Fisher). Briefly, 300 μg protein was pre-cleaned by 20 μl control agarose 
resin, eluted at 1000 ×g for 1 minute, then incubated with 100 μl buffer of 0.02 μg 
Panx1 antibody and 10 μl A/G protein agarose resin for 2 hours at 4℃. The bound 
resin was separated from the mixture at 1000 ×g for 1 minute and washed in IP 
Lysis/Wash buffer following three times centrifugation at 1000 ×g prior to western 
blotting. Nitrocellulose membrane was then incubated with PY416 SFKs 
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monoclonal antibody (anti-rabbit, #6943, CST) at 1:500 followed by light chain 
only horseradish peroxidase-labeled secondary antibody (D110059, Sangon 
Biotech) at 1:5000 for SFKs detection. After stripping, Panx1 was detected by 
incubation with Panx1 antibody at 1:30000 as that described above except that 
light chain only but not light+heavy chains secondary antibody was used. Western 
blotting without IP’d purification was performed as the positive control. Control 
agarose resin that would not interact with primary antibody was used as the 
negative control for IP’d purification. 
 
2.5.4 Data presentation and statistical analysis 
The grey value of signal was quantified using Image J software and normalized to 
β-actin for data comparison. The values were given in percentages of basal level, 
i.e. the averaged value of sham group. All values were given in mean ± SEM. 
Unpaired t-test was used for data analysis if data obeys normal distribution. 
Mann-Whitney test was used for data analysis if data obeys abnormal distribution. 
Differences were considered significant when 
*
p < 0.05 and 
**
p < 0.01. 
 
2.6 Gene expression 
 
2.6.1 RNA extraction 
Trizol reagent (T9424, Sigma-Aldrich) was used to extract mRNA following the 
manufacturer’s instruction. Briefly, 50-100 mg tissue was homogenized in 1 ml 
Trizol reagent and 200 μl chloroform and, shook vigorously for 15 seconds. After 8 
minutes incubation at RT, samples were centrifuged at 12000×g for 15 minutes at 
4℃, separating phase into three layers: (i) RNA-containing colorless aqueous 
upper layer; (ii) a thin middle interphase layer and (iii) a bottom 
DNA-and-protein-containing red organic layer. The upper layer was carefully 
transferred into a new microfuge tube. 500 μl of isopropanol was added per 1 ml of 
Trizol reagent. Stand for 8 minutes and then centrifuge at 12000 ×g for 10 minutes 
at 4℃. After discarding the supernatant, RNA pellet was washed by 1 ml 75% 
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molecular grade ethanol (per 1 ml Trizol used in the initial step). Samples were 
centrifuged at 7500 ×g for 5 minutes at 4℃. The supernatant was discarded and 
the RNA pellet was air dried at room temperature. Finally, the RNA pellet was 
re-suspended in 10-40 μl nuclease free water and incubated on a heat block at 55℃ 
for 10 minutes. After complete dissolution, RNA concentration was measured by 
Nanodrop for later cDNA synthesis. 
RNA concentration was measured by Nanodrop 2000c (Thermo Scientific). The 
sample reader was washed with nuclease free water and dried with KimWipe. 
Following the instruction of the software, the Nanodrop was set to RNA. 1 μl of 
elution nuclease free water was loaded and set as blank. 1 μl of sample was loaded 
and the absorbance measured. The absorbance of UV light by nucleic acid at 260 
nm depends on their concentration. After reading completion, the RNA 
concentration in ng/μl was obtained. The quality of the RNA was also assessed by 
the Nanodrop through measuring the ratios of A260/A280 and A260/A230; 
expected values for high RNA purity are approximately 2.0 and 2.0-2.2, 
respectively. 
 
2.6.2 cDNA preparation 
The GoScript Reverse Transcription System (A5001, Promega) was used for first 
strand cDNA synthesis from total RNA following the manufacturer’s protocol. 
Briefly, 1μg RNA was used for each sample in the reverse transcriptase reaction, 
mixed in a PCR tube with the following components (Table 1): 
 
Component Volume 
RNA (up to 1 μg) x μl 
Random primers (0.5 μg/reaction) 1 μl 
Oligo(dT)15 Primers (0.5 μg/reaction) 1 μl 
Nuclease free water x μl 
Final volume 5 μl 
Table 1. Reagents components for reverse transcription step one. 
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The mixture was incubated at 70℃ for 5 minutes, immediately cooled down on 
ice, and added the following reverse transcription mix (Table 2) to a final 20 μl 
reaction volume. 
 
Component Volume Final concentration 
GoScript 5X reaction buffer 4 μl 1x 
MgCl2 (25 mM) 4 μl 5 mM 
PCR nucleotide mix (10 mM of each 
dNTP) 
1 μl 0.5 mM 
Recombinant RNasin Rinonuclease 
inhibitor (40 U/μl) 
0.5 μl 1 U/μl 
GoScript Reverse Transcriptase 1 μl - 
Nuclease free water 4.5 μl - 
Final volume 15 μl 
 
Table 2. Reagents components for reverse transcription step two. 
 
The final reaction mixture was incubated as following: at 25℃ for 5 minutes for 
primer annealing; at 42℃ for 60 minutes for extension; finally at 70℃ for 15 
minutes to inactivate the reverse transcriptase. The cDNA was stored at -20℃ for 
later use. 
 
2.6.3 Real-time quantitative PCR detecting system (qPCR) 
QPCR was used to detect gene expression of CGRP. Two housekeeping genes, 
peptidylprolyl isomerase A (PPIA) and ACTB, rather than a single housekeeping 
gene were used in this study as reference for reliable result. Primers (forward, 
reverse) were: PPIA (NM_017101.1) 5’TTGCTGCAGACATGGTCAAC3’, 
5’TGTCTGCAAACAGCTCGAAG3’; ACTB (NM_001101.3) 
5’ACGGTCAGGTCATCACTATGG3’, 5’AGCCACCAATCCACACAG3’; and 
CGRP: (NM_001033953.2) 5’AACCTTGGAAAGCAGCCCAGGCATG3’, 
5’GTGGGCACAAAGTTGTCCTTCACCA3’. QPCR was performed using 
GoTaq qPCR Master Mix (Promega) following the manufacturer’s instruction. 
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The reaction component (Table 3) is: 
 
Component  Volume (n=1) Final concentration 
2× GoTaq qPCR Master Mix 10 μl 0.025 U/μl 
cDNA template ×μl - 
Forward primer 0.3 μl 0.33 μM 
Reverse primer 0.3 μl 0.33 μM 
Nuclease free water  X μl - 
Final volume 20 μl   
Table 3. Reagents component for qPCR. 
 
Analysis was performed on 7500 fast Real-Time PCR system (Applied 
BiosystemsTM Waltham, MA, USA) with the following thermal cycling 
conditions (Table 4): 
 
   Cycling Program Cycles 
Hot-start Activation 95°C for 2 min 1 
Denaturation 95°C for 15 s 
40 
Anealing/Extension 60°C for 1 min  
Dissociation 60-95°C  1 
Table 4. QPCR running setting up. 
 
2.6.4 Data presentation and statistical analysis  
Samples were analyzed by the relative fold change (2
-∆∆Ct
 method) normalized to 
the ipsilateral sham tissue. In detail, the individual CGRP mRNA levels were 
normalized to the product-based geometric mean of the two reference genes 
(Vandesompele et al., 2002), calculated as the square-root of the product of the 
reference genes (PPIA × ACTB), i.e.  
①   Individual CGRP mRNA levels = 2−△Ct(CGRP)√Ct(PPIA)∗Ct(β−actin) 
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In the next step, the individual CGRP fold change was obtained from dividing ① 
by the average of ① of sham samples, i.e.  
CGRP fold change = 2−△(individual)△(average)Ct 
Formula 2.6.4. 2
-∆∆Ct
 method for calculating relative gene expression. 
Mann-Whitney test was used for data analysis. Differences were considered 
significant when 
*
p < 0.05. 
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Chapter 3 NR2A contributes to CSD genesis and propagation in rats 
 
The previous study shows that NR2A inhibition by NVP-AAM077 suppresses the 
propagation of CSD in the chick retina (Wang et al., 2012). However, an opposite 
opinion showed that NR2A antagonist TCN-201 applied through intraperitoneal 
injection don’t alter the BOLD accompanied with CSD in rats (Shatillo et al., 
2015). To further investigate whether NR2A could contribute CSD propagation, I 
examined the effect of bath application of TCN-201 on CSD propagation in chick 
retina. In addition, I explored whether NR2A inhibition by NVP-AAM077 and 
TCN-201 could suppress CSD genesis and propagation in microdialysis-based 
CSD model in rats. Finally, the involvement of NR2A in CSD propagation was 
further determined by i.c.v. perfusion of NVP-AAM077 in rats.  
 
3.1 Objectives 
3.1.1 To investigate whether NR2A inhibition could suppress CSD propagation 
in chick retina 
3.1.2 To validate microdialysis-based CSD model under isoflurane anaesthesia 
in rats 
3.1.3 To investigate whether NR2A inhibition could suppress CSD genesis in 
microdialysis-based CSD model 
3.1.4 To investigate whether NR2A inhibition could suppress CSD propagation 
in microdialysis-based CSD model 
3.1.5 To investigate whether i.c.v. perfusion of NR2A antagonist could suppress 
CSD propagation in rats 
 
3.2 Results 
3.2.1 TCN-201 suppressed CSD propagation in chick retina 
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In the DMSO group, the AUC, H, WHH, Sld, Slr and propagation rate of CSD 
had no significant change throughout the experiment (n = 8, Figure 17). 
Compared with the control group, TCN-201 suppressed AUC, WHH, Sld and 
propagation rate and increased Slr of CSD in a concentration-dependent manner. 
At the maximum concentration tested (9 μM), the AUC, WHH, Sld and 
propagation rate were significantly reduced to 73.8% (n = 6, 
***
p < 0.001, Figure 
17 A), 76.10% (n = 6, 
***
p < 0.001, Figure 17 C), 79.91% (n = 6, 
**
p < 0.01, 
Figure 17 D) and 72.77±4.09 (n = 6, 
***
p < 0.001, Figure 17 F) of initial level in 
respective order, meanwhile Slr was increased to 124.30% (n = 6, 
*
p < 0.05, 
Figure 17 E) of initial level in respective order. This inhibitory effect slightly but 
not significantly recovered after drug removal. H was not altered at any 
concentration of drug we tested (n = 6, Figure 17 B). 
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Figure 17. Effects of TCN-201 on the magnitude (A-E) and propagation rate (F) 
of CSD induced by high-K
+
 in the chick retina. Data was plotted as percentage of 
their initial levels and indicated as mean ± SD. Mann-Whitney test with two-tailed 
calculation was used for significance between DMSO (n = 8) and TCN-201 (n = 6) 
groups (
*
p < 0.05, 
**
p ≤ 0.01, 
***
p ≤ 0.001). Wilcoxon matched pairs test with 
two-tailed calculation was used to test whether tissue was restored after drug 
removal. 
 
3.2.2 Validation of microdialysis-based CSD model under isoflurane anaesthesia 
in rats. 
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In the control group, 250 mM K
+
 induced CSD was recorded at genesis site 
throughout experiment (ACSF, Figure 18). The average number, latency and the 
magnitude of the 1
st
 CSD episode were 3.0 ± 0.86 (n = 6, Figure 19 A), 6.53 ± 
1.93 minutes (n = 6, 19 B) and 4.95 ± 1.06 mV × minute (n = 6, Figure 20 A) in 
respective order. No significant difference in any parameter was observed over the 
5 CSD episodes. 
To validate the CSD model under anesthesia with isoflurane, the NMDA receptor 
antagonist, MK-801, with known anti-CSD effect (Obrenovitch and Zilkha, 1996a, 
Marrannes et al., 1988, Wang et al., 2012), was examined through the 
microdialysis probe. At CSD genesis site, the CSD number, latency and 
magnitude had no difference in the 1
st
 episode compared to the control (ACSF) 
group (Figure 19 A and B, Figure 20 A). MK-801 suppressed CSD genesis in a 
concentration dependent manner (Figure 18). MK-801 at 30 μM completely 
abolished CSD in 5 out of 6 experiments during the 20-minute (Table 5). CSD 
number significantly reduced to 0.67 ± 0.33 compared to 2.5 ± 0.62 of the control 
group (n = 6, 
*
p ＜ 0.05, Figure 19 A). At this concentration of MK-801, CSD 
latency (7.52 ± 1.41 minutes) increased 2.5-folds compared to the control group 
(18.49 ± 1.51 minutes) (n = 6, 
***
p ＜ 0.001, Figure 19 B). This inhibitory effect 
on CSD was persistent after the drug removal (i.e. in the 5
th
 CSD episode). 
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Figure 18. Representative CSD traces of the effects of MK-801, NVP-AAM077 
and TCN-201 on tissue susceptibility to CSD induced by K
+
-medium perfused 
through the microdialysis probe. ACSF group set as control for MK-801 and 
NVP-AAM077 groups. DMSO group set as control for TCN-201 group. 
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Figure 19. Effects of MK-801, NVP-AAM077 and TCN-201 on tissue 
susceptibility to CSD induced by K
+
-medium perfused through the microdialysis 
probe. ACSF group (n = 6) set as control for MK-801 (n = 6) and NVP-AAM077 
(n = 6) groups (A and B). DMSO group (n = 7) set as control of TCN-201 (n = 6) 
(C and D). All the values given were means ± SEM. One-way ANOVA test was 
used for statistics among ACSF, MK-801 and NVP-AAM077 groups with 
subsequent Bonferonni test for significance between control and drug treatment 
groups (
*
p < 0.05, 
**
p ≤ 0.01, 
***
p ≤ 0.001). Unpaired t-test with two-tailed 
calculation was used to test for significance between DMSO and TCN-201 groups. 
Paired t-test with one-tailed calculation was used to test whether tissue was 
restored after drug removal between the 4
th
 and 5
th
 CSD episodes. 
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Groups 
Number of 
tested animals 
Number of 
tested animals in which 
CSD was completely blocked 
ACSF Control 6 0 
MK-801 6 5 
NVP-AAM077 6 2 
DMSO Control 6 0 
TCN-201 6 0 
Table 5. The number of animals in which CSD was completely blocked by 
MK-801, NVP-AAM077 and TCN-201 in microdialysis-based model. ACSF 
group set as control for MK-801 and NVP-AAM077 groups. DMSO group set as 
control for TCN-201 group. 
 
3.2.3 NR2A inhibition suppressed CSD genesis in microdialysis-based CSD 
model   
To investigate whether NR2A inhibition could suppress the susceptibility of 
cortical tissue to CSD, the effect of NR2A antagonists NVP-AAM077 and 
TCN-201 on CSD number and latency were examined by local perfused at where 
CSD generated through microdialysis probe. In the NVP-AAM077 group, the 
CSD number and latency in the 1
st
 episode were 2.83 ± 0.40 (n = 6) and 6.45 ± 
1.37 minutes (n = 6) in respective order, which had no significant difference 
compared with control group (Figure 19 A and B). NVP-AAM077 at 0.3, 1 and 3 
μM concentration-dependently reduced CSD number (Figure 18). At the highest 
concentration applied, the reduction in CSD number reached significance (0.83± 
0.31, n = 6) compared with that of control group (2.53 ± 0.62, n = 6, 
*
p ＜ 0.05, 
Figure 19 A), and completely abolished CSD in 2 out of 6 experiments during 
20-minute (Table 5). Conversely to CSD number, NVP-AAM077 at 3 μM 
significantly prolonged CSD latency to 13.94 ± 2.23 minutes (n = 6) compared 
with the corresponding control (7.52 ± 1.41 minutes, n = 6, 
*
p ＜ 0.05, Figure 19 
B). There was no significant recovery on CSD number and latency after the drug 
removal. 
62 
In DMSO control group, the CSD number and latency in the 1
st
 episode were 4.2 
± 0.97 (n = 5, Figure 19 C) and 3.80 ± 0.89 minutes (n = 7, Figure 19 D). DMSO 
at 0.05%, 0.15% or 0.5% had no significant effect on these parameters when 
compared among episodes. In the TCN-201 group, the CSD number and latency 
in the 1st episode were 3.3 ± 0.76 (n = 5) and 5.55 ± 2.01 minutes (n = 6), which 
had no significant difference compared with the corresponding control group 
(Figure 18, Figure 19 C and D). Contrary to NVP-AAM077, TCN-201 didn’t alter 
either CSD number (n = 6) or latency (n = 6) even at 50 μM compared to control 
group (Figure 19 C and D). 
To investigate whether NR2A inhibition could suppress the magnitude of CSD, 
the effect of NR2A antagonists NVP-AAM077 and TCN-201 on AUC, H, WHH, 
Sld and Slr of CSD were examined by local perfused at CSD genesis site through 
microdialysis probes. In the ACSF group, the AUC, H, WHH, Sld and Slr in the 
1
st
 episode were 4.95 ± 1.06 mV × minutes (n = 6, Figure 20 A), 6.12 ± 0.91 mV 
(n = 6, Figure 20 C), 36.05 ± 3.21 seconds (n = 6, Figure 20 E), 31.74 ± 5.40 
mV/minute (n = 6, Figure 20 G) and 19.92 ± 2.02 mV/minute (n = 6, Figure 20 I) 
in respective order. There was no significant difference in any of these parameters 
over the 5 repeated CSD episodes. Under NVP-AAM077 application, the AUC, H, 
WHH and Sld waves were concentration-dependently reduced. Compared with 
control (ACSF) group, NVP-AAM077 at 3 μM significantly reduced AUC from 
5.20 ± 0.94 mV × minutes to 2.36 ± 0.79 mV × minutes (n = 6, 
*
p ＜ 0.01, 
Figure 20 A), H from 6.35 ± 0.82 mV to 3.55 ± 1.17 mV (n = 6, 
*
p ＜ 0.01, 
Figure 20 C), WHH from 36.92 ± 2.09 seconds to 21.02 ± 7.15 seconds (n = 6, 
*
p 
＜ 0.01, Figure 20 E) and Sld from 21.11 ± 3.92 mV/minute to 13.12 ± 4.45 
mV/minute (n = 6, 
*
p ＜ 0.01, Figure 20 G), whereas Slr was not altered (n = 6, 
Figure 20 I). There was no significant recovery on AUC, H, WHH and Sld of CSD 
after the drug removal. 
In DMSO group, the AUC, H, WHH, Sld and Slr of CSD in the 1
st 
episode were 
4.81 ± 0.38 mV × minutes (n = 6, Figure 20 B), 5.02 ± 0.62 mV (n = 5, Figure 20 
D), 37.059 ± 2.92 seconds (n = 5, Figure 20 F), 30.28 ± 3.34 mV/minute (n = 5, 
Figure 20 H) and 20.30 ± 3.14 mV/minute (n = 6, Figure 20 J) in respective order. 
DMSO at 0.05%, 0.15% or 0.5% had no significant effect on these parameters 
63 
when compared among episodes. In the TCN-201 group, the AUC and Sld were 
concentration-dependently reduced. Compared with control group, TCN-201 at 50 
μM reduced the magnitude from 5.15 ± 0.62 mV × minutes to 3.69 ± 0.36 mV × 
minutes (n = 6, 
*
p = 0.043, Figure 20 B), and Sld from 30.22 ± 2.3 mV/minute to 
25.26 ± 1.99 mV/minute (n = 6, 
*
p = 0.043, Figure 20 H), whereas H, WHH or Slr 
was not altered (n = 6, Figure 20 D, F and J). 
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Figure 20. Effects of NVP-AAM077 (A, C, E, G, I) and TCN-201 (B, D, F, H, J) 
perfused through the microdialysis probe on the magnitude of CSD genesis waves. 
All the values shown were means ± SEM. Unpaired t-test with two-tailed 
calculation was used for statistical analysis for significance between the control 
and chemical treatment groups, i.e. ACSF (n = 6) vs NVP-AAM077 (n = 6), and 
DMSO (n = 6) vs TCN-201 (n = 6) (
*
p < 0.05). Paired t-test with one-tailed 
calculation was used to test whether tissue was restored after drug removal 
between the 4
th
 and 5
th
 CSD episodes for NVP-AAM077 testing. 
 
3.2.4 CSD propagation was not altered by NR2A inhibition in 
microdialysis-based CSD model. 
To investigate whether NR2A inhibition could suppress CSD propagation, the 
effect of NR2A antagonists NVP-AAM077 and TCN-201 on AUC, H, WHH, Sld 
and Slr of CSD propagation wave and CSD propagation rate were examined by 
local perfusion of chemicals at CSD genesis site through microdialysis probe. In 
the ACSF group, the AUC, H, WHH, Sld and Slr and CSD propagation rate in the 
1
st
 episode were 4.62 ± 0.73 mV × minutes (n = 6, Figure 21 A), 6.19 ± 1.07 mV 
(n = 6, Figure 21 C), 41.14 ± 31.73 seconds (n = 6, Figure 21 E), 21.24 ± 53.55 
mV/minute (n = 6, Figure 21 G), 18.94 ± 2.66 mV/minute (n = 6, Figure 21 I) and 
7.09 ± 0.63 mm/minute (n = 6, Figure 22 A). No parameter was altered over the 5 
repeated CSD episodes. In the NVP-AAM077 group, no significant difference 
was observed in any parameter of CSD in the 1
st
 episode when compared with 
control (ACSF) group (n = 6, Figure 21 A, C, E, G and I, Figure 22 A). Contrary 
to the effect of NVP-AAM077 on CSD genesis, NVP-AAM077 didn’t alter any 
parameter of propagating CSD at all concentrations we tested compared to control 
group (n = 6, Figure 21 A, C, E, G and I, Figure 22 A). 
In DMSO group, the AUC, H, WHH, Sld and Slr of propagating CSD and CSD 
propagation rate in the 1
st
 episode were 3.69 ± 0.28 mV × minutes (n = 5, Figure 
21 B), 4.12 ± 0.38 mV (n = 3, Figure 21 D), 40.02 ± 3.43 seconds (n = 3, Figure 
21 F), 16.41 ± 1.54 mV/minute (n = 3, Figure 21 H), 17.6 ± 1.19 mV/minute (n = 
3, 21 J) and 6.53 ± 0.83 mm/minute (n = 5, Figure 22 B) in respective order. 
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DMSO at 0.05%, 0.15% or 0.5% had no significant effect on these parameters 
when compared among episodes. In the TCN-201 group, there was no significant 
difference in these parameters of CSD in the 1
st
 episode compared with control 
group (n = 3-5, Figure 21 B, D, F, H and J, Figure 22 B). Similarly with the effect 
of NVP-AAM077 to CSD propagation, TCN-201 didn’t alter any parameter of 
propagating CSD as well compared to control group (n = 3-5, Figure 21 B, D, F, 
H and J, Figure 22 B). 
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Figure 21. Effects of NVP-AAM077 (A, C, E, G, I) and TCN-201 (B, D, F, H, J) 
perfused through the microdialysis probe on the magnitude of CSD propagation 
waves. All the values shown were means ± SEM. Unpaired t-test with two-tailed 
calculation was used for statistical analysis for significance between the control 
and chemicals treatment groups, i.e. ACSF (n = 6) vs NVP-AAM077 (n = 6), and 
DMSO (n = 5) vs TCN-201 (n = 5). Paired t-test with one-tailed calculation used 
to test whether tissue was restored after drug removal between the 4
th
 and 5
th
 CSD 
episodes for NVP-AAM077 testing. 
 
 
Figure 22. Effects of NVP-AAM077 (A) and TCN-201 (B) perfused through the 
microdialysis probe on propagation rate of CSD. All the values shown were 
means ± SEM. Unpaired t-test with two-tailed calculation was used for statistical 
analysis for significance between the control and drug treatment groups, i.e. ACSF 
(n = 6) vs NVP-AAM077 (n = 6), and DMSO (n = 6) vs TCN-201 (n = 4). Paired 
t-test with one-tailed calculation was used to test whether tissue was restored after 
drug removal between the 4
th
 and 5
th
 CSD episodes for NVP-AAM077 testing. 
 
3.2.5 NR2A inhibition by i.c.v. perfusion of NVP-AAM077 suppressed CSD 
propagation in rats 
Distinct from that of CSD genesis, NVP-AAM077 was unable to alter CSD 
propagation in the microdialysis-based CSD model (Figure 21 and 22). I assumed 
that should be caused by that locally perfused chemical couldn’t diffuse to the 
remote site where CSD propagation waves were recorded. To allow chemical 
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diffusing to distant cortical region, contralateral ventricle perfusion was performed 
for further investigating the effect of NR2A inhibition on CSD propagation. 
In the ACSF group, the AUC, H, WHH, Sld and Slr of propagating CSD at the 
anterior recording site (0.4 mm anterior to Bregma) in the 1
st
 episode were 5.67± 
0.64 mV × minutes, 7.94 ± 1.43 mV, 41.83 ± 2.64 seconds, 29.94 ± 4.38 
mV/minute and 22.79 ± 3.57 mV/minute (n = 6, Figure 23 A-E). There was no 
change of these parameters throughout the experiment. In NVP-AAM077 group, 
the AUC, H, WHH, Sld and Slr at the same coordinate in the 1
st
 episode have no 
difference with that of control group (n = 6, Figure 23 A-E). In contrast to that 
perfused via microdialysis, i.c.v. perfusion of 0.3 nmol NVP-AAM077 
significantly suppressed the AUC of CSD propagation wave. In the 
NVP-AAM077 group, the AUC was reduced to 4.20 ± 0.80 mV × minutes 
compared to 6.37 ± 0.50 mV × minutes in the control group (n = 6,
 *
p ＜ 0.05, 
Figure 23 A). H, WHH, Sld or Slr was not altered compared to the control group 
(n = 6,
 
Figure 23 B-E). Similarly, the suppressive effect of NVP-AAM077 on the 
AUC of CSD propagation waves was also observed at 2 mm posterior to Bregma; 
whereas H, WHH, Sld or Slr was not altered at the same coordinate as well (data 
not shown). 
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Figure 23. Effects of NVP-AAM077 perfused into the left lateral ventricle on the 
magnitude of CSD propagation waves at 0.4 mm anterior to Bregma. All the 
values shown were means ± SEM. Unpaired t-test with two-tailed calculation was 
used for statistical analysis for significance between the drug (n = 6) and control 
group (n = 6) (
*
p < 0.05). 
 
In the ACSF group, the propagation rate of CSD in the 1
st
 episode was 4.01 ± 0.21 
mm/minute (n = 6). There was no change of these parameters throughout the 
experiment. In NVP-AAM077 group, the propagation rate in the 1
st
 episode was 
4.47 ± 0.79 mm/minute, which have no difference with that of control group (n = 
6, Figure 24). Interestingly, i.c.v. perfusion of 0.3 nmol NVP-AAM077 
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significantly suppressed CSD propagation rate from 4.03 ± 0.37 mm/minute to 
2.64 ± 0.27 mm/minute compared to the control group (n = 6, 
**
p ＜ 0.01, Figure 
24). 
 
 
Figure 24. Effects of NVP-AAM077 perfused into the left lateral ventricle on the 
propagation rate of CSD. All the values shown were means ± SEM. Unpaired 
t-test was used for statistical analysis for significance between the drug (n = 6) 
and control group (n = 6) (
**
p < 0.05). 
 
3.3 Discussion 
The main findings of this chapter are that NR2A-containing NMDA receptors not 
only contribute to CSD genesis but also CSD propagation in vivo, which was 
supported by that NR2A-containing receptor antagonists NVP-AAM077 and 
TCN-201 suppressed CSD genesis, while i.c.v. perfusion of NVP-AAM077 
suppressed CSD propagation in rats and bath application of TCN-201 suppressed 
CSD propagation in the chick retina. 
Validation of microdialysis-based CSD model under isoflurane anaesthesia 
Several studies report that inhalational anaesthetics suppress CSD (Piper and 
Lambert, 1996, Kudo et al., 2008). In this study, I still consider isoflurane 
anesthesia, but not pentobarbitone, which has the least action on CSD (Kitahara et 
al., 2001), for studying genesis and propagation of CSD based on the following 
reasons: (i) the in vivo experiment lasted almost 7 hours, whereas barbiturates 
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usually only maintain anesthesia from several minutes to 4 hours (Norn et al., 
2015), which don’t meet our requirement; (ii) isoflurane has been widely used in 
other studies for studying CSD (Peeters et al., 2007, Chang et al., 2010, Unekawa 
et al., 2012, Shatillo et al., 2015); indeed, isoflurane provide a stable and 
consistent depth of anesthesia throughout the experiment and the concentration 
can be adjusted according to surgical and CSD recording procedures under study; 
whereas barbiturates generally result in uneven levels of anesthesia; (iii) under 
isoflurane anaesthesia, the profound inhibitory effects of MK-801 on CSD 
magnitude and susceptibility of the cortex to CSD (Figure 19 and Figure 20) are 
consistent with those reported previously (Obrenovitch and Zilkha, 1996b, 
Willette et al., 1994); (iv) the fact that genesis or propagation of CSD was not 
altered in the control group yet was suppressed by NVP-AAM077 and TCN-201, 
suggesting that the suppression of CSD is due to NR2A inhibition, rather than 
isoflurane. Collectively, the above evidence validates that the in vivo study under 
isoflurane anaesthesia is feasible and valid for assessing CSD genesis and 
propagation for NMDA receptor pharmacology. 
NR2A-containing receptors mediate both CSD genesis and propagation 
NVP-AAM077 markedly suppressed K
+
-induced CSD number and increased 
CSD latency when perfused via microdialysis probe at 3 μM (Figure 19). The 
reduced cortical susceptibility to CSD under NR2A inhibition extended our 
previous finding on the crucial role NR2A-containing receptors in mediating CSD 
propagation (Wang et al., 2012). However, TCN-201 at 50 μM didn’t alter the 
CSD number and latency, which is likely attributed to the low efficacy of 
TCN-201 and the limitation of its maximal solubility in DMSO. 
Surprisingly, local application of NVP-AAM077 at 3 μM or TCN-201 at 50 μM 
through the microdialysis probe did not alter the magnitude of CSD propagation 
wave and propagation rate in the rats (Figure 21 and 22). That is on contrast to 
that are observed in chick retina, in which both NVP-AAM077 (Wang et al., 2012) 
and TCN-201 (Figure 17) are effective in suppressing CSD propagation rate and 
magnitude. I suspect that this negative result in vivo may be attributed to the fact 
that the recording site of CSD propagation waves was not exposed to chemicals 
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that were locally perfused at the CSD elicitation site. To clarify whether inhibition 
of NR2A could be effective in CSD propagation in vivo, contralateral ventricle 
perfusion of NVP-AAM077 was considered as this would allow the drug to 
diffuse to distant cortex following cerebrospinal fluid flow. In this study, as 
expected, i.c.v. perfusion of 0.3 nmol NVP-AAM077 markedly suppressed the 
magnitude (Figure 23) and propagation rate of CSD (Figure 24), confirming the 
mediation of NR2A to CSD propagation. 
The importance of NR2A in CSD propagation is supported by the action of 
TCN-201 (Figure 17), which has 300-fold selectivity to NR2A compared with 
NR2B-containing receptors (Bettini et al., 2010). Indeed, at the medium 
concentration of 3 μM of the drug applied, suppressive effects on both magnitude 
and propagation rate of CSD propagation wave were observed in chick retina 
(Figure 17). As the chick retina is devoid of blood vessel, the fact that the 
inhibitory effect of TCN-201 on CSD propagation under this study suggests an 
involvement of neuronal mechanism under NR2A inhibition. Interestingly, this 
data on TCN-201 in chick retina is in contrast to a recent study employing BOLD 
fMRI approach, which shows that TCN-201 is ineffective in CSD BOLD response 
in rats (Shatillo et al., 2015). The discrepancy may be attributed to different 
methods applied for CSD recording: BOLD fMRI (Shatillo et al., 2015) that is 
largely based on brain-specific hemodynamic responses versus intrinsic optical 
signal that is based on neuronal activity of chick retina. Whether TCN-201 could 
alter CSD propagation in vivo using an electrophysiology approach where 
neuronal activities could be monitored remains to be further investigated. It is 
worthy to mention that the efficacy of TCN-201 against CSD propagation in chick 
retina is >30-fold lower than that of NVP-AAM077 (Wang et al., 2012). This 
suggests that a much higher concentration of TCN-201 may be needed for 
sufficient binding to its receptors in future in vivo studies for effectiveness of the 
drug on CSD. Further studies using NR2A knockout animals will help to elucidate 
the role of NR2A in CSD. 
Elucidation of the inhibitory effects of NVP-AAM077 and TCN-201 on CSD in 
vivo suggests that such drug-alike candidates targeting NR2A may constitute a 
highly specific strategy with better efficacy and safety profile for treating CSD 
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associated migraine aura, relative to non-subtype selective NMDA receptors 
(Wang et al., 2012). This possibility is likely due to the following reasons: (i) 
NVP-AAM077 suppresses CSD in chick retina with approximately 320-fold more 
potency, while TCN-201 with approximately 20-fold more potency than 
memantine (Peeters et al., 2007), a clinically acceptable drug for treating 
migraines (Huang et al., 2014); (ii) partial inhibition of CSD by both 
NVP-AAM077 and TCN-201 in rats is also observed with the uncompetitive 
NMDA receptor antagonist, memantine (Peeters et al., 2007, Chen and Lipton, 
2005); (iii) the rapid reversibility of NVP-AAM077 after the drug withdrawal 
resulting from its competitive antagonism supports a likely better safety profile; 
(iv) the high NR2A-preferring character of TCN-201, i.e. > 300 folds selectivity 
to NR2A compared with NR2B-containing receptors, supports a likely less 
side-effect profile. 
Possible mechanism contributing to NR2A in mediating CSD 
The present data suggests that activation of NR2A-containing receptors contribute 
to CSD genesis and propagation. There are several mechanisms which may 
explain the nature of CSD modulation by NVP-AAM077 and TCN-201 in vivo 
and in vitro. It is likely that inhibition of CSD magnitude under NR2A inhibition 
is attributed to their ability to desensitize neurons as NVP-AAM077 competitively 
blocks steady-state NR1/NR2A receptor currents from a cortical neuron (Noh et 
al., 2009); and TCN-201 accelerates NR1/NR2A receptor deactivation (Hansen et 
al., 2012). In addition, NR2A activation permitting calcium ion influx in neurons 
(von Engelhardt et al., 2007) may get involved in mediating CSD, which is 
supported, in part, by the increased calcium influx triggers CSD and accelerates 
CSD propagation in rats (Torrente et al., 2014). Furthermore, the role of NR2A in 
CSD may be associated with its interaction with PSD95. This assumption is 
supported by that uncoupling PSD95 from NR2A suppresses the magnitude of 
CSD in chick retina (unpublished from our group), which is similar with that 
interrupting the interaction of NMDA receptors and PSD95 suppressed the 
magnitude of CSD in cortex of mice (Kucharz et al., 2016). Finally, it is plausible 
to suppose that the contribution of NR2A to CSD may be relevant to SFKs as 
several tyrosine residues in the C-terminal tails of NR2A can be phosphorylated 
75 
by SFKs, e.g. Y1325 and Y1387 (Salter and Kalia, 2004). 
In summary, the present data provides strong evidence on a critical role of NR2A 
in CSD genesis and propagation in vivo and also suggests that drugs preferably 
antagonizing NR2A-containing NMDA receptor may constitute a highly specific 
strategy with fewer side effects for treating CSD associated migraine aura. 
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Chapter 4 SFKs activation involving CSD can be regulated by NR2A 
 
Given that SFKs can potentiate the current of NR2A-containing receptor via 
phosphorylating the Y1325 and Y1387 amino acids in the C-terminal sequence of 
NR2A (Yang and Leonard, 2001) and that SFKs can be activated by exogenous 
NMDA during anoxia (Weilinger et al., 2012), SFKs may also possess 
unidentified function during CSD. This chapter aims to explore if NR2A signaling 
involves SFKs in the evolution of migraine. The following question will be 
addressed: Do SFKs mediate CSD in rats? Does CSD induce SFKs activation? 
Can the CSD-induced SFKs activation be regulated by NR2A? 
 
4.1 Objectives 
4.1.1 To investigate whether CSD could activate SFKs  
4.1.2 To investigate whether SFKs inhibitor could prevent CSD-induced SFKs 
activation 
4.1.3 To investigate whether SFKs inhibitor could suppress CSD propagation. 
4.1.4 To investigate whether inhibition of NR2A could suppress CSD-induced 
SFKs activation 
 
4.2 Results 
 
4.2.1 CSD induced ipsilateral cortical SFKs activation 
A unique band was observed at 60 kDa after incubating PY416 SFKs or total 
SFKs antibody with the protein from the sham group (Figure 25 A and B). In 
addition, the background was clean if incubating protein with secondary antibody 
only for the process of PY416 SFKs detection, or for total SFKs detection after 
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stripping (Figure 25 C and D), suggesting the immunoreactive specificities of 
PY416 SFKs and total SFKs in our preparation. 
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Figure 25. Control study for the specificities of PY416 SFKs and total SFKs 
antibodies, which indicated by the 60 kDa protein bands from the cortical tissue 
by western blot (A and B). There was no striking band observed in the absence of 
primary antibodies before (C) or after (D) stripping. 
 
In the sham group, the relative intensity of phosphorylated SFKs at Y416 and total 
SFKs were 0.43 ± 0.06 and 1.59 ± 0.58 respectively (n = 3, Figure 27). In the 
CSD group (n = 5), the relative intensity of phosphorylated SFKs in the ipsilateral 
cortex was 1.60 ± 0.17, which was significantly increased when compared with 
that of the sham group (n = 3, 
**
p < 0.01, Figure 26 and 27). By contrast, the level 
of total SFKs was 1.82 ± 0.52, which had not different from that of sham group (n 
= 5, Figure 27). 
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Figure 26. Representative immunoblotting of PY416 SFKs and total SFKs in the 
ipsilateral cortex of rats treated with ACSF, PP3 or PP2 in response to CSD. Equal 
loading of samples was indicated by the β-actin bands. Phospho-Y416 levels 
indicated activated SFKs and total SFKs levels indicated SFKs expression. 
Samples from the sham group set as control. 
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Figure 27. Quantitative analysis of relative intensity of ipsilateral cortical PY416 
SFKs and total SFKs normalized to β-actin after CSD treated with ACSF or 2.5 
nmol PP2 or PP3 i.c.v. perfused in rats. All the values were shown as means ± 
SEM. Mann-Whitney test was used for comparison the relative intensity of PY416 
SFKs and total SFKs between two independent groups. 
*
p < 0.05 when compared 
between sham (n = 3) and CSD (n = 5) groups with two-tailed calculation, and 
that compared between PP2 (n = 3) and PP3 (n = 3) groups with one-tailed 
calculation. 
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4.2.2 SFKs inhibitor prevented CSD-induced SFKs activation 
In the PP3 group, the level of phosphorylated SFKs in the ipsilateral cortex was 
1.26 ± 0.07, which had different from that of CSD group (n = 3). Similarly, total 
SFKs level was not altered by 2.5 nmol PP3 (n = 3, Figure 26 and 27). In the PP2 
group, the level of phosphorylated SFKs was reduced to 0.61 ± 0.06. This 
reduction was significantly different from that of the PP3 group (n = 3, 
*
p < 0.05, 
Figure 26 and 27). On contrary, the level of total SFKs was not altered by PP2 
compared with PP3 group (n = 3, Figure 26 and 27). 
 
4.2.3 SFKs inhibitor suppressed CSD 
In the PP3 control group, high-K
+
 induced CSD was identified by a transient 
negative shift of DC potential in all rats (Figure 28). The CSD number (n = 5, 
Figure 29 A) and latency (n = 4, Figure 29 B) were 1.60 ± 0.25 and 1.37 ± 0.27 
minutes in respective order. The SFKs inhibitor, PP2, at 2.5 nmol perfused into 
the contralateral ventricle significantly prolonged CSD latency when compared to 
that of PP3 group with prolonged to 3.08 ± 0.52 minutes (n = 5, 
*
p < 0.05, Figure 
29 B). PP2 slightly reduced CSD number but this reduction did not reach 
significance (n = 5, Figure 29 A). 
In addition, in the PP3 control group, the AUC, H, WHH, Sld and Slr of 
propagating CSD were 10.04 ± 0.64 mV × minute, 11.26 ± 0.98 mV, 47.55 ± 8.80 
seconds, 71.49 ± 14.90 mV/minute and 25.40 ± 2.79 mV/minute respectively (n = 
5, Figure 29 C-G). PP2 at 2.5 nmol significantly suppressed the AUC when 
compared to that of PP3 group with AUC reduced to 7.63 ± 0.43 mV × minute (n 
= 5, 
*
p < 0.05, Figure 29 C). The H, WHH, Sld and Slr were not altered by PP2 (n 
= 5, Figure 29 D-G). 
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Figure 28. Representative traces in DC potential indicating CSD wave after i.c.v. 
perfusion of 2.5 nmol SFKs inhibitor PP2 or PP3 as inactive analog. 
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Figure 29. Effects of PP2 perfused into the left lateral ventricle on the cortical 
susceptibility to CSD and the magnitude of CSD propagation waves. All the 
values shown were means ± SEM. Unpaired t-test with two-tailed calculation was 
used for statistical analysis for significance between the drug (n = 5) and control 
(n = 5) group (
*
p < 0.05). 
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In the sham group, both PY416 SFKs and total SFKs were detected in CSD 
ipsilateral cortex at the size of 60 KDa (Figure 30). The relative intensity of 
phosphorylated SFKs and total SFKs were 0.37 ± 0.03 and 0.81 ± 0.05 
respectively (n = 3, Figure 31). As described above, CSD significantly increased 
the level of phosphorylated SFKs to 0.69 ± 0.11 (n = 5, 
*
p < 0.05), whereas the 
total SFKs was not altered (n = 5, Figure 31). 
Similar as PP2 (Figure 27), in the NVP-AAM077 group, the level of 
phosphorylated SFKs induced by CSD was markedly reduced to 0.35 ± 0.04 when 
compared with that of CSD group (n = 5, 
*
p < 0.05, Figure 31). However, 
reduction of total SFKs in the CSD ipsilateral cortex was not observed (n = 5, 
Figure 31). 
 
 
Figure 30. Representative immunoblotting of ipsilateral cortical PY416 SFKs and 
total SFKs in rats treated with ACSF or NVP-AAM077 (0.3 nmol) in the presence 
of CSD. Samples from the sham group were used as the control. Equal loading 
was indicated by β-actin bands. PY416 levels indicated the activated SFKs and 
that total SFKs level indicated SFKs expression. 
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Figure 31. Quantitative analysis of relative intensity of PY416 SFKs and total 
SFKs normalized to β-actin after CSD treated with ACSF or NVP-AAM077 (0.3 
nmol). All the values shown were means ± SEM. Mann-Whitney test with 
one-tailed calculation was used for statistical analysis between sham (n = 3) and 
CSD (n = 5) group (
*
p < 0.05). Unpaired t-test with two-tailed calculation was 
used for statistical analysis between CSD and NVP-AAM077 (n = 5) group (
*
p < 
0.05). 
 
4.3 Discussion 
The key finding in this study are that SFKs activity plays an important role in 
mediating CSD. This is supported by that ipsilateral cortical SFKs 
phosphorylation at active site Y416 was elevated in response to CSD, which is 
prevented by the SFKs inhibitor, PP2 that is i.c.v. perfused into rats (Figure 26 and 
27). Additionally, SFKs are found to be a key modulator of CSD propagation as 
inhibition of SFKs by PP2 suppresses both CSD magnitude and cortical 
susceptibility to CSD (Figure 29). Furthermore, both CSD-induced SFKs 
activation (Figure 31) and CSD propagation (Figure 23 and 24) was suppressed by 
NR2A antagonist NVP-AAM077. 
Mechanism of SFKs-mediating CSD 
Although the mechanism of action of SFKs associated with CSD is not fully 
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known, it is likely to involve the interaction of NR2A-containing NMDA 
receptors for the following reasons: (i) both SFKs inhibition (Figure 29) and 
NR2A inhibition (Bu et al., 2016) were found to suppress CSD propagation; (ii) 
CSD-induced SFKs activation can be prevented by NR2A antagonist (Figure 31); 
(iii) several amino acid sites of NR2A subunit can be phosphorylated by SFKs 
(Cheung and Gurd, 2001); (iv) Src potentiates the currents of recombinant 
NR1/2A receptor by reducing the affinity of NR2A for Zn
2+
 (Kohr and Seeburg, 
1996), a NR2A preferring antagonist (Gielen et al., 2009, Paoletti and Neyton, 
2007) that is known to reduce CSD propagation in rats (Aiba et al., 2012); (v) 
SFKs interacting with NMDA receptors is known to be via PSD95 in the model of 
chronic pain (Salter and Pitcher, 2012). Uncoupling interaction of PSD95 and 
NMDA receptors can suppress CSD amplitude in rats (Kucharz et al., 2016), 
which is in line with that interrupting the direct interaction of PSD95 and NR2A 
suppressed CSD magnitude in chick retina (unpublished data). The above 
evidences prompt a functional positive loop comprising SFKs and NR2A in 
mediating CSD, in which CSD-induced SFKs activation further promotes CSD 
propagation via NR2A. 
SFKs may also mediate CSD through P2X7 receptor for the following evidences: 
(i) SFKs can be regulated by P2X7 receptor in glia in the CNS (Bravo et al., 2015); 
and (ii) anti-P2X7 receptor antibody suppresses the cortical susceptibility to CSD 
and the magnitude of CSD in rats (unpublished from our group), which is in line 
with the inhibitory effect of SFKs inhibitor on CSD. 
It is necessary to discuss that migraine aura in believed to involve only a single 
CSD event (Smith et al., 2006) and the experimental protocol in this chapter was 
designed to elicit one single CSD, despite this occasionally 2 CSD waves were 
seen due to variation of individual rat cortex susceptibility to the 5-minutes KCl 
application. This finding therefore provides evidence linking CSD and SFKs 
activity that may contribute to migraine pathogenesis.  
In summary, this data extends a previous study that synaptic Src phosphorylation 
was observed in the rat hippocampal slice following NMDA signaling (Weilinger 
et al., 2016) and adds insight into SFKs activation that is one of the most 
85 
important mechanisms for a number of neuro-pathological conditions related to 
inflammatory response (Okutani et al., 2006), cerebral ischemia (Zhang et al., 
2007, Kumar et al., 2014) and stroke (Weilinger et al., 2012, Weilinger et al., 
2016). Selectively targeting SFKs may represent a promising alternative for 
prophylactic treatment of migraine aura and headache. 
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Chapter 5 SFKs contribute to CSD-induced Panx1 channels opening 
Previous study shows that anoxia causes Panx1 channels opening via activating 
SFKs (Weilinger et al., 2012). In addition, CSD can trigger neuronal Panx1 
channels opening (Karatas et al., 2013). It suggests that SFKs may also play a role 
during CSD. The activation of SFKs by CSD (Chapter 4) further raises the 
possibility that CSD may trigger Panx1 channels opening via SFKs. 
 
5.1 Objectives 
5.1.1 To investigate whether CSD could induce Panx1 expression in cortex of 
rats. 
5.1.2 To investigate whether CSD could induce neuronal Panx1 opening in 
cingulate, motor and somatosensory cortices. 
5.1.3 To investigate whether SFKs inhibition could suppress CSD-induced 
neuronal Panx1 opening in the discrete cortices. 
 
5.2 Results 
 
5.2.1 Panx1 protein expression was not altered by CSD. 
A unique band was observed at 45 kDa after incubating Panx1 antibody with the 
protein from the sham group (Figure 32), suggesting the immunoreactive 
specificity of Panx1 in our preparation, and that Panx1 channel expression in the 
cerebral hemispheres. 
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Figure 32. Control study for the specificity of Panx1 antibody. Panx1 was 
indicated by the 45 kDa protein band from the cortical tissue by western blot. 
 
In the sham group, the level of Panx1 was 1.02 ± 0.08 in the ipsilateral cortex (n = 
3). Panx1 expression level was not altered after CSD with 1.15 ± 0.19 (n = 3, 
Figure 33 and 34). 
 
 
Figure 33. Representative immunoblotting of Panx1 in ipsilateral cortex with or 
without CSD. 
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Figure 34. No change in Panx1 protein expression was detected after CSD. All 
the values shown were means ± SEM. Mann-Whitney test with two-tailed 
calculation was used for significance between sham (n = 3) and CSD (n = 3) 
groups. 
 
5.2.2 CSD triggered neuronal Panx1 opening in cingulate, motor and 
somatosensory cortices. 
In the formal experiment, Panx1 in layers V and VI of cortex was selected for 
investigating the activity of channels, based on the following reasons: (i) The 
number of PI-positive cells (per mm
2
) was significantly increased in the V and VI 
layers of cortex after CSD (n = 6), compared with the sham group (n = 4, 
*
p < 
0.05, 
**
p < 0.01, Figure 35 B and C); and (ii) the previous study shows a 
preferential distribution of Panx1 in the V and VI layers of cortex (Zoidl et al., 
2007).  
In addition, the distribution of PI uptake in V and VI layers of different 
coordinates of ipsilateral cortex also was investigated given the limited time of PI 
diffusion in brain in 5 minutes after CSD induction. Compared with the sham 
group (n = 2), CSD-induced PI staining was increased between 0.4 mm anterior 
and 2 mm posterior to Bregma in ipsilateral cortex. Differently, at the remote 
regions, i.e. 3-5 mm posterior to Bregma, the PI uptake was not altered (n = 2, 
Figure 35 D). Therefore, PI staining would be investigated in the V and VI layers 
of ipsilateral cortex at 0.4 mm anterior to Bregma in our formal experiment. 
 
R
el
at
iv
e 
d
en
si
ty
(v
s
ß
-a
ct
in
)
Sham CSD
0.0
0.5
1.0
1.5
89 
C.
A. B.
D.
+ 0 .4 - 1 - 2 - 3 - 4 - 5
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
C S D
S h am
D istan ce  to  B reg m a  (m m )
P
I 
p
o
s
it
iv
e
 c
e
ll
s
 /
 m
m
2
I II III IV V V I
0
2 0 0
4 0 0
6 0 0
8 0 0
C S D
S h am
* *
*
C ortica l lay ers
P
I 
p
o
s
it
iv
e
 c
e
ll
s
 /
 m
m
2
Sham CSD
50 μm50 μm
Representative images of PI staining in V and VI
layers of cortex at 0.4 mm anterior to Bregma
Ipsilateral hemisphere
Bregma 0.36 mm
I
II
III
IV
V
VI
S
Cg
M
LV
(Layers)
1 mm
 
Figure 35. The distribution of CSD-induced PI staining in ipsilateral cortex of the 
rats. (A) Schematic representation of coronal section of unilateral hemisphere. S = 
somatosensory cortex, M = motor cortex, Cg = cingulate cortex, LV = lateral 
ventricle. I–VI indicate the different cortical layers. Dotted line in a box shows the 
selected field for panel (B). (B) Representative images of CSD-induced PI 
staining (red fluorescence) in layers V and VI of the ipsilateral motor cortices at 
0.4 mm anterior to Bregma at 400× magnification. Representative PI-positive 
cells were indicated by arrows shown in the field indicating Panx1 channels 
opening. (C) Statistical analysis of CSD-induced PI staining in the layers I–VI of 
ipsilateral cortices at 0.4 mm anterior to Bregma. (D) Statistical analysis of 
CSD-induced PI staining in the layers V and VI of ipsilateral cortices between 0.4 
mm anterior to 5 mm posterior to Bregma. All the values shown are means ± SEM. 
Unpaired t-test with one-tailed calculation was used for statistical analysis 
between groups (
*
p < 0.05, 
**
p < 0.01). 
 
NeuN was used for neurons labeling. The preliminary experiments suggest the 
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specific immunoreactivity of NeuN to neurons as there were striking nuclear and 
cytoplasmic staining in cortical cells and cerebellar granule (Figure 36 left and 
middle columns), but not in cerebellar Purkinje cells (Figure 36 middle column) 
in the presence of NeuN antibody. It is similar with the previous study (Wolf et al., 
1996). In addition, no cell staining was observed under primary antibody omission 
condition in cortex as negative control (Figure 36 right column).  
 
 
Figure 36. Coronal section with or without NeuN antibody at 1:1000 for testing 
the specificity of immunoreactivity. There are striking nuclear and cytoplasmic 
immuno-staining of neurons (arrow) in cortex and granule cells in cerebellum but 
not Purkinje cells (arrow head) in cerebellum in the presence of NeuN antibody. 
Granule cells and Purkinje cells in cerebellum were carried out as immuno-postive 
and –negative control for NeuN staining respectively. No cell staining was 
observed under primary antibody omission condition in cortex. The 400 × field 
comes from the area where is selected by white box from the 40 × field. 
 
In the sham group, the average number of PI positive cells in cingulate, motor and 
somatosensory cortices was 424.3 ± 100.30 per mm
2 
(n = 6), 210.0 ± 58.99 per 
mm
2
 (n = 6) and 129.2 ± 26.39 per mm
2
 (n = 4, Figure 37 and 38). The PI positive 
cells content in motor and somatosensory cortices was similar; whereas the 
cingulate had higher number in the sham group with 2-3 folds compared with that 
Cortex
NeuN antibody at 1:1000
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Cerebellum
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of motor and somatosensory cortices respectively (Figure 38). Following CSD, 
the number of PI positive cells was significantly increased to 787.6 ± 46.81 per 
mm
2
 (n = 6, 
**
p ＜ 0.01), 660.9 ± 43.92 per mm2 (n = 5, ***p ＜ 0.001) and 
569.3 ± 41.21 per mm
2
 (n = 6, 
***
p ＜ 0.001) in the ipsilateral cingulate, motor 
and somatosensory cortices compared to the sham group (Figure 38). 
In the sham group, the number of NeuN positive cells in ipsilateral cingulate, 
motor and somatosensory cortices were 1118 ± 48.65 per mm
2
, 847.60 ± 88.60 per 
mm
2
, 877.7 ± 102.1 per mm
2
 in respective order (Figure 37 and 39). There was no 
significant different in NeuN positive cells content after CSD or PP3, PP2 
administration in these cortical regions (Figure 37 and 39).  
Similar with PI positive cells, the number of PI/NeuN double staining cells were 
significantly increased by CSD in ipsilateral cingulate (600.9 ± 42.49 per mm
2
, n 
= 6, 
**
p ＜ 0.01), motor (667.3 ± 37.91 per mm2, n = 5, ***p ＜ 0.001) and 
somatosensory cortices (544.6 ± 25.20 per mm
2
, n = 6, 
***
p ＜ 0.001) compared 
to that in sham group with 319.0 ± 67.43 per mm
2
 (n = 6), 90.05 ± 16.36 per mm
2
 
(n = 6) and 72.22 ± 18.56 per mm
2
 (n = 4, Figure 40). 
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Figure 37. Representative images of CSD-induced PI staining (labeled in red) of 
NeuN positive cells (labeled in green) in cortical layers V and VI of ipsilateral 
motor cortex treated with ACSF or 2.5 nmol PP3 or 2.5 nmol PP2 in 1/20 mm
2
. PI 
positive neurons (labeled in yellow) were indicated by arrows shown in the insert 
indicating neuronal Panx1 channel opening. 
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Figure 38. Effects of PP2 (2.5 nmol) on PI positive cells in cingulate, motor and 
somatosensory cortices in the presence of CSD. All the values shown were means 
± SEM. 
**
p < 0.01, 
***
p < 0.001, unpaired t-test with two-tailed calculation was 
used for comparing PI staining between sham (n = 6) and CSD (n = 6) groups. 
*
p 
< 0.05, 
**
p < 0.01, 
***
p < 0.001, Mann-Whitney test with one-tailed calculation 
was used for statistical analysis for CSD vs PP3 (n = 3) groups, and PP3 vs PP2 (n 
= 3) groups. 
 
 
Figure 39. Effects of PP2 (2.5 nmol) on NeuN positive cells in cingulate, motor 
and somatosensory cortices in the presence of CSD. All the values shown were 
means ± SEM. Unpaired t-test with two-tailed calculation was used for comparing 
NeuN staining between sham (n = 6) and CSD (n = 6) groups. Mann-Whitney test 
with two-tailed calculation was used for significance between CSD (n = 6) and 
PP3 (n = 3), and that between PP3 and PP2 (n = 3). 
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Figure 40. Effects of PP2 (2.5 nmol) on PI positive neurons in cingulate, motor 
and somatosensory cortices in the presence of CSD. All the values shown were 
means ± SEM. 
**
p < 0.01, 
***
p < 0.001, unpaired t-test with two-tailed calculation 
was used for comparing neuronal PI staining between sham (n = 6) and CSD (n = 
6) groups. 
*
p < 0.05, 
***
p < 0.001, Mann-Whitney test with one-tailed calculation 
was used for statistical analysis for CSD vs PP3 (n = 3) groups, and PP3 vs PP2 (n 
= 3) groups. 
 
5.2.3 SFKs inhibitor suppressed CSD-induced neuronal Panx1 channels opening 
in cingulate, motor and somatosensory cortices. 
In the PP3 group, the number of PI positive cells was similar with that in CSD 
group in ipsilateral cingulate, motor and somatosensory cortices (Figure 38), 
indicating PP3 has no effect on CSD-induced Panx1 channels opening. 
Interestingly, CSD-induced PI staining was significantly reduced to 591.8 ± 25.35 
(n = 3, 
*
p ＜ 0.05), 225.9 ± 98.19 per mm2 (n = 3, **p ＜ 0.01) and 111.1 ± 
29.39 per mm
2
 (n = 3, 
***
p ＜ 0.001) by 2.5 nmol PP2 in cingulate, motor and 
somatosensory cortices in respective order when compared with that of PP3 group 
with 899.9 ± 63.17 per mm
2
 (n = 3), 714.7 ± 68.59 per mm
2
 (n = 3) and 509.2 ± 
41.86 per mm
2
 (n = 3, Figure 38).  
Similar with PI positive cells, the number of PI/NeuN double staining cells were 
not altered by 2.5 nmol PP3 compared to CSD group in these cortical regions 
(Figure 40). However, 2.5 nmol PP2 significantly reduced CSD-induced number 
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of PI positive neurons to 424 ± 12.96 per mm
2
 (n = 3, 
*
p ＜ 0.05), 118.5 ± 51.85 
per mm
2 
(n = 3, 
***
p ＜ 0.001) and 81.47 ± 37.58 per mm2 (n = 3, ***p ＜ 0.001) 
in ipsilateral cingulate, motor and somatosensory cortices when compared with 
that of PP3 group with 744.37 ± 50.10 per mm
2 
(n = 3), 652.5 ± 59.69 per mm
2 
(n 
= 3) and 453.7 ± 33.38 per mm
2 
(n = 3) in respective order (Figure 40). 
 
5.3 Discussion 
The present results demonstrate that CSD-induced SFKs activation contributes to 
neuronal Panx1 channels opening in cortex. This is supported by that SFKs 
inhibitor suppressed single CSD-induced neuronal PI uptake in the ipsilateral 
cingulate, motor and somatosensory cortices; meanwhile the total Panx1 
expression was not altered. 
CSD-induced Panx1 channel opening in discrete cortical regions 
The distribution of single CSD-activated Panx1 channels in the ipsilateral 
cingulate, motor and somatosensory cortices, extends the early study showing that 
CSD-induced Panx1 channels opening in cortex (Karatas et al., 2013). The fact of 
the levels of activated Panx1 are increased in multiple cortical regions (Figure 38 
and 40) indicates that the elevation is attributed to CSD rather than mechanical 
stimulation by surgery that is known one of the underlying causes of Panx1 
activation (Bravo et al., 2015). Interestingly, Panx1 channels are activated by CSD 
in the cingulate cortex is not supported by the previous observation that the 
depolarization of CSD waves is less efficient in the middle cortical regions (e.g. 
cingulate cortex), compared with the lateral regions (Eiselt et al., 2004). It is likely 
that the degree of Panx1 channels opening is not correlated to the magnitude of 
CSD. Given that PI uptake is not sensitive to CSD in the regions away from PI 
perfusion site in my result (Figure 35 D), whether Panx1 is also activated by CSD 
in those cortical regions still needs further investigation. 
It is necessary to mention that both single and multiple CSD can trigger PI uptake 
in cortical NeuN (immuno-react with neurons) but not in ALDH1L1 
(immuno-react with astrocyte) positive cells in isoflurane anaesthetic mice 
96 
(Karatas et al., 2013), which supports our study that the CSD-induced Panx1 
activation is of neuron original in discrete cortices to some extent. 
The mediation of SFKs to CSD-induced Panx1 channels opening 
A key finding in this study is that CSD triggers neuron al Panx1 opening via SFKs. 
I speculate CSD could couple SFKs to Panx1 for channel opening for the 
following reasons: (i) SFKs contributes to CSD-induced neuronal Panx1 channels 
opening in the discrete cortices; (ii) both Panx1 channels and SFKs are expressed 
in postsynaptic region (Thomas and Brugge, 1997, Bravo et al., 2015) and have a 
physical interaction in hippocampus (Weilinger et al., 2016); (iii) a putative 
phosphorylation site at Y308 of Panx1 matched consensus sequence for SFKs 
function to anoxia-induced Panx1 channels opening (Weilinger et al., 2012). 
These evidences prompt us that CSD may also recruit SFKs to activate Panx1 
channels by a physical interaction. 
It needs to mention that the SFKs inhibitor PP2 can’t discriminate the different 
members of SFKs (Hanke et al., 1996, Liu et al., 1999). Because the commercial 
antibodies or inhibitors of different members of SFKs are unavailable, I didn’t 
investigate the involvement of subtypes of SFKs in Panx1 channels opening 
induced by CSD. Further investigation is required in the future. 
In conclusion, I identified a mechanism through which SFKs activation induced 
by CSD leads to the opening of Panx1 channels. Given the important role of 
Panx1 in CSD-induced headache-like behavior (Karatas et al., 2013), this work 
that links SFKs and Panx1 channels may represent a new insight into migraine 
pathology.   
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Chapter 6 NR2A contributes to CSD-induced Panx1 channels opening and 
the interaction of SFKs and to Panx1 
 
The above research demonstrates that (i) NR2A-containing receptors contribute to 
CSD-induced SFKs activation and (ii) CSD triggers Panx1 channels opening via 
SFKs in the ipsilateral cortex. In this study, I aim to investigate whether NR2A 
could contribute to CSD-induced Panx1 channels opening. In addition, given that 
NMDA receptor/SFKs/Panx1 complex functions during anoxia (Weilinger et al., 
2016), it is reasonable to propose that NR2A may also regulate CSD-induced 
Panx1 channels opening via coupling SFKs to Panx1. 
 
6.1 Objectives 
6.1.1 To investigate whether NR2A inhibitor could suppress CSD-induced 
neuronal Panx1 channels opening in discrete cortices. 
6.1.2 To investigate whether CSD could induce the interaction of SFKs and 
Panx1.  
6.1.3 To investigate whether NR2A inhibitor could suppress CSD-induced 
interaction of SFKs and Panx1. 
 
6.2 Results 
 
6.2.1 NR2A antagonist suppressed CSD-induced neuronal Panx1 channels 
opening in cingulate, motor and somatosensory cortices. 
In the CSD group, the number of NeuN positive cells in ipsilateral cingulate, 
motor and somatosensory cortices were 1024 ± 124.2 per mm
2
, 929.4 ± 54.4 per 
mm
2
 and 677.7 ± 72.49 per mm
2
 in respective order (Figure 41 and 42). There 
was no significant different in NeuN positive cells content after 0.3 nmol 
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NVP-AAM077 administration in these cortical regions (Figure 42). 
As described above (Figure 38), the number of PI positive cells were 787.6 ± 
46.81 per mm
2
 (n = 6), 660.9 ± 43.92 per mm
2
 (n = 5) and 569.3 ± 41.21 per mm
2
 
(n = 6) in the ipsilateral cingulate, motor and somatosensory cortices of CSD 
group in respective order (Figure 43). 0.3 nmol NVP-AAM077 significantly 
prevented the CSD-induced PI staining in motor and somatosensory cortices. In 
the NVP-AAM077 group, the level of CSD-induced PI positive cells reduced to 
308.1 ± 57.86 per mm
2
 (n = 5, 
**
p ＜ 0.01) and 294.6 ± 22.96 per mm2 (n = 4, 
**
p ＜ 0.01) in respective order (Figure 43). However, the content of PI staining 
in cingulate cortex was not altered by NVP-AAM077 (n = 4, Figure 43). 
Similarly, reduction of number of PI/NeuN double staining cells was also 
observed in ipsilateral motor and somatosensory cortex with i.c.v. administration 
of 0.3 nmol NVP-AAM077 (Figure 44). In NVP-AAM077 group, these value 
were 228.8 ± 72.66 per mm
2 
(n = 5) and 355.2 ± 72.76 per mm
2 
(n = 5), which is 
significantly different from that of the CSD group with 667.3 ± 37.91 per mm
2 
(n 
= 5, 
***
p ＜ 0.001) and 544.6 ± 25.20 per mm2 (n = 6, **p ＜ 0.01, Figure 44). 
By contrast, the level of CSD-induced PI positive neurons in cingulate cortex (n = 
6) was not altered by NVP-AAM077 (n = 4, Figure 44). 
 
 
Figure 41. Representative images of CSD-induced PI staining (labeled in red) on 
NeuN positive cells (labeled in green) in layers V and VI of motor cortex of rats 
treated with ACSF or NVP-AAM077 (0.3 nmol) in 1/20 mm
2
. PI-/NeuN double 
99 
staining (labeled in yellow) was pointed by arrows in the insert. 
 
 
Figure 42. Effect of NVP-AAM077 (0.3 nmol) on NeuN staining in the presence 
of CSD in cingulate, motor and somatosensory cortices. All values shown were 
means ± SEM. Unpaired t-test with two-tailed calculation was used for statistical 
analysis for significance between CSD (n = 6) and NVP-AAM077 (n = 6) groups. 
 
 
Figure 43. Effect of NVP-AAM077 (0.3 nmol) on PI staining in the presence of 
CSD in cingulate, motor and somatosensory cortices. All values shown were 
means ± SEM. Unpaired t-test with two-tailed calculation was used for statistical 
analysis for significance between CSD (n = 6) and NVP-AAM077 (n = 5) groups 
(
**
p < 0.01). 
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Figure 44. Effect of NVP-AAM077 (0.3 nmol) on NeuN staining in the presence 
of CSD in cingulate, motor and somatosensory cortices of rats. All values shown 
were means ± SEM. Unpaired t-test with two-tailed calculation was used for 
statistical analysis for significance between CSD (n = 6) and NVP-AAM077 (n = 
5) groups (
**
p < 0.01, 
***
p < 0.001). 
 
6.2.2 CSD promoted ipsilateral cortical SFKs and Panx1 interaction 
A unique band was observed at 60 kDa after incubating PY416 SFKs antibody 
with the protein from the sham group (Figure 45), indicating the immunoreactive 
specificity of PY416 SFKs in our preparation. In addition, there was no band 
observed if incubating the control agarose resin with Panx1 antibody complex in 
the process of IP’d purification, suggesting that PY416 SFKs are specifically 
purified from Panx1 complex in our preparation.  
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Figure 45. Control study for the immunoreactive specificity of PY416 SFKs for 
co-IP. PY416 SFKs was indicated by the 60 kDa protein bands from the ipsilateral 
cortex by western blot.  
 
Immunoprecipitation followed by western blot study showed that intensive bands 
at the size of 60 kDa were detected in all 3 groups (Figure 46), indicating that 
PY416 SFKs are present in the Panx1 complex of the cerebral hemisphere. 
Similarly, total Panx1 was also observed (Figure 46) with the same molecular 
weight (45 kDa) as that described before when samples were not 
immune-precipitated with the Panx1 antibody (Figure 33). 
In the sham group, the relative intensity of PY416 SFKs in Panx1 complex was 
0.55 ± 0.13 (n = 3, Figure 47). In the CSD group, marked increase in the intensity 
was observed and the level of PY416 SFKs protein was 1.74 ± 0.13, which is 
significantly different from that of the sham group (n = 4, 
*
p < 0.05, Figure 47), 
indicating CSD promotes the interaction between phosphorylated SFKs and 
Panx1 protein in the ipsilateral cortex. 
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Figure 46. Co-immunoprecipitation assays from ipsilateral cortex of rats treated 
with ACSF or NVP-AAM077 (0.3 nmol) after CSD induction. Panx1 was 
immunoprecipitated and pulldown of Panx1 and PY416 SFKs was assessed by 
immunoblotting. Equal loading was indicated by total Panx1 immunoblotting. 
 
 
Figure 47. Quantitative analysis of relative intensity of IP’ed PY416 SFKs 
normalized to total Panx1 in ipsilateral cortex of rats treated with ACSF or 
NVP-AAM077 (0.3 nmol) after CSD. All the values shown were means ± SEM. 
Mann-Whitney test with two-tailed calculation was used for statistical analysis 
between sham (n = 3) and CSD (n = 4) groups (
*
p < 0.05). Unpaired t-test with 
two-tailed calculation was used for statistical analysis between CSD and 
NVP-AAM077 (n = 4) groups (
**
p < 0.01). 
 
6.2.3 NR2A antagonist suppressed CSD-induced cortical Src and Panx1 
interaction 
No change in CSD-induced total Panx1 expression was observed under 
NVP-AAM077 application (Figure 46). Similar to the SFKs inhibitor, i.c.v. 
R
el
at
iv
e 
d
en
si
ty
(v
s 
P
ax
n
1
)
ACSF ACSF NVP
0.0
0.5
1.0
1.5
2.0
CSDSham
0.3 nmol
*
**
103 
perfusion of 0.3 nmol NVP-AAM077 resulted in a reduction of phosphorylated 
SFKs at Y416 amino acid in the Panx1 complex from the ipsilateral cortex with 
the relative density of 1.18 ± 0.13 and this was significantly different from that of 
CSD group (n = 4, 
**
p < 0.01, Figure 47). 
 
6.3 Discussion 
This study, for the first time, demonstrated that CSD-induced SFKs coupling to 
neuronal Panx1 channels in the ipsilateral cortex of rats. The interaction of SFKs 
and Panx1 was attenuated by inhibition of NR2A. Corresponds to this, the 
CSD-induced Panx1 channels opening was also reduced by NR2A inhibition. 
These results provide strong evidence to support that CSD-induced interaction of 
activated SFKs and Panx1 contributes to Panx1 channels opening, which can be 
regulated by NR2A-containing NMDA receptor. 
CSD triggers Panx1 opening via coupling to SFKs 
A key finding in this study is that CSD promotes the interaction of activated SFKs 
and Panx1 in cortex. SFKs are known to directly interact with the putative Y308 
site on the intracellular C-terminus of Panx1 channels in hippocampus (Weilinger 
et al., 2012, Weilinger et al., 2016, Thompson, 2015) and that CSD is reported to 
promote Panx1 channels activity in cortex (Karatas et al., 2013). I therefore 
propose that activated SFKs may functional link to Panx1 channels during CSD. 
This study shows that there is a physical link of the activation state of SFKs and 
Panx1 in the rat ipsilateral cortical protein complex where Panx1 is 
immunoprecipitated with agarose resin. More importantly, the coupling of 
activated SFKs to Panx1 channel is largely promoted by CSD, suggesting a 
functionally link between SFKs and Panx1 during CSD. That CSD-induced 
neuronal Panx1 opening is prevented by the SFKs inhibitor (Chapter 5) further 
emphasizes the importance of the functional link between SFKs coupling to 
Panx1 activity during CSD and highlights that the interaction is of neuronal origin. 
These results are consistent with a model in which SFKs are involved in migraine 
pathogenesis in part the initiation of CSD-induced inflammatory response induced 
by CSD via neuronal Panx1 channels (Karatas et al., 2013). 
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Mechanism underlying CSD-induced SFKs coupling to Panx1 
As expected, inhibition of NR2A not only prevented CSD-induced SFKs 
phosphorylation (Figure 31), but also attenuated SFKs coupling to Panx1 (Figure 
47) and Panx1 channels opening (Figure 44). These evidences identified a link 
between NR2A and Panx1 during CSD, in which the CSD-activated SFKs 
coupling to Panx1 channels is regulated by NR2A-containing NMDA receptor. 
The CSD-induced Panx1 opening is not altered by NR2A inhibition in cingulate 
cortex (Figure 43 and d), although SFKs inhibition prevents CSD-induced Panx1 
opening in this region (Figure 38 and 40). It is assumed that NR2B rather than 
NR2A subunit may function to Panx1 activation via SFKs in cingulate cortex 
based on three considerations: (i) pan-NMDA receptor antagonist prevents 
CSD-induced Panx1 channels opening (Karatas et al., 2013); (ii) NR2B 
contributes to cortex susceptibility to CSD in rats (Menniti et al., 2000) and (iii) 
NR2A/B have synergistic effect on CSD as co-application of NR2A and NR2B 
antagonists have stronger inhibitory effect on CSD than individual used alone in 
vitro (Jia et al., 2015). However, given in the absence of direct evidence for the 
action of NR2B in the SFKs-Panx1 signaling in response to CSD, further 
investigation will be required in the future. 
It is relevant to consider that a region of activated Panx1 channels remains even 
when SFKs or NR2A activity was inhibited in motor and somatosensory cortices 
(Figure 38 and 40, Figure 43 and 44). This may be attributed to the extracellular 
high K
+ 
with the following evidences: (i) Panx1 channels can be activated at 
resting potential when the concentration of extracellular K
+
 at near 100 mM 
(Silverman et al., 2009); (ii) during CSD attack, the concentration of extracellular 
K
+
 rapidly rises and reach levels as high as near 80 mM (Smith et al., 2006). 
Alternatively, the remained activated Panx1 is probably attributed to the cleavage 
of the C-terminal of Panx1 channels as breaking the C-terminus of Panx1 by 
proteolytic action of caspases can open the channel pore (Chekeni et al., 2010). 
The above considerations imply the variability and complexity of the modulation 
of Panx1 during CSD. 
In summary, this work reveals a previously unknown migraine mechanism 
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involving SFKs. It concludes that NR2A regulates CSD-induced SFKs coupling to 
neuronal Panx1 in the cortex of rat (Figure 48), which extends the previous study 
that CSD triggered Panx1 channels opening and subsequently inflammatory 
response and the trigeminovascular mechanism of migraine in the animal model 
(Karatas et al., 2013). Targeting the elements of NR2A/SFKs/Panx1 signaling 
pathway might constitute an effective strategy preventing migraine and other 
neurological diseases associated with CSD.  
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Figure 48. Schematic depiction of NR2A signaling regulates CSD-induced rapid 
SFKs activation coupling to neuronal Panx1 channels in cortex of rats. (A) The 
pharmacological inhibition of NR2A signaling in our investigation. (B) The 
demonstrated signaling pathway in the study may trigger subsequent 
inflammatory response in the meninges leading to migraine headache. Red 
arrows-bars indicate the steps that CSD triggered. Black T-bars indicate the 
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inhibitory effect by inhibitors. Dotted lines indicate the cascades referring to other 
study. Abbreviations: NMDA, N-methyl-D-aspartic acid; SFK, sarcoma family 
kinase; CSD, cortical spreading depression; Panx1, pannexin1. 
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Chapter 7 NR2A contributes to CSD-induced CGRP gene expression 
 
CGRP mRNA is significantly increased in motor, somatosensory and visual 
cortices of the ipsilateral hemisphere of rats 24 hours after multiple, but not single 
CSD (Wang et al., 2016b). In addition, the increase of CGRP gene expression in 
trigeminal ganglion, medulla pons and cervical spinal cord can be prevented by 
NMDA antagonist in nitroglycerin-induced migraine model of rats (Greco et al., 
2016). Furthermore, my data showed the critical role of NR2A-containing 
receptor in mediating CSD. In the light of the above findings, it is plausible to 
propose that NR2A could regulate CSD-induced CGRP gene expression in 
ipsilateral discrete cortices 24 hours after multiple CSD. 
 
7.1 Objectives 
7.1.1 To investigate whether NR2A inhibition could suppress multiple CSD. 
7.1.2 To investigate whether the elevation of CGRP mRNA in motor, 
somatosensory and visual cortices 24 hours after CSD could be prevented by 
NR2A inhibition. 
 
7.2 Results 
 
7.2.1 Multiple CSD was suppressed by NR2A inhibition 
In the sham group, ACSF administration was insufficient to elicit CSD in all sham 
rats (n = 3). In the CSD group, 1 μl of topical 3 M KCl onto the dura resulted in 
the first CSD wave that began ~2 – 3 minutes after administration. The number 
and magnitude of CSD in the 1
st
 5 minutes-K
+
 application was 2.0 ± 0.41 (n = 4, 
Figure 49 A) and 5.04 ± 0.41 mV × minutes (n = 4, Figure 49 B) in respective 
order. There was no significant difference in the number or magnitude of CSD 
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episodes over the 5 high-K
+
 applications, indicating CSD was not altered 
throughout experiment under isoflurane anesthesia. When summed up, the 
accumulative number and magnitude of CSD for each rat were 8.50 ± 1.32 (n = 4, 
Figure 50 A) and 72.35 ± 15.07 mV × minutes (n = 4, Figure 50 B) in the CSD 
group. 0.3 nmol NVP-AAM077 significantly suppressed the CSD magnitude to 
42.56 ± 0.62 mV × minutes (n = 4, 
*
p ＜ 0.05, Figure 50 B), whereas CSD 
number (6.40 ± 0.51, n = 5, Figure 50 A) was not altered compared to the CSD 
group. 
 
 
Figure 49. Statistical analysis of the magnitude and number of CSD propagation 
waves induced by topical application of 3 M KCl into the burr hole with dura 
intact on the parietal bone of the rats. There was no significant difference in the 
number or magnitude of CSD episodes over the 5 high-K
+
 applications if i.c.v. 
perfusion of ACSF prior to the 1
st
 high-K
+
 applications (n = 4). One-way ANOVA 
was used for comparing among the CSD episodes. 
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Figure 50. Effects of NVP-AAM077 (0.3 nmol) i.c.v. perfused prior to the 1
st
 KCl 
applications on the cortical susceptibility to CSD and the accumulated magnitude 
of CSD. All the values shown are means ± SEM. Unpaired t-test with one-tailed 
calculation was used for statistical analysis for significance between 
NVP-AAM077 (n = 4) and CSD (n = 4) group (
*
p < 0.05). 
 
7.2.2 NVP-AAM077 suppressed CSD-induced CGRP mRNA expression in visual 
cortex, but not motor or somatosensory cortex. 
In the sham group, CGRP mRNA levels in the ipsilateral motor, somatosensory, 
and visual cortices were similar (Figure 51). In CSD group, The CGRP mRNA 
levels were significantly increased in the ipsilateral motor (9.26 ± 1.2, n = 3), 
somatosensory  (16.29 ± 1.51, n = 3) and visual cortices (11.72 ± 1.79, n = 3) 24 
hours after multiple CSD when compared with sham group with 1.0 ± 0.36 (n = 3, 
*
p ＜ 0.05), 1.0 ± 0.41 (n = 3, *p ＜ 0.05) and 1.0 ± 0.36 (n = 3, *p ＜ 0.05) in 
respective order (Figure 51), which was consistent with our previous study (Wang 
et al., 2016b). Interestingly, 0.3 nmol NVP-AAM077 significantly suppressed the 
CGRP mRNA levels to 5.85 ± 1.31 (n = 5, 
*
p ＜ 0.05) in visual cortex compared 
to the corresponding CSD group (Figure 51). However, the CGRP mRNA levels 
in motor (5.95 ± 2.14, n = 5) and somatosensory cortex (10.85 ± 4.471, n = 4) was 
not altered by NVP-AAM077 (Figure 51). 
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Figure 51. Effect of NR2A (0.3 nmol) to CGRP mRNA expression 24 hours after 
multiple CSD in ipsilateral motor, somatosensory and visual cortices. 
Mann-Whitney test with two-tailed calculation was used for statistical analysis,
 *
p 
< 0.05, sham (n = 3) vs CSD (n = 3) groups, CSD vs NVP-AAM077 (n = 5) 
groups. 
 
7.3 Discussion 
This data firstly confirmed that NR2A mediates multiple CSD. Further 
quantification of CGRP mRNA demonstrated that multiple CSD-induced CGRP 
gene expression in ipsilateral motor, somatosensory and visual cortices. This 
elevation of CGRP mRNA was inhibited by the inhibition of NR2A-containing 
NMDA receptors in visual, but not motor and somatosensory cortices, suggesting 
a critical role of NR2A in mediating CSD-induced CGRP gene expression in 
discrete cerebral cortices. 
Validation of multiple CSD model for NR2A pharmacology 
Herein, neither the cortical susceptibility to CSD nor the magnitude of CSD is 
altered among the 5 CSD episodes (Figure 49) under isoflurane anesthesia in the 
control group, which is consistent with our previous study (Wang et al., 2016b), 
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suggesting a stable and consistent procedure of multiple CSD elicitation in our 
preparation. Importantly, i.c.v. perfusion of 0.3 nmol NVP-AAM077 prior to the 
1
st
 high-K
+
 application significantly suppresses the accumulated magnitude of 
CSDs is consistent with that single CSD is suppressed by NR2A inhibition in the 
chick retina (Wang et al., 2012) and rats (Bu et al., 2016), confirming the validity 
of the CSD mode for NR2A pharmacology. 
Different with the typical single CSD event accompanied with migraine aura in 
human (Hadjikhani et al., 2001), this experimental protocol was designed to elicit 
multiple CSD similar to that used in other laboratories (Peeters et al., 2007, 
Sukhotinsky et al., 2011, Bu et al., 2016). The two facts that up to hundreds of 
CSD waves occur over days following the brain injury (Hartings et al., 2016), and 
that a subset of migraineurs suffer episodic migraine attack over months (Dodick 
et al., 2014), suggesting a clinical relevance of multiple CSD. 
CSD-induced CGRP gene expression 
A significant increase in CGRP mRNA in the ipsilateral motor, somatosens and 
visual cerebral cortices is observed 24 hour after multiple CSD, suggesting that 
unilateral multiple CSD is sufficient to induce CGRP gene expression in these 
cerebral cortical regions. In addition, the fact that CGRP mRNA levels are 
similarly increased in multiple cortical regions indicates that the elevation is 
attributed to CSD, rather than depolarization in the immediate area of K
+
 
application (Del Bianco et al., 1991). 
It is reported that CGRP receptor inhibition suppresses the magnitude of CSD and 
the tissue susceptibility to CSD both in the chick retina (Wang et al., 2016a) and 
the brain slice (Tozzi et al., 2012). In addition, application of exogenous CGRP 
reverses the inhibitory effect of CGRP receptor antagonist to CSD (Tozzi et al., 
2012), suggesting a critical role of CGRP/CGRP receptor signaling in CSD 
elicitation. More limited studies also report that CGRP is elevated in plasma and 
jejunum of rodent TBI models (Hang et al., 2004), and that both peripheral and 
central administration of CGRP antibodies attenuates CGRP-induced light 
aversive behavior as a measure of migraine-associated photophobia in mice 
(Mason et al., 2016), raising the possibility that the CGRP gene expression post 
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multiple CSD may involve in the associated diseases. 
Mechanism underlying NR2A regulated CGRP gene expression induced by CSD 
A key finding is that multiple CSD-induced CGRP gene expression is mediated by 
NR2A-containing receptor in visual cortex. The mechanism remains unknown, 
however, several possibilities may account for the elevation of CGRP by CSD. 
Firstly, mitogen-activated protein kinase (MAPK) pathway is probably an output 
for NR2A signaling in mediating CSD-induced CGRP gene expression based on 
the following observations: (i) a proteomic analysis isolates NMDA receptor 
multiprotein complexes of the sequential protein kinases of the MAPK pathway, 
including Raf, MAPK and extracellular signal–regulated kinase (ERK) from 
mouse brain (Husi et al., 2000), which may involve in synaptic plasticity by 
regulating various transcription factors and controlling gene expression (Adams 
and Sweatt, 2002); (ii) CSD can upregulate the level of ERK phosphorylation in 
the trigeminal ganglion (Iwashita et al., 2013) where the CSD-induced CGRP 
synthesis (Yisarakun et al., 2015) and release (Akerman et al., 2002) are observed 
as well; and (iii) in an nitroglycerin-induced migraine model of rat, 
phosphor-ERK are up-regulated in the brain neurons, whereas their expression 
levels are decreased in headache-free intervals of the migraine compared to the 
stages of migraine attack (Guo et al., 2016).  
Another possibility is that NR2A may mediate CSD-induced CGRP gene 
expression through a SFKs mechanism for two reasons: (i) NR2A contributes to 
CSD-induced SFKs activation in cortex of rats (Figure 30 and 31); and (ii) the 
nerve growth factor (NGF)-induced increase in capsaicin evoked release of CGRP 
is blocked by the SFKs inhibitor in acute isolated DRG of rats (Park et al., 2010). 
However, given the mediation of Src to the NGF-induced release of CGRP is 
observed within several hours (Park et al., 2010), whether SFKs involve in the 
CGRP expression at the later phase of CSD, i.e. at the 24
th
 hour, requires further 
investigation. 
It is relevant to consider that a region of CGRP gene expression even remains 
when NR2A activity is inhibited in somatosensory and motor cortices (Figure 51), 
which implies other unrevealed signals in mediating CSD-induced CGRP gene 
113 
expression in these regions. While speculative, one mechanism may be the 
generation of reactive oxygen species (ROS). A recent analysis of the literature 
concludes that oxidative stress is a shared feature of most migraine triggers 
encountered in clinical practice (Borkum, 2016). Likewise, the ROS-responsive 
cyclo-oxygen-ase-2 (COX-2) gene is reported to be upregulated by CSD (Urbach 
et al., 2006). Moreover, ROS-induced CGRP gene expression can be inhibited 
with antioxidant treatment in rat trigeminal ganglia (Raddant and Russo, 2014). In 
light of these observations, I speculate that CSD-induced ROS production may 
lead to upregulation of CGRP gene in cortex. However, this does not mean that 
the assumed ROS/CGRP signaling pathway is specific in the somatosensory and 
motor cortical regions as ROS is widely expressed in the whole cortex (Bolognin 
et al., 2013). The distinct signaling involving CGRP gene expression after CSD in 
discrete cortices requires further investigation. 
In summary, I conclude that NR2A-containing receptor contributes to the 
CSD-induced upregulation of CGRP gene in the visual cortex. The significance of 
this finding is that NR2A may be a mechanism by which CGRP levels become 
elevated post CSD for a prolonged period in some migraine patients with visual 
aura. These data extends my early study showing NR2A mediates a rapid cellular 
response post CSD, i.e. NR2A contributes to the CSD-induced SFKs coupling to 
Panx1 channels, and highlight the essential involvement of NR2A in both repaid 
and later events post CSD. 
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Chapter 8 General discussion 
 
This thesis demonstrates that the contribution of NR2A-containing NMDA 
receptor to CSD genesis and propagation, and reveals two strands of downstream 
signaling pathways of NR2A in CSD involving SFKs, Panx1 and CGRP in the rat 
cortex. It can be summarized as: (i) NR2A-containing NMDA receptor contributes 
to CSD genesis and propagation (chapter 3); (ii) SFKs play a critical role during 
CSD as SFKs can be activated by CSD and SFKs contribute to CSD propagation 
(chapter 4); (iii) CSD coupling activated SFKs to neuronal Panx1 channels, which 
is regulated by NR2A (chapters 4-6); and (iv) NR2A contributes to CSD-induced 
CGRP gene expression in visual cortex (chapter 7). 
CSD has been demonstrated to be dependent on activation of the NMDA receptor 
in the neocortex of a variety of species (Gorji et al., 2001). In this project, 
NR2A-containing NMDA receptor inhibition not only suppresses CSD 
propagation but also genesis, implicating a therapeutic potential by blocking 
NR2A subunit in migraine. In addition, the specificity of targeting NR2A rather 
than blockade of channel pore of NMDA receptor in mediating CSD (Peeters et al., 
2007, Olah et al., 2013) highlights the potential of clinical use of NR2A with less 
side effects. 
Herein, I identify a previous unknown element SFK in mediating CSD. The fact 
that inhibition of SFKs activity can suppress the cortical susceptibility to CSD and 
CSD propagation (Chapter 5) probably could be attributed to the involvement of 
SFKs substrates (Yeatman, 2004). Among these, the NMDA receptors can be 
considered as a candidate because multiple C-terminal sites of tyrosine of both 
NR2A and NR2B subunits can be phosphorylated by SFKs (Salter and Kalia, 
2004), and that both of the subunits contribute to the CSD propagation (Menniti et 
al., 2000, Bu et al., 2016). In addition, the contribution of NR2A to CSD-induced 
SFKs activation (Chapter 5) could be linked to the regulation of CSD by SFKs 
forming a positive loop, which leads to a better understanding of 
NR2A-containing NMDA receptor in mediating CSD. 
This work also first links two important elements, i.e. NR2A and Panx1, in CSD, 
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which is demonstrated by that CSD couples activated SFKs to neuronal Panx1 
channels, which is positively regulated by NR2A. It extends a previous study with 
CSD caused Panx1 channels opening followed by inflammatory factors (e.g. 
nuclear factor κB and interleukin-1β) releasing to meninges and consequently 
triggered headache-like behavior in mice (Karatas et al., 2013). The significance 
is that clarifies a mechanism of CSD-induced Panx1 channels opening and 
provides an evidence for the involvement of NR2A in the CSD-induced headache 
in animal model. 
Furthermore, this study gives an explanation to the CSD-induced CGRP gene 
expression in visual cortex, as evidenced by the suppressing effect of NR2A 
inhibition to CSD propagation and the elevation of CGRP mRNA. The less 
efficiency of NR2A inhibition to the CSD-induced CGRP gene expression in 
motor and somatosens cortices may imply the distinct roles of NR2A to the 
consequences of CSD through CGRP in the discrete regions of cortex. 
In conclusion, this project demonstrates the contribution of NR2A-containing 
NMDA receptor to CSD genesis and propagation and identifies a signaling 
pathway, which extends the previous understanding of NR2A in CSD pathology. 
In addition, given the critical roles of NR2A, Panx1 channels and CGRP in the 
generation and consequences of CSD, the revealed element, i.e. SFKs, for CSD 
physiopathology may represent a hub that widely participants in the diseases 
associated with CSD via a range of signaling transduction. Targeting the NR2A 
signaling pathway involving SFKs, Panx1 and CGRP may be a potential strategy 
to prevent and/or relieve migraine and TBI. Nonetheless, a limitation of animal 
CSD studies remains extrapolation to humans, especially as CSD propagation is 
limited by prominent sulci in the human brain that are absent in the lissencephalic 
rodent brain (James et al., 1999). Within this limitation, whether NR2A and its 
relative signaling could function to migraine in human still needs further 
investigation. 
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Chapter 9 Further work 
 
(i) Is CSD suppressed by the NR2A antagonist applied through clinical route? 
Our data provides solid evidence showing both CSD genesis and propagation can 
be suppressed by central administration of NR2A antagonists. However, whether 
peripheral administration of chemicals antagonizing NR2A could suppress CSD 
remains controversy as that the BOLD response of CSD is not altered by 
intraperitoneal injection of TCN-201 with an estimated dosage at 10 mg/kg based 
on its similarity in potency to ifenprodil in rats (Shatillo et al., 2015). I assume 
that the ineffectiveness of peripheral application of TCN-201 on CSD may be 
caused by (i) low efficiency of TCN-201 to CSD; (ii) lack of exploring effective 
concentration of TCN-201 in the guaranty of its selectivity of NR2A; (iii) the 
different methods applied for CSD recording: BOLD fMRI (Shatillo et al., 2015) 
vs electrophysiology. In this case, it would be worthwhile to further investigate 
whether CSD could be suppressed by NR2A antagonist applied through clinical 
acceptable route.  
In the preliminary experiment, I carried out one experiment in a rat using caudal 
vein injection of NVP-AAM077 at 2.4 mg/kg, at which the drug is selective for 
NR2A subunit (Fox et al., 2006). Five repeated CSD episodes were induced by 
topical application of 2 M KCl for 15 minutes, each followed by 40 minutes tissue 
recovery. With expected, at this dose, the drug injected 40 minutes prior to the 2
nd
 
CSD induction, has an inhibitory tendency to tissue susceptibility to CSD as 
reflected by the reduced CSD number, propagation rate and prolonged CSD 
latency (Figure 52). Maximum inhibitory effects of NVP-AAM077 on CSD were 
observed at the 110
th
 minutes after drug application. This result further supports 
the key role of NR2A in mediating CSD, indicating drug-alike candidates 
targeting NR2A may constitute a highly specific strategy for the treatment of 
migraine. More data is required for studying the pharmacokinetic profile of the 
drug in the future.  
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Figure 52. This figure shows inhibitory effects of pre-treatment of NVP-AAM077 
2.4 mg/kg through caudal vein on cortex susceptibility to CSD induced by topical 
application of 2 M KCl in the rat (n=1). Reducing tendency to CSD number, 
propagation rate and increasing tendency on CSD latency were observed, whereas 
the CSD magnitude was not altered after drug application. 
 
(ii) Does SFKs inhibition suppress CSD-induced interaction of SFKs and 
Panx1? 
The present study shows that CSD promotes the SFKs-Panx1 interaction and 
Panx1 channels opening. Inhibition of SFKs by PP2 significantly suppresses 
Panx1 channels opening, suggesting that CSD triggers Panx1 opening via 
activating SFKs. However, it lacks a direct evidence as whether SFKs inhibitor 
could prevent CSD-induced SFKs-Panx1 interaction to further confirm that SFKs 
functioning to Panx1 channels by physical interaction. 
 
(iii) Are CSD-induced SFKs activation and phospho-SFKs coupling to Panx1 
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channels different between parts of cortex? 
It has been demonstrated that CSD propagation is inhomogeneous in ipsilateral 
cortex (Eiselt et al., 2004). Specifically, the amplitudes of K
+
-induced CSD in the 
cortical parts nearby middle line, e.g. cingulate cortex, was much smaller than that 
in the lateral cortical parts (Eiselt et al., 2004). Herein, the IHC data showed that 
CSD-induced Panx1 channels opening is not mediated by NR2A in ipsilateral 
cingulate cortex, although Western blotting result shows that NR2A contributes to 
CSD-induced phospho-SFKs coupling to Panx1 in whole ipsilateral cortex, which 
raising the possibility that the NR2A/SFKs/Panx1 signaling is regional specific. In 
this case, it is necessary to investigate whether CSD-induced NR2A/SFKs/Panx1 
cascade differs among cingulate, motor and somatosensory cortices. 
 
(iv) How do SFKs mediate CSD?  
This study reveals a critical role of SFKs in mediating CSD. Although the 
mechanism remains unknown, it is likely that SFKs may mediate CSD via 
interacting with NR2A, and especially with the Y1325 and/or Y1387 amino acid(s) 
of NR2A as discussed in chapter 4. It would be worth investigating that whether 
CSD could recruit phospho-SFKs to activate NR2A and whether disrupting the 
interaction of SFKs and NR2A could suppress CSD. 
 
(v) Does NR2A mediate CSD-induced CGRP gene expression via SFKs? 
It is known that NR2A contributes to single CSD-induced SFKs activation and 
multiple CSD-induced CGRP gene expression. In addition, a previous study 
shows a Src/CGRP signaling as Src inhibition suppressed the NGF-induced 
release of CGRP in capsaicin-pretreated acute isolated DRG (Park et al., 2010). 
Based on the above evidences, I assume that NR2A may mediate the multiple 
CSD-induced CGRP gene expression via SFKs. 
 
119 
(vi) The requirement of more data for further confirmation. 
In order to make the conclusion that CSD activates SFKs more robust, further 
work is required to increase sample number for the sham, PP2 and PP3 groups 
used in western blotting (Figure 27). Besides that, more sample number is also 
required for PP2 and PP3 groups of IHC to confirm the contribution of SFKs to 
CSD-induced Panx1 channels opening (Figure 38 and 40). 
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NR2A contributes to genesis and 
propagation of cortical spreading 
depression in rats
Fan Bu1,2, Ruoxing Du2, Yi Li3, John P Quinn4 & Minyan Wang1,2
Cortical spreading depression (CSD) is a transient propagating excitation of synaptic activity followed 
by depression, which is implicated in migraine. Increasing evidence points to an essential role of NR2A-
containing NMDA receptors in CSD propagation in vitro; however, whether these receptors mediate 
CSD genesis in vivo requires clarification and the role of NR2A on CSD propagation is still under debate. 
Using in vivo CSD in rats with electrophysiology and in vitro CSD in chick retina with intrinsic optical 
imaging, we addressed the role of NR2A in CSD. We demonstrated that NVP-AAM077, a potent 
antagonist for NR2A-containing receptors, perfused through microdialysis probes, markedly reduced 
cortex susceptibility to CSD, but also reduced magnitude of CSD genesis in rats. Additionally, NVP-
AAM077 at 0.3 nmol perfused into the contralateral ventricle, considerably suppressed the magnitude 
of CSD propagation wave and propagation rate in rats. This reduction in CSD propagation was also 
observed with TCN-201, a negative allosteric modulator selective for NR2A, at 3 μM, in the chick retina. 
Our data provides strong evidence that NR2A subunit contributes to CSD genesis and propagation, 
suggesting drugs selectively antagonizing NR2A-containing receptors might constitute a highly specific 
strategy treating CSD associated migraine with a likely better safety profile.
Cortical Spreading Depression (CSD) is a temporary excitation of synaptic activity1,2, followed by depression that 
propagates slowly across the cerebral cortex. CSD is implicated in pathophysiological mechanisms of migraine 
aura3–5 and may lead to migraine headache via central modulation involving the activation of neuronal PANX1 
protein6. CSD is accompanied by a rapid disruption of ionic homeostasis, release of neurotransmitters, neuropep-
tides and changes in cerebral blood flow; however, the molecular pathways that mediate the initial phase of CSD 
and its role in the development of migraine are still poorly understood.
N-methyl-D-aspartate (NMDA) receptor activation is known to contribute to CSD genesis and propagation as 
the non-competitive inhibitor, MK801, appears to be the most effective anti-CSD compound in rats7,8. However, 
this drug is perceived as an unlikely anti-CSD candidate for migraine aura treatment because of unacceptable 
side effects resulting from the blockade of normal neuronal function9,10. The NMDA receptor is composed of two 
mandatory NR1 subunits and at least two NR2 (A-D) or a NR3 (A-B) subunit11. NR2A typically mediate synaptic 
transmission whereas NR2B-containing receptors are located extrasynaptically12,13 on astrocytes14. Increasing 
evidence has demonstrated that these two major receptor subunits, NR2A15 and NR2B8,16 play critical roles in 
CSD modulation, thus drugs selectively antagonizing these subunits have been proposed as potential candidates 
for migraine therapy, having better efficacy and a better safety profile8,15.
However, whether NR2A-containing receptors modulate susceptibility of the cortex to CSD is unknown. 
Additionally, whether NR2A-containing receptors contribute to CSD propagation is still a matter of debate15,16. 
We have demonstrated that inhibition of NR2A-containing receptors by NVP-AAM077, an antagonist that is 
preferably selective for NR2A at the concentration applied, resulted in suppression of CSD propagation in chick 
retina, a tissue which lacks blood vessels15, suggesting involvement of neuronal and glial activity. However, using 
blood oxygen level dependent (BOLD) fMRI approach, NR2A inhibition under TCN-201, a negative allosteric 
modulator selective for NR2A-containing NMDA receptors, application did not alter CSD propagation features 
in rats16. Therefore, the role of NR2A in CSD propagation requires further clarification in vivo.
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The primary aim of this study was to explore the role of NR2A-containing receptors in CSD genesis and 
propagation in rats by investigating effects of NVP-AAM077. The involvement of NR2A in CSD propagation was 
subsequently confirmed using another pharmacological tool TCN-201 at concentrations selective for binding to 
NR2A in chick retina.
Results
Validation of microdialysis-based CSD model under isoflurane anaesthesia. At the CSD genesis 
site of the control group (ACSF, n = 6), the average number, latency and the magnitude of the 1st CSD episode 
was 3.0 ± 0.86 (Fig. 1B), 6.53 ± 1.93 minutes (Fig. 1C) and 4.95 ± 1.06 mV × minute (Fig. 2A, n = 6), in respec-
tive order. There was no significant difference in any of these parameters over the five repeated CSD episodes 
(Figs 1B,C and 2A). To validate the CSD model under anesthesia with isoflurane, the non-competitive NMDA 
Figure 1. Representative CSD traces (A) and effects of MK-801 and NVP-AAM077 on tissue susceptibility 
to CSD induced by high K+ perfused through the microdialysis probe. Three groups including ACSF solution 
(n = 6) as control, MK-801 (n = 6) and NVP-AAM077 (n = 6) were considered. All the values given are 
means ± SEM. One-way ANOVA test was used for statistics of multiple comparisons, with subsequent 
Bonferonni test for significance between control and drug treatment groups (*p < 0.05, **p ≤ 0.01, 
***p ≤ 0.001). Paired t-test used to test whether tissue was restored after drug removal between the 4th and 5th 
CSD episodes.
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receptor antagonist, MK801, with known anti-CSD effect7,15, was examined through the microdialysis probe. 
MK-801 suppressed CSD genesis in a concentration dependent manner (Fig. 1, n = 6). MK801 at 30 μM sig-
nificantly reduced CSD number (0.67 ± 0.33) compared to the control group (2.5 ± 0.62) (One-Way ANOVA, 
p = 0.019, F = 5.236) (Fig. 1B). At this concentration, CSD latency increased 2.5-folds by MK801 compared to the 
control group (One-Way ANOVA, p = 0.001, F = 9.88) (Fig. 1C) and CSD waves were completely abolished in five 
out of six experiments during the 20-minute recording period (Fig. 1A). This inhibitory effect of MK801 on CSD 
was persistent after the drug removal (i.e. in the 5th CSD episode, Fig. 1A–C).
Suppression of CSD genesis by NVP-AAM077 applied through microdialysis. To investigate 
whether NVP-AAM077 alters CSD genesis, the microdialysis-based CSD model was used for local application of 
both K+-medium and the drug. In the control group, CSD number in the 2nd, 3rd and 4th episodes was 3.0 ± 0.86, 
2.67 ± 0.8, and 2.53 ± 0.62 respectively (Fig. 1A,B, n = 6). NVP-AAM077 at 0.3, 1 and 3 μM perfused through 
microdialysis probes concentration dependently reduced CSD number to 2.33 ± 0.61, 1.67 ± 0.49 and 0.83 ± 0.31 
in respectively order (Fig. 1A,B, n = 6). At the highest concentration applied, the reduction in CSD number 
reached significance (p = 0.036, F = 5.236, n = 6, Fig. 1B).
In the control group, CSD latency in the 2nd, 3rd and 4th CSD episodes was 6.85 ± 1.57, 7.18 ± 1.52, and 
7.52 ± 1.41 minutes, in respective order (Fig. 1A). Conversely to CSD number, NVP-AAM077 all three concentra-
tions applied prolonged CSD latency to 9.39 ± 2.15, 10.56 ± 2.43 and 13.94 ± 2.23 minutes in the corresponding 
CSD episodes. The drug at 3 μM perfused through the microdialysis probe significantly prolonged CSD latency 
when compared with the corresponding control (p = 0.041, F = 9.88, Fig. 1A,C, n = 6). There was no significant 
effect of NVP-AAM077 on CSD number and latency after the drug removal.
In the control group, CSD magnitude in the 2nd, 3rd and 4th CSD episodes was 4.94 ± 1.08, 5.45 ± 0.86, and 
5.20 ± 0.94 mV × minute, in respective order. NVP-AAM077 also significantly reduced CSD magnitude in a 
concentration dependent manner (Fig. 2A, n = 6). NVP-AAM077 at 0.3, 1 and 3 μM reduced the magnitude 
to 4.66 ± 0.48, 3.36 ± 0.82 and 2.36 ± 0.79 (t-test, p = 0.043, F = 1.411) mV × minute, in respective order. This 
inhibitory effect slightly recovered to 3.00 ± 0.67 mV × minute after the drug removal, which, however, did not 
reach significance when compared with that of the 4th episode in NVP-AAM077 (3 μM) group.
Suppression of CSD propagation by NVP-AAM077 perfused into contralateral ventricle but 
not via the microdialysis probe. Distinct from that of NVP-AAM077 on CSD genesis, perfusion of 
NVP-AAM077 through the microdialysis probe was unable to alter the magnitude of CSD propagation wave at 
the propagation site (Fig. 2B, n = 6). This route of delivery did not alter the velocity of CSD at all concentrations 
tested when compared with the control group (Fig. 2C, n = 6).
To allow NVP-AAM077 diffusing to distant cortical layer for investigating CSD propagation under NR2A 
inhibition, perfusion of the drug into contralateral ventricle was performed (see methods). In the control group, 
the magnitude of CSD propagation wave at the anterior recording site (0.4 mm to bregma) and propagation rate 
was 5.67 ± 0.64 mV × minute, and 4.0 ± 0.2 mm/minute respectively (Fig. 3A,B, n = 6). There was no change 
of these parameters throughout the experiment. In contrast to that perfused via microdialysis probe, 0.3 nmol 
of NVP-AAM077 perfused into the contralateral ventricle significantly suppressed both the magnitude of CSD 
propagation wave (Fig. 3A, t-test, p = 0.044, t = 2.302) and propagation rate (Fig. 3B, t-test, p = 0.013, t = 3.008). 
In the drug group, the magnitude of CSD propagation wave was reduced to 4.20 ± 0.80 mV × minute compared 
to 6.37 ± 0.50 mV × minute in the control group (Fig. 3A, n = 6). Similarly, the propagation rate slowed down to 
2.64 ± 0.27 mm/minutes compared to 4.02 ± 0.37 mm/minutes in the control group (Fig. 3B, n = 6) when meas-
ured between the two recording electrode implantation sites.
Suppression of CSD by TCN-201 in chick retina. To confirm NR2A-containing NMDA receptors are 
involved in CSD propagation, we examined the effect of TCN-201 that was previously reported to have better 
Figure 2. Effects of NVP-AAM077 perfused through the microdialysis probe on the magnitude of both CSD 
genesis (A), propagation waves (B) and propagation rate (C). All the values shown are means ± SEM. Unpaired 
t-test was used for statistical analysis for significance between the drug (n = 6) and control group (n = 6) 
(*p < 0.05). Paired t-test used to test whether tissue was restored after drug removal between the 4th and 5th CSD 
episodes.
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selectivity for NR2A than NVP-AAM07717 in CSD propagation in chick retina. Effect of NVP-AAM077 on CSD 
propagation was also designed for comparison.
In the Ringer’s group, there was no significant change in the magnitude and propagation rate over repeated 
CSD episodes throughout the experiment (Fig. 4, n = 6). Compared with the Ringer’s group, both CSD magni-
tude and propagation rate were markedly suppressed by NVP-AAM077 in a concentration-dependent manner 
(Fig. 4A,B, n = 6), which is in consistent with that reported previously15. At the maximum concentration tested 
(0.3 μM), the magnitude and propagation rate of CSD was reduced to 31.5% (Kruskal–Wallis test, p = 0.0001, 
H = 20.47) and 52% (Kruskal–Wallis test, p = 0.003, H = 18.97) of initial level respectively. This inhibitory effect 
significantly recovered to 80.2% (Wilcoxon matched pairs test, p = 0.03, W = 21) and 88.2% (Wilcoxon matched 
pairs test, p = 0.032, W = 20.56) of initial level after drug removal (high concentration vs drug removal).
Similar to the result of NVP-AAM077, but to a lesser extent, TCN-201 at both the medium and highest con-
centrations applied, markedly reduced the magnitude and propagation rate (Fig. 4A,B, n = 6), when compared 
with their respective DMSO group (n = 8). At 9 μM, the magnitude and propagation rate of RSD was reduced to 
73.8% (Kruskal–Wallis test, p = 0.0001, H = 20.47) and 72.8% (Kruskal–Wallis test, p = 0.003, H = 18.97) of the 
initial level respectively. This inhibitory effect did not recover after drug removal (Fig. 4).
Discussion
Our in vivo data reveals, for the first time, a critical role of NR2A-containing receptors in CSD genesis as 
demonstrated by that NVP-AAM077 perfused via microdialysis probes not only reduced cortex susceptibility 
to K+-induced CSD but also suppressed the magnitude of CSD elicitation in rats (Figs 1 and 2). Additionally, 
the electrophysiology study with NVP-AAM077 in rats (Fig. 3) and the application of TCN-201 in chick ret-
ina (Fig. 4) extended our previously findings on NR2A-containing receptor activation contributing to CSD 
propagation15.
Validation of microdialysis-based CSD model under isoflurane anesthesia. Several studies 
reported that inhalational anaesthetics suppress CSD18,19. In this study, we still considered isoflurane anesthe-
sia, but not pentobarbitone, which has the least action on CSD20, for studying genesis and propagation of CSD 
for the following reasons: (1) our in vivo experiment lasted almost 7 hours, whereas barbiturates usually only 
Figure 3. Effects of NVP-AAM077 perfused into the left lateral ventricle on the magnitude of CSD propagation 
(A) and propagation rate (B). All the values shown are means ± SEM. Unpaired t-test was used for statistical 
analysis for significance between the drug (n = 6) and control group (n = 6) (*p < 0.05).
Figure 4. Effects of NVP-AAM077 (n = 6) and TCN-201 (n = 6) on the magnitude (A) and propagation rate 
(B) of CSD propagation induced by K+ in the chick retina. Data was plotted as percentage of their initial levels 
and indicated as mean ± SD. Kruskal–Wallis test was used for statistical analysis of multiple comparisons, with 
subsequent Dunns test for significance (*p < 0.05, **p ≤ 0.01, ***p ≤ 0.001, TCN-201 vs. DMSO control (n = 8) 
or NVP-AAM077 vs. Ringer’s control (n = 6)). Wilcoxon matched pairs test was used to test whether tissue was 
restored after drug removal (#p < 0.05, 0.3 μM NVP-AAM077 vs. drug removal).
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maintain anesthesia from several minutes to 4 hours21, which did not meet our requirement; (2) Isoflurane has 
been widely used in other studies for studying CSD8,16,22,23; indeed, isoflurane provided a stable and consistent 
depth of anesthesia throughout the experiment and the concentration could be adjusted according to surgical 
and CSD recording procedures under study; whereas barbiturates generally result in uneven levels of anesthesia21; 
(3) Under isoflurane anaesthesia, the profound inhibitory effects of MK801 on CSD magnitude and susceptibility 
of the cortex to CSD (Fig. 1) were consistent with those reported previously24,25; (4) The fact that neither genesis 
nor propagation of CSD was altered in the control group yet was suppressed by NVP-AAM077, suggests that 
the suppression of CSD was due to NR2A inhibition, rather than to isoflurane. Collectively, the above evidence 
validates that the in vivo study under isoflurane anaesthesia is feasible and valid for assessing CSD genesis and 
propagation for NMDA receptor pharmacology.
NR2A-containing receptors mediate both CSD genesis and propagation. NVP-AAM077 mark-
edly suppressed K+-induced CSD number and increased CSD latency when perfused via microdialysis probes at 
0.3 μM (Fig. 1). The reduced cortex susceptibility to CSD under NR2A inhibition extended our previous finding 
on the crucial role NR2A-containing receptors in mediating CSD propagation15.
Surprisingly, local application of NVP-AAM077 at 0.3 μM through the microdialysis probe did not alter the 
magnitude of CSD propagation wave and propagation rate in rats (Fig. 2B,C), which is in contrast to that was 
reported in chick retina, in that NVP-AAM077 was effective in suppressing CSD propagation rate and magni-
tude15. We suspected that this negative result in vivo may be attributed to the fact that the anterior CSD propa-
gation site was not exposed to NVP-AAM077 when the drug was locally perfused through microdialysis probes 
at the CSD elicitation site (Fig. 5A). To clarify whether NVP-AAM077 was effective in CSD propagation in vivo, 
contralateral ventricle perfusion of NVP-AAM077 (total 0.3 nmol) was considered as this would allow the drug 
to diffuse to distant cortex by following cerebrospinal fluid flow. Indeed, it has previously been demonstrated in 
rats that a larger molecule, insulin, could flow to almost the whole cortex in rats within 2 hours after contralateral 
ventricle injection, with approximate 1/100 of the drug distributed to the contralateral cortical tissue 30 minutes 
after injection26. In our study, as expected, the 0.3 nmol of NVP-AAM077 perfused into the contralateral ventricle 
was found to markedly suppress both the magnitude of CSD propagation wave (Fig. 3A) and propagation rate in 
rats (Fig. 3B), confirming NR2A mediates CSD propagation15.
The importance of NR2A in CSD propagation was further supported by the action of TCN-201 (Fig. 4), which 
has 300-fold selectivity to NR2A compared with NR2B-containing receptors17. Indeed, at the medium concen-
tration of 3 μM of the drug applied, suppressive effects on both propagation rate and magnitude of CSD propa-
gation wave was observed in chick retina (Fig. 4). As the chick retina is devoid of blood vessels, the fact that the 
inhibitory effect of TCN-201 and NVP-AAM077 on CSD propagation under our study suggests an involvement 
of neuronal or glial mechanism under NR2A inhibition. Interestingly, this data on TCN-201 in chick retina is in 
contrast to a recent study employing BOLD fMRI approach, which showed that TCN-201 was ineffective in CSD 
BOLD response in rats16. The discrepancy may be attributed to different methods applied for CSD recording: 
BOLD fMRI16 that is largely based on brain-specific hemodynamic responses versus intrinsic optical signal that 
is based on neuronal activity of chick retina (Fig. 4). Whether TCN-201 could alter CSD in vivo using an electro-
physiology approach where neuronal activities could be monitored requires further investigation. It is noted that 
the efficacy of TCN-201 against CSD in chick retina is > 30-fold lower than that of NVP-AAM077 (Fig. 4A). This 
suggests that a much higher concentration of TCN-201 may be needed for sufficient binding to its receptors in 
future in vivo studies for effectiveness of the drug on CSD. Further studies using NR2A knockout animals will also 
help to elucidate the role of NR2A in CSD.
Elucidation of the inhibitory effects of NVP-AAM077 on CSD in in vivo suggests that NVP-AAM077 or 
such drug-alike candidates targeting NR2A may constitute a highly specific strategy with better efficacy and 
safety profile for treating CSD associated migraine aura, relative to non-subtype selective NMDA receptors15. 
This possibility is likely due to the following reasons: (1) NVP-AAM077 suppressed CSD in chick retina 
(Fig. 4) with approximately 320-fold more potency than memantine8, a clinically acceptable drug for treating 
migraines27. (ii) Partial inhibition of CSD by NVP-AAM077 in rats was also observed with the non-competitive 
NR2A subunit antagonist, memantine8,9. (iii) The rapid reversibility of NVP-AAM077 after the drug withdrawal 
(Figs 1–3) resulting from its competitive antagonism supports a likely better safety profile. (iv) Our latest prelim-
inary data demonstrated that using a clinical acceptable route of administration (intravenous), pre-treatment of 
NVP-AAM077, at a dose of 2.4 mg/kg that preferably antagonizes NR2A-containing receptors28, suppressed tissue 
susceptibility to CSD induced by topical application of KCl (data was not shown).
Mechanism contributing to the role of NR2A in CSD. The present data suggests activation of 
NR2A-containing receptors contributes to CSD genesis and propagation. There are several mechanisms which 
may explain the nature of CSD modulation by NVP-AAM077 and TCN-201 in vivo and in vitro. It is likely that 
inhibition of CSD genesis and propagation wave under NR2A inhibition is attributed to their ability to desensi-
tize neurons (as NVP-AAM077 competitively blocks steady-state NR1/NR2A receptor currents from a cortical 
neuron)29; whereas TCN-201 accelerates NR1/NR2A receptor deactivation30. This notion was supported by that 
the inhibitory effect of NVP-AAM077 and TCN-201 on CSD propagation was observed in the chick retina, a 
tissue devoid of blood vessels, suggesting neuronal mechanism under NR2A inhibition. Alternatively, the sup-
pression of CSD in response to NR2A inhibition may be based on the NR2A-mediated steady-state current per-
mitting calcium ion influx in neurons31; whilst the increased calcium influx triggers and accelerates CSD in rats32. 
Finally, the role of NR2A in CSD may also be associated with its interaction with postsynaptic density protein 
95 (PSD95) as NMDA receptor desensitization can be regulated by direct binding of NR2 to PDZ1-2 domains 
of PSD95 in neuronal and non-neuronal cells33. Further investigations are required to understand mechanism 
underlying NR2A-containing receptors in mediating CSD genesis and propagation. It is known that the NR2B 
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containing NMDA receptor is also involved in CSD elicitation and propagation in rats using electrophysiology8 
and BOLD fMRI16. Therefore, it is reasonable to propose that CSD genesis and propagation requires both NR2A 
and NR2B activation. Further synergistic effect on CSD under both NR2A and NR2B inhibition in vivo remains 
to be examined.
In summary, our data provides strong evidence that NR2A subunit contributes to CSD genesis and propa-
gation, suggesting drugs selectively antagonizing NR2A-containing receptors might constitute a highly specific 
strategy treating CSD associated migraine with a likely better safety profile.
Methods
All animal procedures were approved by the Ethical Review Panels of Soochow University and performed in 
accordance with the associated guidelines. All efforts were made to minimize animal suffering to reduce the 
number of animals used.
In vivo CSD in rats with electrophysiology. Animal use and anaesthesia. Adult, male Sprague Dawley 
rats (n = 30, 317 ± 40 g, mean ± SD, Shanghai SLAC Laboratory Animal Corporation Ltd) were housed with food 
Figure 5. Schematic representation of electrode implantation sites (left) and representative traces in 
DC potential of CSD (right) induced by K+ through microdialysis probe (upper) and topical application 
(lower) in the anaesthesized rat. (A) In microdialysis based CSD experiment (upper), CSD wave in the genesis 
site was recorded by perfusion of 250 mM KCl through the microdialysis probe implanted at 2 mm posterior 
to bregma in the rat right cortex. CSD propagation wave was simultaneously recorded through the Ag/AgCl 
electrode implanted at 1.5 mm anterior to bregma. Drugs or ACSF was perfused through the microdialysis 
probe for pharmacology study. (B) In intracerebral ventricle (i.c.v) based experiment (lower), CSD was induced 
by topical application of 3 M KCl through the hole with dura intact at 5 mm posterior to bregma in the right 
skull. CSD propagation wave was recorded at both 2 mm posterior to and 0.4 mm anterior to bregma. The drug 
or ACSF was perfused into contralateral ventricle through a cannula implanted (lower left). CSD magnitude 
is indicated as Area under the curve (AUC, dotted line, right upper trace). CSD latency (L) and CSD number 
are used to assess the susceptibility of the cortex to K+ induced CSD. CSD propagation rate is used to assess the 
susceptibility of the cortex to CSD propagation as calculated by the distance dividing by the time delay  
(D, right).
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and water available ad libitum. Rats were anaesthetised with isoflurane (5% for induction, 2.5–3.5% during the 
surgery, 1–1.5% for maintenance) in O2:N2O (1:2), with the animal breathing spontaneously. The depth of anaes-
thesia was monitored and adjusted through careful examination of the electroencephalogram (EEG) signal and 
through observation of the animal. Rectal temperature of animals was maintained at 37 °C. CSD induction was 
carried out one hour after the surgery for tissue stabilization.
Microdialysis-based CSD experiment. To record CSD genesis and propagation waves, two burr holes were 
drilled on the right parietal bone (Fig. 5A). (i) Microdialysis probes incorporating an electrode (ME-H1, Applied 
Neuroscience, London) were implanted through the posterior burr hole (coordinates: 2 mm posterior and 2 mm 
lateral to bregma, 1.4–1.5 mm deep from the cortical surface) for recording of CSD genesis waves; (ii) Ag/AgCl 
electrodes (0.1 mm i.d, Applied Neuroscience, London) were implanted into the ipsilateral cortex through the 
anterior burr hole (coordinates: 1.5 mm anterior and 2 mm lateral to bregma, 0.9 mm deep from the cortical sur-
face) for recording of CSD propagation waves; separate Ag/AgCl reference electrodes were placed under the scalp 
of rats. EEG and Direct Current (DC) potential were derived from the potential between microdialysis probes 
or Ag/AgCl electrodes and reference electrodes. The microdialysis probe was perfused with artificial cerebrospi-
nal fluid (ACSF) at 1 μl/minute with a syringe pump (CMA100, CMA/Microdialysis, Solna, Sweden). For CSD 
elicitation, a medium containing 250 mM K+ (K+-medium, composition in mM: 2.5 NaCl, 250 KCl, 1.18 MgCl2, 
1.26 CaCl2; pH 7.3 adjusted with 1 M NaOH, not buffered) was used; It is noted that a higher concentration of 
K+ at 250 mM was required to induce CSD compared to 160 mM employed when halothane was used as the 
anaesthetic34. This difference in K+ requirement could be due to the anaesthetics (isoflurane vs halothane) hav-
ing different effects on CSD18, but this effect can be ignored as all experiments were carried out under the same 
anesthetic condition.
One hour after the surgery, drugs or ACSF were perfused through the microdialysis probe at 1 μl/minute. In 
order to examine the effects of NVP-AAM07 on CSD genesis and propagation, the following series of experiments 
were carried out. The known non-competitive NMDA receptor antagonist, MK801, was used as the reference. 
These series are: (i) ACSF (Control, n = 6); (ii) MK801 (Sigma-Aldrich, Dorset, UK, n = 6); (iii) NVP-AAM077 
(n = 6), which was synthesized following the procedures described in the literature35 and further purified by 
HPLC. It should be noted that the microdialysis probe used in this study has ~10% recovery rate, i.e. the ratio of 
the drug penetration through the semi-permeable membrane of the probe into the cortex relative to its original 
concentration. An estimation of 0.3 μM of NVP-AAM077 was expected to diffuse into the cortex surrounding 
the microdialysis probe implantation site when the maximum concentration at 3 μM of the drug was applied, at 
which, the drug is preferably selective for NR2A subunit36.
Five consecutive CSD episodes were elicited in each experiment by perfusion of K+-medium through micro-
dialysis probes for 20 minutes followed by 40 minutes ACSF perfusion to allow tissue recovery. These five episodes 
were: (i) initial ACSF control; (ii) low concentration of the drug or ACSF; (iii) medium concentration of the drug 
or ACSF; (vi) high concentration of the drug or ACSF; (v) post-treatment with ACSF solution. The drug at each 
concentration (0.3, 1, 3 μM for NVP-AAM077 or 3, 10, 30 μM for MK801) was perfused through microdialysis 
probes for 20 minutes before and during high K+-medium perfusion for the 2nd, 3rd and 4th CSD episodes.
Intracerebroventricular injection experiment. To ensure NVP-AAM077 diffusion to a wider cortical region for 
investigation of CSD propagation under NR2A inhibition, a separate set of in vivo experiment by perfusion of 
NVP-AAM077 into the left lateral ventricle was designed. Three burr holes were drilled in the right and left pari-
etal bones (Fig. 5B) for the following purposes: (i) one burr hole (1 mm i.d) with dura intact was drilled in the 
right parietal bone (coordinates: 5 mm posterior and 2 mm lateral to bregma) for inducing CSD by topical appli-
cation of 1 μl of 3 M KCl for 1 minute; (ii and iii) two burr holes were drilled on the ipsilateral area (coordinates: 
2 mm posterior and 0.4 mm anterior to bregma respectively, 2 mm lateral) and Ag/AgCl recording electrodes 
were implanted into the cortex (0.9 mm deep from the cortical surface) through these burr holes for recording 
CSD propagation waves. The DC potential was derived between the Ag/AgCl electrodes and a reference electrode 
placed under the scalp; (vi) A stainless steel cannula (inner diameter: 0.38 mm, RWD Life Science, Shenzhen, 
China) was implanted into the contralateral ventricle (coordinates: 0.8 mm posterior and 1.6–1.8 mm lateral to 
bregma, 3.5 mm deep from the cortical surface) and held in place by acrylic dental cement for the drug or ACSF 
perfusion. These burr holes were kept moisture with ACSF throughout the experiment.
After one hour stabilization post-surgery, two CSD episodes were induced by topical application of 1 μ1 of 
KCl at 3 M with 40 minute interval. NVP-AAM077 (0.3 nmol, n = 6) or ACSF (Control, n = 6) was perfused at 
1 μl/minute for 10 minutes using a syringe pump (CMA100, CMA/Microdialysis, Solna, Sweden) into the con-
tralateral ventricle immediately after the 1st CSD wave of each episode was completed.
Recording of EEG and extracellular direct current potential. EEG and DC signal recording was as reported pre-
viously34. Briefly, EEG and DC signals were amplified using an AC/DC pre-amplifier (NL834, Neurolog System, 
Digitimer Ltd., Welwyn Garden City, UK). All the recorded variables were continuously digitised, displayed and 
recorded by a computer using Labview 11.0 (NI Instruments) via an analogue/digital-converter (USB6009, NI 
Instruments). In the microdialysis-based experiment, CSD at the induction site was recognized as a transient, 
negative shift superimposed on the sustained shift resulting from the imposed high extracellular K+ concentra-
tion (Fig. 5A, lower trace). CSD propagation wave was recognized by a transient, negative shift but in the absence 
of the sustained depolarization shift (Fig. 5A, upper trace and 5B).
In vivo data presentation and statistical analysis. Details on CSD number, latency and magnitude in rats were 
quantified as that described previously (Wang et al.34). Labview program was used to determine (i) CSD number 
in each episode; (ii) Latency (minute), the time required to elicit the 1st CSD wave from the start of depolarization 
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induced by high K+-medium. In the case of the CSD wave being completely abolished by drug(s), the latency 
was counted as 20 minutes. CSD number and latency were used to reflect cortex susceptibility to CSD; (iii) Area 
under the curve (AUC, mV × minute) of CSD waves was used to reflect CSD magnitude. The magnitude of each 
CSD wave in each CSD episode was averaged for data comparison. Values were counted as zero when CSD waves 
were abolished; (vi) CSD propagation rate (mm/minute). The velocity of each CSD wave in each CSD episode 
was averaged for data comparison. All values were given in mean ± SEM. CSD number and latency was analysed 
using one-way ANOVA with subsequent Bonferonni test for significance between drugs and control group. CSD 
magnitude and propagation rate were analysed using unpaired t-test between the drug and control group. Paired 
t-test was used to test the significance of the effect of drug removal.
In vitro CSD in chick retina with intrinsic optical imaging. CSD induction in chick retina and intrinsic 
optical imaging. Twenty six male chicks (purchased at 1 day old, WuXi Yangzichang Ltd, Wuxi, China) were 
housed for at least a week before use (aged 8–28 days). As described previously37, posterior eyeball was positioned 
in a chamber, which was perfused at 0.5 ml/minute with Ringer’s solution. The tissue was stabilized for at least 
30 minutes before CSD induction and temperature kept constant at 32 °C.
Retinal CSD was induced as previously described15,37. Briefly, ten repeated CSD episodes were induced by 
ejection of 1 μl of KCl (0.1 μM) at the eyeball with 20-minute interval for tissue recovery. The retina was illu-
minated for 25 ms at 1 Hz using a high-power LED spotlight (625 nm peak wavelength, SLS-0307-A, Mightex; 
Pleasanton, CA, USA) and the illumination was driven by a computer-controlled power supply (Sirius LED con-
troller, SLC-SA04-U; Mightex, Pleasanton, USA). The reflected light was simultaneously recorded with a mon-
ochrome camera (QIC-F-M-12, Media Cybernetics, Marlow, UK). Image sequences were taken at 1 Hz over a 
3-minute period, started as CSD was elicited. Camera exposure and illumination were synchronized using the 
same external trigger (TG5011, TTi, UK). Image Pro Plus software (IPP 7.0; Media Cybernetics UK, China) was 
used for image acquisition, storage and analysis.
In vitro experimental design for drug testing. Four groups were designed and the concentration range of each 
drug was carefully selected to ensure that each drug tested was preferably selective for NR2A subunit: (i) TCN-
201 (Tocris, Bristol, UK) at 1, 3 and 9 μM (n = 6); (ii) NVP-AAM077, at 0.03, 0.1 and 0.3 μM (n = 6) as the posi-
tive control; (iii) DMSO (Sigma-Aldrich, Dorset, UK) at 0.001%, 0.03% and 0.1% as the TCN-201 vehicle group 
in respective order (n = 8); It should be noted the maximum concentration of DMSO without affecting CSD in 
chick retina was 0.1% DMSO per our preliminary experiment; (vi) Ringer’s solution as the control (n = 6) for 
NVP-AAM077 group.
For each group tested, ten CSD episodes were induced in each experiment, with two separate CSDs for 
each of the different and consecutive tests: (i) initial Ringer’s control; (ii) low concentration of drug or vehicle; 
(iii) medium concentration of drug or vehicle; (vi) high concentration of drug or vehicle; (v) post-treatment with 
Ringer’s control (i.e. drug removal). For each test sequence, the perfusion medium was changed immediately after 
the end of the 2nd, 4th, 6th, and 8th CSD recording when required, so that the preparation was adequately perfused 
with the proper drug, vehicle, or Ringer’s medium for the subsequent test.
In vitro data presentation and statistical analysis. As reported previously (Wang et al.15), for each image 
sequence, an area of interest (AOI) parallel to the CSD wave front was delineated manually. For each image within 
the sequence, the gray levels of the pixels constituting the AOI were averaged and plotted against the time as an 
indicator to characterize CSD. For each CSD wave, the area under the curve (AUC, gray levels × minute) of the 
transient cellular depolarization was calculated and used as an index of the magnitude of propagating CSD. For 
each CSD wave, propagation rate was also calculated to reflect the degree of tissue excitability. The calculated val-
ues within each different test were averaged and all corresponding data were given as mean ± SD in percentages of 
their respective baselines. Kruskal–Wallis test was used with subsequent Dunn’s test for comparison of the mag-
nitude and propagation rate of RSD between the drug and respective control group. Wilcoxon matched pairs test 
was used to test the significance of the difference for the last two tests with each drug (i.e. effect of drug removal).
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Abstract
Objective: The neuropeptide calcitonin gene-related peptide (CGRP) has now been established as a key player in
migraine. However, the mechanisms underlying the reported elevation of CGRP in the serum and cerebrospinal fluid of
some migraineurs are not known. A candidate mechanism is cortical spreading depression (CSD), which is associated
with migraine with aura and traumatic brain injury. The aim of this study was to investigate whether CGRP gene
expression may be induced by experimental CSD in the rat cerebral cortex.
Methods: CSD was induced by topical application of KCl and monitored using electrophysiological methods.
Quantitative PCR and ELISA were used to measure CGRP mRNA and peptide levels in discrete ipsilateral and contra-
lateral cortical regions of the rat brain 24 hours following CSD events and compared with sham treatments.
Results: The data show that multiple, but not single, CSD events significantly increase CGRP mRNA levels at 24 hours
post-CSD in the ipsilateral rat cerebral cortex. Increased CGRP was observed in the ipsilateral frontal, motor, somato-
sensory, and visual cortices, but not the cingulate cortex, or contralateral cortices. CSD also induced CGRP peptide
expression in the ipsilateral, but not contralateral, cortex.
Conclusions: Repeated CSD provides a mechanism for prolonged elevation of CGRP in the cerebral cortex, which may
contribute to migraine and post-traumatic headache.
Keywords
CGRP, migraine, traumatic brain injury, post-traumatic headache, gene expression
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Introduction
Migraine is a complex, multifactorial neurological dis-
order that is conservatively estimated to affect 12% of
Americans (1). The most prominent characteristic of
migraine is the disabling headache, which manifests as
a throbbing, unilateral pain made worse with routine
activity, and coincident with nausea/vomiting and/or
photophobia/phonophobia. Approximately one-third
of migraineurs experience a premonitory aura, which
typically manifests as a disruption in the ipsilateral
visual hemifield (2). The pathophysiological substrate
of the visual aura is cortical spreading depression
(CSD), a transient wave of neuronal and glial depolar-
ization, followed by a sustained depression of electrical
activity (3,4). CSD is associated with a massive trans-
location of ions and release of nitric oxide, arachidonic
acid, glutamate, and ATP (5,6). The sudden rise in
extracellular Kþ, arachidonic acid and nitric oxide is the
likely trigger for CSD-induced activity in meningeal noci-
ceptors (7) and central trigeminovascular neurons (8).
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CSD may also lead to migraine by potentiation of an
inflammatory response in the dura (9).
In addition to the connection between migraine and
CSD, it is well accepted that CSD also occurs following
acute brain injuries, such as traumatic brain injury
(TBI) and strokes (10–12). Whereas the pattern of
brain injury-triggered CSD is heterogeneous and influ-
enced by many factors, a common feature is that there
are multiple CSD events, often about every 30 minutes
for many hours to days (11). For example, 72% of sub-
arachnoid hemorrhage patients experience clusters of
repetitive CSD events (13), and 56% of TBI patients
experience repeated spreading depression events
(mostly CSD), with a total of 1328 events observed in
58 patients over 67 hours (14). Hence, brain injury in
humans can lead to tens to hundreds of CSD events
over days. Repeated CSD events have also been
observed for hours to days in some, but not all,
animal TBI models (12).
It has been shown that multiple CSD events can
modulate many genes at early (hours) and late (days
to weeks) time points across a variety of gene ontol-
ogies (15,16). A potential candidate for regulation by
CSD is calcitonin gene-related peptide (CGRP).
CGRP is a vasoactive neuropeptide that is
widely distributed in the central and peripheral ner-
vous systems. Clinical and preclinical studies have
established CGRP as a key player in migraine (17).
Intravenous CGRP administration to migraineurs is
sufficient to elicit a migraine-like headache (18,19),
and CGRP levels have been reported to be elevated
in both the serum and CSF of migraineurs (20).
Importantly, CGRP receptor antagonists and
CGRP-blocking antibodies can ameliorate migraine
symptoms (21,22).
In this report, we have asked whether CSD is suf-
ficient to alter CGRP expression. Such a link would fit
in the context of interesting, but limited, evidence of
CGRP involvement in CSD (17,23). In particular, a
calcium-dependent release of CGRP was observed
during CSD and inhibition of CGRP receptors
reduced the magnitude of CSD in rat neocortical
slices (24). Elevated CGRP may modulate neurotrans-
mission and possibly contribute to sensory hypersen-
sitivity (17,25). For this scenario, we reasoned that the
elevated synthesis, if it occurred, would likely be main-
tained for a relatively long time (24 hours). Similar
prolonged times were also required for activation of
CGRP gene expression in trigeminal ganglia organ
cultures (26), and by epigenetic reprogramming of
glial cells (27). We therefore proposed that CSD
might be a mechanism by which cortical levels of
CGRP become elevated for a prolonged period in
migraine and TBI patients.
Materials and methods
Animals
Adult male Sprague–Dawley rats (n¼ 36, 240–440 g;
Shanghai SLAC Laboratory Animal Corporation,
Ltd.) with food and water ad libitum were used.
Experimental procedures were performed in the
animal unit of Soochow University. All rats were
healthy, with no drug treatments or previous tests car-
ried out prior to experimentation. Animals were housed
two per cage in specific pathogen-free conditions with
standard bedding material and rat special synthetic
feed. Animals were allowed to acclimate to the housing
room for 7 days prior to the experiment, then matched
by body weight into experimental groups of sham and
CSD, which were performed randomly on different
days using one rat per day at various times during the
day. No animals were excluded from the analysis.
During the experiment, rats were given isoflurane anes-
thesia, which was monitored by absence of whisker
movements and lack of reaction to brief tail pinches.
After surgeries, animals were given an antibiotic and
anti-inflammatory, as described below, and outwardly
appeared healthy. Euthanasia was by excess isoflurane
exposure. All procedures were approved by the Ethic
Review Panel of Soochow University under agreement
with XJTLU, and performed in accordance with
Chinese national guidelines and in adherence to
ARRIVE guidelines.
CSD induction
Animals were anesthetized with isoflurane (5% induc-
tion, 2.5–3.5% during surgery, 1.0–1.5% maintenance)
in O2: N2O (1:2). A small incision was made and two
small burr holes were drilled carefully in the skull right
frontoparietal region (1mm i.d.; Figure 1). The poster-
ior hole (4mm posterior, 2mm lateral to bregma) was
prepared with extra care to minimize damage to the
underlying dura. A silver chloride recording electrode
was implanted through the anterior hole (3mm anterior,
2mm lateral to bregma) for recording of CSD waves. A
reference electrode was placed under the scalp. Both
holes were moisturized with artificial cerebrospinal
fluid (ACSF; 125mM NaCl, 2.5mM KCl, 1.18mM
MgCl2, 1.26mM CaCl2, pH 7.3). Rectal temperature
was maintained at 37C. Upon completion of surgery,
rats were maintained under anesthesia for at least 1 hour
to allow for stabilization and tissue recovery.
For the multiple CSD group (n¼ 14), 1 ml of 3 M
KCl was carefully dropped into the posterior hole for
single CSD wave elicitation. As soon as the first CSD
wave was detected at the recording site, KCl was
removed using a tissue, followed by washout with
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ACSF and placement of ACSF-moistened cotton over
the hole. For the sham group (n¼ 12), 1 ml ACSF was
used. In both groups, five repeated CSD or sham epi-
sodes were elicited at 40-minute intervals. Both electro-
encephalogram (to monitor depth of anesthesia) and
direct current potentials (to monitor CSD events)
were recorded and analyzed using LabVIEW. The elec-
trode was removed and wound sutured after the fifth
CSD episode. Ibuprofen (5–10mg) and mupirocin oint-
ment (0.4–0.8mg) were applied. At 24 hours after the
fifth CSD episode, the rat was re-anesthetized for
euthanasia and tissue removal.
For the single CSD group (n¼ 5), CSD induction,
CSD recording, and post-surgery care were the same as
that for the repeated CSD, except that only one CSD
episode was elicited by 1 ml of 3 M KCl. For the sham
group (n¼ 5), 1 ml ACSF was used. At 24 hours, the rat
was re-anesthetized for euthanasia and tissue removal.
qPCR
All quantitative polymerase chain reaction (qPCR)
assays on multiple CSD tissue samples were performed
blinded at the University of Iowa using coded samples
shipped from XJTLU. Some of those samples were also
tested at XJTLU as an internal control for measure-
ments on the single CSD samples, which were done at
XJTLU. In both locations, the same protocols and
reagents were used. Whole cortex or cortical regions
(50–100mg) were homogenized in 1ml TRIzol
(Sigma-Aldrich) and RNA concentration and purity
measured by Nano-Drop (Thermo Scientific); 1 mg
total RNA was reverse transcribed into cDNA using
the GoScriptTM RT system (Promega). qPCR was per-
formed in duplicate using 1/20th of the cDNA reaction
on a Bio-Rad CFX Connect using SYBR-Green
Master Mix (Takara Clontech), except for 18S rRNA,
which used 1/20,000th of the cDNA. Primers (forward,
reverse) were: CGRP (NM_001033953.2)
50AACCTTGGAAAGCAGCCCAGGCATG30, 50GT
GGGCACAAAGTTGTCCTTCACCA30; and three
reference genes: peptidylprolyl isomerase A (PPIA)
(NM_017101.1) 50TTGCTGCAGACATGGTCAA
C30, 50TGTCTGCAAACAGCTCGAAG30; b-actin
(ACTB) (NM_001101.3) 50ACGGTCAGGTCATCAC
TATGG30, 50AGCCACCAATCCACACAG30; and
18S rRNA (NR_046237.1) 50ATGGCCGTTCTTA
GTTGGTG30, 50AACGCCACTTGTCCCTCTAA30.
All qPCR data from multiple CSD samples were ana-
lyzed using both absolute quantification of CGRP
mRNA (with standard curves) and relative fold
change (2Cq method) normalized to each contralat-
eral hemisphere. The single CSD samples were analyzed
only by the relative fold change (2Cq method) nor-
malized to the sham tissue. Standard curves were gen-
erated using plasmids containing PCR products in
pCR2.1 (Invitrogen) (confirmed by sequence). CGRP
mRNA levels were normalized to the product-based
geometric mean of the three reference genes (28), calcu-
lated as the cube-root of the product of the reference
genes (PPIA b-actin 18S)1/3 divided by 10,000.
Similar results were observed when CGRP levels were
normalized to each individual reference gene. CGRP
levels are mean SEM.
ELISA
Protein extraction and detection from cortex homogen-
ates followed the manufacturer’s instructions using the
CSD induction
(AP: –4 mm, L: 2 mm)
CSD recording
(AP: +3 mm, L: 2 mm)
(a)
(b)
KCl
(–)
AUC
2m
V
Time (min)
0 1 2 3 4
Figure 1. Cortical spreading depression (CSD) induction and
propagation in the rat cortex. (A) CSD was induced with topical
application of 1ml 3 M KCl (or artificial cerebrospinal fluid for
sham) onto the dura via a posterior burr hole. An anterior hole
was used for CSD recording. A total of 36 rats were used. Of
these, 26 rats were used for multiple CSD experiments including
14 for CSD induction and 12 for sham. To minimize the animal use,
three of 14 rats in the CSD group and three of 12 in the sham
group were also used for measuring calcitonin gene-related pep-
tide (CGRP) levels in addition to CGRP mRNA. In the single CSD
group, 10 rats were used with five for CSD and sham, respectively.
(B) A representative trace showing CSD propagation and magni-
tude (indicated as area under the curve, AUC, grey lines).
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rat CGRP enzyme-linked immunosorbent assay
(ELISA) kit (Bertin Pharma). To minimize the
number of animals, cortical regions were snap frozen,
pulverized, and split to allow both protein and RNA
extractions. Due to the small amounts of tissue, it was
necessary to combine motor, somatosensory, and visual
cortices for protein, and set aside cingulate and frontal
cortices for only RNA. All protein samples were rap-
idly homogenized within 15 seconds in 2 N acetic acid
at 2ml/100mg tissue, then heated at 90C for 10 min-
utes, centrifuged at 10,000 g for 30 minutes, dried for 1
hour, and stored at 80C. Immediately before assay,
samples were reconstituted with enzyme immunoassay
(EIA) buffer, and analyzed using a microplate reader.
CGRP levels are meanSEM.
Data analysis
For qPCR data, statistical analyses were performed
using GraphPad Prism software as follows: compari-
sons across groups were done using an ordinary one-
way analysis of variance (ANOVA) Kruskal–Wallis
test; comparisons between ipsilateral versus contralat-
eral hemispheres within the group were done using one-
tailed Wilcoxon –t-test; comparisons between CSD and
sham groups were done using one-tailed Mann–
Whitney t-test. For ELISA data, normal distribution
was confirmed by SPSS 16.0 software, and statistical
analyses were performed using GraphPad Prism soft-
ware with comparisons across groups using one-way
ANOVA; comparisons between ipsilateral versus
contralateral hemisphere within the group using one-
tailed paired t-test; comparisons between CSD and
sham groups using one-tailed unpaired t-test.
Results
Detection of experimentally induced CSD in rats
In the sham group, ACSF administration was insuffi-
cient to elicit CSD. In the CSD group, 1 ml of topical
3 M KCl onto the dura resulted in a CSD wave that
began 2–3 minutes after administration (Figures 1A
and 1B). CSD propagation was identified by a transi-
ent, negative shift of the direct current–potential, which
was observed in all CSD rats monitored by this means.
For the rats that underwent multiple CSD events, the
magnitude of each event was approximately 9mV
minutes and there was no significant difference in the
number or magnitude of CSD episodes over the 5 KCl
applications (p¼ 0.89) (not shown). When summed up,
the mean accumulative magnitude of CSD for each rat
was 53.0 10.2mVminutes in the multiple CSD
group (n¼ 14) and 5.9 1.8mVminutes (n¼ 5) in
the single CSD group. Generally, only a single CSD
wave was observed after each of the applications;
although in four rats a second wave was observed
after one of the applications in the multiple CSD group.
Increased cortical CGRP gene expression
at 24 hours post-multiple CSD
In the sham group, the copy number of contralateral
and ipsilateral CGRP mRNA was 13.5 2.9 and
14.1 2.2, respectively (p¼ 0.69), indicating that the
surgical procedure did not significantly change CGRP
gene expression (Figure 2A).
In the CSD group, the copy number of CGRP
mRNA in the contralateral hemisphere was 18.6 2.2,
which is not significantly different from that of contra-
lateral hemisphere in sham rats (p¼ 0.14; Figure 2A),
demonstrating that repeated unilateral CSD does not
affect CGRP gene expression in the contralateral
hemisphere. In contrast, repeated CSD events in the ipsi-
lateral hemisphere significantly increased the CGRP
mRNA copy number to 79.1 22.7 at 24 hours post-
CSD (p< 0.001; Figure 2A). Comparison of relative
ipsilateral CGRP levels normalized to the contralateral
hemisphere of each rat agrees with the measured abso-
lute levels. The sham group showed a 1.3 0.4-fold
increase between hemispheres, whereas the CSD group
had a significantly greater 3.8 0.8-fold increase
(p¼ 0.004; Figure 2B).
No increased CGRP gene expression
at 24 hours post-single CSD
In the single CSD group, CSD ipsilateral cortex did not
show a significant change in CGRP mRNA levels.
There was a 1.28 0.06-fold change compared with
that in sham ipsilateral group (p¼ 0.11; Figure 3).
Contralateral samples were not included in this test,
as it was shown that surgery did not significantly alter
CGRP gene expression during the multiple CSD tests
(Figure 2). Thus, it is very unlikely an elevation of
CGRP gene expression in the contralateral cortex
would be observed with single CSD.
Regional induction of CGRP in the cortex
We then examined CGRP mRNA levels in discrete
regions of the cortex. In the sham group, CGRP
mRNA levels in the contralateral and ipsilateral fron-
tal, motor, somatosensory, and visual cortices were
similar (Figure 4A). The cingulate had slightly higher
CGRP mRNA levels in the sham contralateral
(16.7 4.0) and ipsilateral (32.9 12.0) cortices
(Figure 4A), which is consistent with a previous
report that the rat cingulate has elevated CGRP relative
to other cortical regions (29). There was no significant
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change in CGRP mRNA content between contralateral
and ipsilateral hemispheres of sham frontal, cingulate,
or somatosensory cortices (p¼ 0.16, 0.11, and 0.22, in
respective order), indicating that the surgery does not
alter CGRP mRNA expression in these regions.
However, a slight, but significant, increase in CGRP
mRNA was observed in the motor and visual cortices
of sham rats (p¼ 0.016 and 0.031, respectively;
Figure 4A).
Following CSD, CGRP mRNA levels were signifi-
cantly increased in the ipsilateral frontal, motor, som-
atosensory, and visual cortices when compared with
sham (p¼ 0.013, 0.001, 0.001, and 0.001, respectively;
Figure 4A). In contrast, CSD did not alter CGRP
mRNA levels in the ipsilateral cingulate cortex com-
pared with sham (p¼ 0.45; Figure 4A). As with the
whole cortex, comparison between CSD and sham
cohorts of the relative CGRP levels normalized to the
contralateral hemisphere of each rat agreed with the
absolute levels. In the CSD rats, there were significant
increases in the ipsilateral compared with contralateral
hemispheres of the frontal cortex (8.0 1.8, p¼ 0.013),
motor cortex (9.5 3.1, p¼ 0.013), somatosensory
cortex (15.3 4.0, p¼ 0.001), and visual (14.5 5.4,
p¼ 0.001) compared with sham rats (Figure 4B).
Also, as seen with absolute expression data, the nor-
malized cingulate cortex did not exhibit a CSD-induced
increase over sham (1.6 0.3, p¼ 0.45; Figure 4B).
Increased CGRP peptide expression
at 24 hours post-multiple CSD
Aliquots of somatosensory, motor, and visual cortices
used for RNA analyses were combined and used for
parallel peptide measurements (see Methods). In the
sham group, CGRP peptide levels were 1.4 0.5 ng/g
tissue in the ipsilateral hemisphere and 1.8 0.1 ng/g
tissue in contralateral (p¼ 0.27), indicating that surgi-
cal procedures do not alter overall CGRP expression
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Figure 2. Ipsilateral calcitonin gene-related peptide (CGRP) mRNA is upregulated 24 hours post-multiple cortical spreading
depression (CSD). (a) Absolute levels of CGRP mRNA were significantly elevated in the ipsilateral (ipsi), but not contralateral (contra),
cortex post-CSD. There was no significant increase in the sham-treated rats. Data for individual rats are shown with lines connecting
the paired cortices. (b) Comparison of CGRP mRNA levels between contralateral and ipsilateral cortices shown for individual rats
(left panel) and as the fold change (right panel). Increased relative expression of CGRP mRNA in the ipsilateral normalized to
contralateral cortex. In both (a) and (b), sham (n¼ 6), CSD (n¼ 8), **p< 0.01; ***p< 0.001.
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Figure 3. Ipsilateral calcitonin gene-related peptide (CGRP)
mRNA is not altered 24 hours post-single cortical spreading
depression (CSD). Comparison of CGRP levels between ipsilat-
eral (ipsi) cortices of CSD rats (n¼ 5) normalized to sham rats
(n¼ 5). There was no significant difference (p¼ 0.11).
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under these conditions (Figure 4). In the CSD ipsilat-
eral cortex, the CGRP level was 4.0 0.6 ng/g tissue,
which was about 2.9-fold higher than sham ipsilateral
cortex (p¼ 0.014; Figure 5).
Discussion
In this study, we have shown that unilateral multiple
CSD is sufficient to upregulate CGRP mRNA and pep-
tide levels in the ipsilateral cerebral cortex. The RNA
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Figure 4. Multiple cortical spreading depression (CSD)-induced calcitonin gene-related peptide (CGRP) mRNA expression shows
regional specificity. (a) Top view of rat brain cortical regions used for dissections. Cortical regions are designated as 1¼ frontal,
2¼ cingulate, 3¼motor, 4¼ somatosensory, and 5¼ visual. The CSD recording and induction sites are also indicated. (b) Absolute
levels of CGRP mRNA were significantly elevated in ipsilateral (ipsi) frontal, motor, somatosensory (SS), and visual cortices, but not in
the cingulate (Cing) cortex, or the contralateral (contra) hemispheres, 24 hours post-multiple CSD. (c) Significant increases in relative
ipsilateral CGRP mRNA were observed in the frontal, motor, somatosensory, and visual cortices, but not in the cingulate cortex, at 24
hours post-multiple CSD. In both panels, sham (n¼ 6), CSD (n¼ 6), *p< 0.05; **p< 0.01; ***p< 0.001.
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induction was widespread across much of the cerebral
cortex: in the frontal, motor, somatosensory, and visual
cortices, but not in the cingulate cortex. The lack of
induction in the cingulate is consistent with reports
that CSD propagation is less efficient in this region
(30). Importantly, the fact that CGRP mRNA levels
were similarly increased in multiple cortical regions
indicates that the elevated expression is attributed to
CSD, rather than depolarization in the immediate
area of KCl application. These data extend an earlier
in vitro study showing that CSD induced CGRP release
in rat neocortical slices (24). Thus, CSD might contrib-
ute to the elevated CGRP in the CSF of some migraine
patients. However, it is very unlikely that cortical
CGRP contributes to the elevation of CGRP in the
external jugular vein during migraine. Indeed, Piper
et al. (31) clearly documented that CGRP release into
the external jugular vein was not increased by experi-
mental CSD in the cat. Whether CSD increases synthe-
sis in the trigeminal ganglia remains to be determined.
A recent study reported that CSD increases the number
of CGRP-positive cells in rat trigeminal ganglia (32),
which may point to increased synthesis. Overall, these
data provide evidence linking CSD and CGRP expres-
sion that may contribute to migraine pathogenesis.
A key finding of our study was that multiple CSD
events were required for robust induction of the CGRP
gene. The experimental protocol we used was designed
to elicit multiple CSD events similar to that used in
other laboratories (9,23,33–35), but which also likely
differs from human migraine. Indeed migraine aura is
believed to involve only a single CSD event. On the
other hand, TBI is commonly associated with up to
hundreds of CSD waves that can occur over days fol-
lowing the injury (10–12). To our knowledge, the pos-
sibility that individuals with a history of head trauma
and spreading depression exhibit elevated CGRP levels
has not been investigated. However, in a recent study,
Elliott and colleagues observed a sustained elevation of
CGRP in the brainstem (most likely from the trigeminal
nerve) for at least 4 weeks in rodents exposed to con-
trolled cortical impact injury (36). This injury can cause
one to four CSD events over several hours (37). More
limited studies have also reported elevated CGRP in
other rodent TBI models (38,39). Whether from TBI
or migraine, there is increasing evidence that CSD
affects behavior and likely potentiates nociception that
may in part involve CGRP. CSD activates meningeal
nociceptors and central trigeminovascular neurons
(7,8,40), and an immediate effect of CSD is reduced
movement and freezing responses (41,42). Nonetheless,
a limitation of animal CSD studies remains extrapola-
tion to humans, especially as CSD propagation is lim-
ited by prominent sulci in the human brain that are
absent in the lissencephalic rodent brain. Within this
limitation, we predict that TBI may increase CGRP
levels to alter brain plasticity and predispose patients
to migraine-like post-traumatic headaches.
How might CSD increase cortical CGRP gene
expression? While speculative, one mechanism may be
generation of reactive oxygen species (ROS).
Migraineurs have elevated plasma levels of a ROS-
induced lipid peroxidation products (43). In rats,
CSD produces ROS in the cortex and trigeminal
nerve (44,45). Likewise, the ROS-responsive COX2
gene has been reported to be upregulated by CSD
(16). Moreover, ROS-induced CGRP gene expression
can be inhibited with antioxidant treatment in rat tri-
geminal ganglia (26). In light of these observations, we
speculate that CSD-induced ROS production can lead
to pro-inflammatory cascades that upregulate the
CGRP gene. Interestingly, a recent analysis of the lit-
erature concluded that oxidative stress is a shared fea-
ture of most migraine triggers (43).
We have provided evidence showing that CSD upre-
gulates CGRP gene expression in the cortex. Given the
promising potential of CGRP-based therapeutics for
treating and preventing migraine, a link between CSD
and CGRP further emphasizes the importance of CSD
as a target for migraine drug development (46,47). The
significance of our finding is that CSD may be a mech-
anism by which CGRP levels become elevated for a
prolonged period in some migraine patients. While
there are multiple mechanisms that can potentially
increase CGRP expression, including nitric oxide (48)
and cytokines (33,48,49), this is the first report of a
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Figure 5. Ipsilateral calcitonin gene-related peptide (CGRP)
peptide levels are upregulated post-multiple cortical spreading
depression (CSD). CGRP peptide levels are significantly elevated
in ipsilateral (ipsi) cortex 24 hours post-CSD (n¼ 3), but not the
contralateral (contra) hemispheres, nor in sham rats (n¼ 3),
*p< 0.05.
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physiological in vivo mechanism that may elevate
cortical CGRP gene expression in migraine and post-
traumatic headache. Given CGRP’s role as a
neuromodulator (17), this elevation may potentially
contribute to cortical hyperexcitability and sensory
abnormalities in migraine.
Article highlights
. Multiple CSD events can trigger CGRP gene expression in discrete regions of the rat cerebral cortex.
. This is the first in vivo evidence for a mechanism to initiate and maintain elevated CGRP levels in migraine
and post-traumatic headache.
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